<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><front><journal-meta><journal-id journal-id-type="nlm-ta">Vaccines (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Vaccines (Basel)</journal-id><journal-id journal-id-type="pmc-domain-id">2764</journal-id><journal-id journal-id-type="pmc-domain">vaccines</journal-id><journal-id journal-id-type="publisher-id">vaccines</journal-id><journal-title-group><journal-title>Vaccines</journal-title></journal-title-group><issn pub-type="epub">2076-393X</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC8402453</article-id><article-id pub-id-type="pmcid-ver">PMC8402453.1</article-id><article-id pub-id-type="pmcaid">8402453</article-id><article-id pub-id-type="pmcaiid">8402453</article-id><article-id pub-id-type="pmid">34452042</article-id><article-id pub-id-type="doi">10.3390/vaccines9080917</article-id><article-id pub-id-type="publisher-id">vaccines-09-00917</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>The Promise and Challenges of Cyclic Dinucleotides as Molecular Adjuvants for Vaccine Development</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Yan</surname><given-names initials="H">Hongbin</given-names></name><xref ref-type="aff" rid="af1-vaccines-09-00917">1</xref><xref rid="c1-vaccines-09-00917" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-0958-7728</contrib-id><name name-style="western"><surname>Chen</surname><given-names initials="W">Wangxue</given-names></name><xref ref-type="aff" rid="af2-vaccines-09-00917">2</xref><xref ref-type="aff" rid="af3-vaccines-09-00917">3</xref><xref rid="c1-vaccines-09-00917" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Tripp</surname><given-names initials="RA">Ralph A.</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-vaccines-09-00917"><label>1</label>Department of Chemistry, Brock University, St. Catharines, ON L2S 3A1, Canada</aff><aff id="af2-vaccines-09-00917"><label>2</label>Human Health and Therapeutics Research Centre, National Research Council Canada, Ottawa, ON K1A 0R6, Canada</aff><aff id="af3-vaccines-09-00917"><label>3</label>Department of Biological Sciences, Brock University, St. Catharines, ON L2S 3A1, Canada</aff><author-notes><corresp id="c1-vaccines-09-00917"><label>*</label>Correspondence: <email>tyan@brocku.ca</email> (H.Y.); <email>Wangxue.Chen@nrc.gc.ca</email> (W.C.)</corresp></author-notes><pub-date pub-type="epub"><day>17</day><month>8</month><year>2021</year></pub-date><pub-date pub-type="collection"><month>8</month><year>2021</year></pub-date><volume>9</volume><issue>8</issue><issue-id pub-id-type="pmc-issue-id">388950</issue-id><elocation-id>917</elocation-id><history><date date-type="received"><day>28</day><month>6</month><year>2021</year></date><date date-type="accepted"><day>10</day><month>8</month><year>2021</year></date></history><pub-history><event event-type="pmc-release"><date><day>17</day><month>08</month><year>2021</year></date></event><event event-type="pmc-live"><date><day>29</day><month>08</month><year>2021</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-04-02 13:25:14.430"><day>02</day><month>04</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2021 by the authors.</copyright-statement><copyright-year>2021</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="vaccines-09-00917.pdf"/><abstract><p>Cyclic dinucleotides (CDNs), originally discovered as bacterial second messengers, play critical roles in bacterial signal transduction, cellular processes, biofilm formation, and virulence. The finding that CDNs can trigger the innate immune response in eukaryotic cells through the stimulator of interferon genes (STING) signalling pathway has prompted the extensive research and development of CDNs as potential immunostimulators and novel molecular adjuvants for induction of systemic and mucosal innate and adaptive immune responses. In this review, we summarize the chemical structure, biosynthesis regulation, and the role of CDNs in enhancing the crosstalk between host innate and adaptive immune responses. We also discuss the strategies to improve the efficient delivery of CDNs and the recent advance and future challenges in the development of CDNs as potential adjuvants in prophylactic vaccines against infectious diseases and in therapeutic vaccines against cancers.</p></abstract><kwd-group><kwd>cyclic dinucleotide</kwd><kwd>c-di-GMP</kwd><kwd>bacterial second messenger</kwd><kwd>immunostimulation</kwd><kwd>vaccine adjuvant</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-vaccines-09-00917"><title>1. Introduction</title><p>Host innate immunity is the first line of defence against invading microbial pathogens and cancers and also plays a critical role in the development of autoimmune diseases. Innate immune cells, such as macrophages, granulocytes, dendritic cells (DCs), natural killer (NK) cells, and mast cells, contain specific pathogen-recognition receptors (PRRs), which sense pathogen-associated molecular patterns (PAMPs) and induce the production of proinflammatory cytokines/chemokines and subsequently activate the adaptive immune response. A variety of PRRs has now been identified and characterized, including the Toll-like receptors (TLRs), nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs), and Retinoic acid-inducible gene (RIG)-I-like receptors (RLRs). In addition, cyclic dinucleotides (CDNs), including bacterial second messengers bis-(3&#8242;,5&#8242;)-cyclic diguanosine monophosphate (c-di-GMP) and bis-(3&#8242;,5&#8242;)-cyclic diadenosine monophosphate (c-di-AMP), 3&#8242;5&#8242;-3&#8242;5&#8242; cyclic GMP-AMP (3&#8242;3&#8242;-cGAMP) produced by <italic toggle="yes">Vibrio cholerae</italic>, and metazoan second messenger 2&#8242;5&#8242;-3&#8242;5&#8242; cyclic GMP-AMP (2&#8242;3&#8242;-cGAMP, hereafter cGAMP), bind to an endoplasmic reticulum (ER)-associated sensor termed as a stimulator of interferon genes (STING) [<xref rid="B1-vaccines-09-00917" ref-type="bibr">1</xref>,<xref rid="B2-vaccines-09-00917" ref-type="bibr">2</xref>,<xref rid="B3-vaccines-09-00917" ref-type="bibr">3</xref>,<xref rid="B4-vaccines-09-00917" ref-type="bibr">4</xref>]. The finding that CDNs can trigger the innate immune response in eukaryotic cells through the STING signalling pathway, leading to the type I interferons (IFN) production, has prompted the extensive research and development of CDNs as potential vaccine adjuvants and agents for cancer immunotherapy [<xref rid="B5-vaccines-09-00917" ref-type="bibr">5</xref>].</p><p>In this review, we summarize the structure and chemical synthesis, the biological characteristics, the current status of CDN vaccine adjuvant research, including their superior adjuvant activities, in vivo mode of action, and application in the development of infectious disease and cancer vaccines. We also examine the strategies to improve the efficient delivery of CDNs and future challenges in advancing the lead CDN adjuvant candidate into clinical trials and ultimately in human clinical use.</p></sec><sec id="sec2-vaccines-09-00917"><title>2. Discovery and Chemical Structure of CDNs</title><p>In their investigation of the regulation of cellulose synthesis in <italic toggle="yes">Acetobacter xylinum</italic> (now classified as <italic toggle="yes">Gluconacetobacter xylinus</italic>), Benziman and co-workers discovered a cyclic oligonucleotide that appeared to be an activator of cellulose synthase [<xref rid="B6-vaccines-09-00917" ref-type="bibr">6</xref>,<xref rid="B7-vaccines-09-00917" ref-type="bibr">7</xref>]. This activator was subsequently identified in the same laboratory as bis-(3&#8242;&#8594;5&#8242;)-cyclic diguanylic acid (also known in the literature as 3&#8242;,5&#8242;-cyclic diguanylic acid, c-di-GMP, or c-diGMP, <xref ref-type="fig" rid="vaccines-09-00917-f001">Figure 1</xref>), with the mass spectrometric and NMR data in agreement with samples generated by enzymatic synthesis from guanosine triphosphate (GTP) catalyzed by diguanylate cyclase [<xref rid="B8-vaccines-09-00917" ref-type="bibr">8</xref>]. The crystal structure of chemically synthesized c-di-GMP was subsequently resolved by Rich and co-workers [<xref rid="B9-vaccines-09-00917" ref-type="bibr">9</xref>].</p><p>The adenylyl analog of c-di-GMP, c-di-AMP, together with the diadenylate cyclase activity of the nucleotide-binding domains of the DNA-integrity scanning protein A (DisA), were discovered in 2008 [<xref rid="B10-vaccines-09-00917" ref-type="bibr">10</xref>]. The DisA protein was shown to control a sporulation checkpoint in <italic toggle="yes">Bacillus subtilis</italic> in response to DNA double-strand breaks. Since this discovery, the roles of c-di-AMP in bacterial physiology were rapidly expanded [<xref rid="B11-vaccines-09-00917" ref-type="bibr">11</xref>,<xref rid="B12-vaccines-09-00917" ref-type="bibr">12</xref>].</p><p>A guanosine/adenosine hybrid CDN, 3&#8242;3&#8242;-cGAMP (3&#8242;5&#8242;-3&#8242;5&#8242; cyclic GMP-AMP or c(GpAp)), was also found in a <italic toggle="yes">V. cholerae</italic> strain expressing dinucleotide cyclase DncV [<xref rid="B13-vaccines-09-00917" ref-type="bibr">13</xref>], which is involved in intestinal colonization and chemotaxis of <italic toggle="yes">V. cholerae</italic>.</p><p>In two back-to-back publications in <italic toggle="yes">Science</italic> in 2013, Chen and co-workers reported the roles of cyclic GMP-AMP synthase in the activation of the type I interferon pathway [<xref rid="B14-vaccines-09-00917" ref-type="bibr">14</xref>], and the identification of 2&#8242;2&#8242;-cyclic GMP-AMP (2&#8242;2&#8242;-cGAMP) [<xref rid="B15-vaccines-09-00917" ref-type="bibr">15</xref>] as the endogenous ligand for cyclic GMP-AMP synthase. Very shortly after the publication of these original results, it was determined that the endogenous ligand is, in fact, 2&#8242;3&#8242;-cyclic GMP-AMP (2&#8242;3&#8242;-cGAMP) [<xref rid="B16-vaccines-09-00917" ref-type="bibr">16</xref>].</p><p>In the ensuing few years since its discovery, c-di-GMP attracted very little attention until around 2004/2005 when its roles as a bacterial second messenger were recognized, and the field quickly expanded with the potential of this cyclic dinucleotide and its analogs as immunostimulatory agents and vaccine adjuvants. The rapidly growing interest in cyclic dinucleotides is clearly reflected by the expansion of the number of published records in the last two decades (<xref ref-type="fig" rid="vaccines-09-00917-f002">Figure 2</xref>).</p></sec><sec id="sec3-vaccines-09-00917"><title>3. c-di-GMP as a Universal Bacterial Second Messenger</title><p>Intracellular levels of c-di-GMP are regulated through the actions of diguanylate cyclases (DGC) and phosphodiesterases (PDE), usually as a response to an environmental stimulus, i.e., first messenger. In signalling cascades involving c-di-GMP, binding of this second messenger with effector molecules, which are usually proteins and, in some cases, RNA such as riboswitches, allows for the regulation of the processes mediated by these effector molecules. Most DGCs contain a conserved GGDEF domain, although DGC cyclase enzymes with GGEEF, AGDEF, and GGDEM domains have also been identified [<xref rid="B17-vaccines-09-00917" ref-type="bibr">17</xref>]. PDEs, on the other hand, typically contain EAL (or less frequently HY-GYP) domains. Interestingly, numerous other proteins containing these domains are enzymatically inactive.</p><p>In the last 15 years or so, significant progress has been made toward the identification of effector molecules that are key to the biological processes or phenotypes regulated by c-di-GMP. The first such effector protein identified was the cellulose synthase from <italic toggle="yes">G. xylinus</italic> (formerly <italic toggle="yes">A. xylinum</italic>) [<xref rid="B8-vaccines-09-00917" ref-type="bibr">8</xref>,<xref rid="B18-vaccines-09-00917" ref-type="bibr">18</xref>], where the cellulose synthesis is activated by c-di-GMP. Almost 20 years after the discovery of the regulation of cellulose synthase activity via the allosteric binding with c-di-GMP, the PilZ domain was identified to be responsible for the binding to c-di-GMP [<xref rid="B19-vaccines-09-00917" ref-type="bibr">19</xref>]. Indeed, PilZ was subsequently found to be a common c-di-GMP binding domain among bacterial species, regulating bacterial motility [<xref rid="B20-vaccines-09-00917" ref-type="bibr">20</xref>,<xref rid="B21-vaccines-09-00917" ref-type="bibr">21</xref>,<xref rid="B22-vaccines-09-00917" ref-type="bibr">22</xref>,<xref rid="B23-vaccines-09-00917" ref-type="bibr">23</xref>] and virulence [<xref rid="B24-vaccines-09-00917" ref-type="bibr">24</xref>]. Other proteins such as the PelD protein from <italic toggle="yes">Pseudomonas aeruginosa</italic> [<xref rid="B25-vaccines-09-00917" ref-type="bibr">25</xref>], LapD protein from <italic toggle="yes">P. fluorescens</italic> [<xref rid="B26-vaccines-09-00917" ref-type="bibr">26</xref>], the transcription factor VpsT from <italic toggle="yes">V. cholera</italic>, the transcription factor FleQ (flagellar transcriptional regulator) from <italic toggle="yes">P. aeruginosa</italic> [<xref rid="B27-vaccines-09-00917" ref-type="bibr">27</xref>], and the Bcam1349 protein from <italic toggle="yes">Burkholderia cenocepacia</italic> [<xref rid="B28-vaccines-09-00917" ref-type="bibr">28</xref>] have also been identified as effector proteins in c-di-GMP-mediated processes. Furthermore, riboswitches [<xref rid="B29-vaccines-09-00917" ref-type="bibr">29</xref>,<xref rid="B30-vaccines-09-00917" ref-type="bibr">30</xref>] and self-splicing ribozyme [<xref rid="B31-vaccines-09-00917" ref-type="bibr">31</xref>] have been shown to be another class of effector molecules. Located in the 5&#8242;-untranslated upstream of the open reading frames of DGC and PDE proteins, binding of these riboswitches to c-di-GMP can serve as a regulator for the expression of DGC and PDE proteins.</p><p>Taken together, c-di-GMP mediated signalling networks have been shown to affect the regulation of a wide range of biological processes and phenotypes in bacteria (<xref ref-type="fig" rid="vaccines-09-00917-f003">Figure 3</xref>), enabled by the binding of this second messenger to an effector molecule.</p></sec><sec id="sec4-vaccines-09-00917"><title>4. c-di-GMP and Analogs Generated to Date</title><p>While c-di-GMP can be isolated from bacterial cultures [<xref rid="B32-vaccines-09-00917" ref-type="bibr">32</xref>], this approach is very limited in the amount of accessible material. Furthermore, the generation of modified c-di-GMP via this approach is usually unfeasible. With this in mind, a number of methods have been described toward the synthesis of c-di-GMP and analogs, allowing for access to a relatively large amount of material for structural, bacterial, and immunological applications.</p><p>The vast majority of CDN analogs reported to date are based on phosphate or modified phosphate backbone in nature. To date, CDNs with all possible combinations of canonical nucleobases have been synthesized [<xref rid="B33-vaccines-09-00917" ref-type="bibr">33</xref>]. <xref ref-type="app" rid="app1-vaccines-09-00917">Figure S1</xref> summarizes the c-di-GMP analogs reported to date that feature modifications in nucleobases, various sugar residues (e.g., ribose, deoxyribose, and 2&#8242;-modified ribose), phosphate, and phosphorothioate. A selection of CDNs containing both 2&#8242;-5&#8242; and 3&#8242;-5&#8242; internucleoside phosphate/phosphorothioate linkages (<xref ref-type="app" rid="app1-vaccines-09-00917">Figure S2</xref>) have also been made available through chemical synthesis. Among the chemistry reported for the synthesis of c-di-GMP analogs, some features are of important consideration: versatility of the chemistry, ease to scale up the process, and to purify the final product. It is worth noting that c-di-GMP [<xref rid="B34-vaccines-09-00917" ref-type="bibr">34</xref>,<xref rid="B35-vaccines-09-00917" ref-type="bibr">35</xref>], c-di-araGMP and c-di-dGMP [<xref rid="B36-vaccines-09-00917" ref-type="bibr">36</xref>], and other analogs [<xref rid="B37-vaccines-09-00917" ref-type="bibr">37</xref>], 3&#8242;3&#8242;-cGAMP and 2&#8242;3&#8242;-cGAMP [<xref rid="B38-vaccines-09-00917" ref-type="bibr">38</xref>,<xref rid="B39-vaccines-09-00917" ref-type="bibr">39</xref>] and their analogs [<xref rid="B39-vaccines-09-00917" ref-type="bibr">39</xref>,<xref rid="B40-vaccines-09-00917" ref-type="bibr">40</xref>] have also been generated enzymatically.</p><p>Furthermore, CDN analogs where the phosphate backbone is replaced with bis-carbamate, amide, urea, thiourea, carbodiimide, and triazolyl have also been synthesized (<xref ref-type="app" rid="app1-vaccines-09-00917">Figure S3</xref>) to explore their applications in bacterial physiology. In addition, conjugates of c-di-GMP with other molecular entities (<xref ref-type="app" rid="app1-vaccines-09-00917">Figure S4</xref>) have also been synthesized to study biological processes involving this bacterial second messenger. These conjugates are particularly useful to visualize c-di-GMP when a fluorophore is covalently attached or to pull-down molecules that bind to c-di-GMP when biotin is conjugated to c-di-GMP.</p></sec><sec id="sec5-vaccines-09-00917"><title>5. Immunostimulatory Function of CDNs in Host Innate Immune Responses</title><p>It is now well established that CDNs activate innate immunity by directly binding to STING to induce the production of type I IFN and inflammatory cytokines via TANK-binding kinase 1 (TBK1) and interferon regulatory factor 3 (IRF3) pathway (<xref ref-type="fig" rid="vaccines-09-00917-f004">Figure 4</xref>) [<xref rid="B41-vaccines-09-00917" ref-type="bibr">41</xref>,<xref rid="B42-vaccines-09-00917" ref-type="bibr">42</xref>]. However, alternative pathways also exist. McFarland et al. have identified the oxidoreductase RECON as a cytosolic sensor for bacterial CDNs in modulating the inflammatory gene activation via its antagonistic effects on STING and nuclear factor kappa B (NF-&#954;B) [<xref rid="B43-vaccines-09-00917" ref-type="bibr">43</xref>]. In addition, it was reported that c-di-GMP could induce antigen-specific antibody and balanced T helper type 1 (Th1)/Th2/Th17 cell responses through a novel IFN-I-independent, STING-NF-&#954;B-tumour necrosis factor (TNF)-&#945; pathway, which is distinct from STING-mediated DNA adjuvant activity that requires IFN-I, but not TNF-&#945;, production [<xref rid="B44-vaccines-09-00917" ref-type="bibr">44</xref>]. The critical role of TNF-&#945; signalling in this pathway was confirmed in studies using TNFR1(&#8722;/&#8722;) mice. Moreover, Chang et al. have recently suggested A (2B) adenosine receptors in the intestinal epithelium as a potential pathway for extracellular CDNs to enter intracellular cytosols [<xref rid="B45-vaccines-09-00917" ref-type="bibr">45</xref>].</p><sec id="sec5dot1-vaccines-09-00917"><title>5.1. In Vitro Immunostimulatory Functions of CDNs</title><p>The in vitro immunostimulatory function of CDNs has been studied in cultured human and murine cells such as immature DCs and macrophages. These studies have identified DCs and macrophages as the major target cells of c-di-GMP and c-di-AMP. Analyses of DC subsets revealed conventional DCs as principal responders to c-di-AMP stimulation [<xref rid="B47-vaccines-09-00917" ref-type="bibr">47</xref>]. Both c-di-GMP and c-di-AMP were able to promote the activation and maturation of murine and human DCs [<xref rid="B48-vaccines-09-00917" ref-type="bibr">48</xref>,<xref rid="B49-vaccines-09-00917" ref-type="bibr">49</xref>] and induce the production of IFN-&#946; and interleukin (IL)-6, but not TNF, in RAW264.7 macrophage cells and mouse primary bone marrow-derived macrophages (BMDMs) [<xref rid="B50-vaccines-09-00917" ref-type="bibr">50</xref>]. In cultured human immature DCs, c-di-GMP upgraded the surface expression of costimulatory molecules CD80 and CD86, maturation marker CD83, and MHC class II. c-di-GMP treatment also altered the expression of chemokine receptors C-C Motif Chemokine Receptor 1 (CCR1), CCR7, and C-X-C Motif Chemokine Receptor 4 (CXCR4), and increased the production of IL-12, IFN-&#947;, IL-8, CC chemokine ligand 2 (CCL2), C-X-C motif chemokine ligand 10 (CXCL10), and CCL5 by DCs. Studies on M1- and M2-polarized THP-1 and murine BMDMs showed that both murine and human M1-polarized macrophages showed increased STING expression and treatment with a STING agonist (DMXAA) reprogramed M2 macrophages toward an M1-like subtype [<xref rid="B51-vaccines-09-00917" ref-type="bibr">51</xref>].</p><p>c-di-GMP-matured DCs showed enhanced T-cell stimulatory activity [<xref rid="B48-vaccines-09-00917" ref-type="bibr">48</xref>,<xref rid="B49-vaccines-09-00917" ref-type="bibr">49</xref>]. Stimulation of bone marrow-derived DCs (BMDCs) with CDNs induced marked metabolic products (nitric oxide and the cytokine BAFF) that are different from those induced by TLR ligands [<xref rid="B52-vaccines-09-00917" ref-type="bibr">52</xref>]. The BAFF production appears to be correlated with the improved (i.e., more rapid and persistent) antibody responses in both aged and young mice [<xref rid="B52-vaccines-09-00917" ref-type="bibr">52</xref>]. Recent studies have also shown that c-di-GMP differentiated lung monocyte-derived DCs (MoDCs) into Bcl6<sup>+</sup> mature MoDCs and promoted lung memory T helper cells through a process mediated by soluble TNF. MoDCs are essential for c-di-GMP-induced lung mucosal responses in this model and are responsible for lung IgA responses, but they are dispensable for vaccine-induced systemic immune responses [<xref rid="B53-vaccines-09-00917" ref-type="bibr">53</xref>]. In addition to type 1 IFN, physiologically relevant levels of c-di-AMP and c-di-GMP also stimulated a robust IL-1&#946; production in murine BMDMs by the activation of NLRP3 inflammasome through a unique pathway associated with the recognition of intracellular infections, but independent of the STING pathway [<xref rid="B54-vaccines-09-00917" ref-type="bibr">54</xref>].</p><p>CDNs (such as c-di-GMP) also synergized with B cell receptor signals to directly activate B cells and promote antibody responses in a STING-dependent manner [<xref rid="B55-vaccines-09-00917" ref-type="bibr">55</xref>]. Similarly, costimulation of T cells with cGAMP and TCR ligands induced IFN-I production and regulated the growth and function of T cells through the mTORC1 pathway [<xref rid="B56-vaccines-09-00917" ref-type="bibr">56</xref>]. Studies in unfractionated human peripheral blood mononuclear cell (PBMC) cultures have shown that both 2&#8242;3&#8242;-cGAMP and 3&#8242;3&#8242;-cGAMP were highly potent in driving the expansion and maturation of functional antitumor or antiviral antigen-specific CD8<sup>+</sup> T cells via the induction of type I IFNs [<xref rid="B57-vaccines-09-00917" ref-type="bibr">57</xref>,<xref rid="B58-vaccines-09-00917" ref-type="bibr">58</xref>,<xref rid="B59-vaccines-09-00917" ref-type="bibr">59</xref>]. 3&#8242;3&#8242;-cGAMP-primed HIV-1-specific CD8<sup>+</sup> T cells produced higher levels of perforin and granzyme B expressions than lipopolysaccharides (LPS)- or TLR7/8 agonist R848-primed ones and were more potent to suppress HIV-1 [<xref rid="B58-vaccines-09-00917" ref-type="bibr">58</xref>,<xref rid="B59-vaccines-09-00917" ref-type="bibr">59</xref>]. c-di-AMP and, to a lesser extent, c-di-GMP also played a divergent role in regulating <italic toggle="yes">Porphyromonas gingivalis</italic> LPS-induced cytokine responses in human gingival keratinocytes [<xref rid="B60-vaccines-09-00917" ref-type="bibr">60</xref>]. c-di-AMP treatment increased the extracellular MCP-1 and vascular endothelial growth factor (VEGF) levels and intracellular IL-1 receptor antagonist level and restored decreased extracellular IL-8 levels induced by LPS. In the presence of LPS, c-di-GMP increased extracellular VEGF level, whereas c-di-AMP suppressed intracellular IL-1&#946; levels [<xref rid="B60-vaccines-09-00917" ref-type="bibr">60</xref>].</p></sec><sec id="sec5dot2-vaccines-09-00917"><title>5.2. In Vivo Immunostimulatory Functions of CDNs</title><p>In corroboration with the in vitro results, experimental studies in animal models have confirmed the immunostimulatory function of CDNs in inducing host innate immune responses and enhancing the adaptive immune responses. Systemic (intraperitoneal, i.p.) or mucosal (intranasal, i.n.) administration of mice with c-di-GMP induced an acute and transient local recruitment of inflammatory cells (neutrophils and macrophages) and activation of DCs [<xref rid="B48-vaccines-09-00917" ref-type="bibr">48</xref>,<xref rid="B61-vaccines-09-00917" ref-type="bibr">61</xref>,<xref rid="B62-vaccines-09-00917" ref-type="bibr">62</xref>,<xref rid="B63-vaccines-09-00917" ref-type="bibr">63</xref>]. Intranasal c-di-GMP administration also induced the production of chemokines CXCL1, CCL2, CCL3, CXCL2, and CCL5 [<xref rid="B63-vaccines-09-00917" ref-type="bibr">63</xref>]. Similarly, systemic or local administration of cGAMP induced high levels of type I IFNs in mice but minimal inflammatory gene expression [<xref rid="B64-vaccines-09-00917" ref-type="bibr">64</xref>]. Intranasal administration of c-di-GMP in mice greatly enhanced the antigen uptake by CD11c<sup>+</sup> cells through both pinocytosis and receptor-mediated endocytosis, which was dependent on the increased STING expression [<xref rid="B65-vaccines-09-00917" ref-type="bibr">65</xref>]. In this regard, c-di-GMP selectively activated DCs with high pinocytosis efficiency and induced the production of IL-12p70, IFN&#947;, IL-5, IL-13, IL-23, IFN&#955;, and IL-6, but interestingly not IFN&#946; production, in this model [<xref rid="B65-vaccines-09-00917" ref-type="bibr">65</xref>].</p><p>The immunostimulatory properties of CDNs have been explored for their potential as novel immunotherapeutics for the treatment of infections, cancer, and other immunological disorders. Intranasal, subcutaneous (s.c.), intramuscular (i.m.), i.p., and intramammary administration with CDNs induced robust innate immune responses and enhanced host resistance against infection with a wide range of pathogenic bacteria, such as <italic toggle="yes">Bordetella pertussis</italic>, <italic toggle="yes">Acinetobacter baumannii</italic>, <italic toggle="yes">Staphylococcus aureus</italic>, <italic toggle="yes">Klebsiella pneumoniae</italic>, <italic toggle="yes">Clostridium perfringens</italic>, and various serotypes of <italic toggle="yes">Streptococcus pneumoniae</italic> [<xref rid="B48-vaccines-09-00917" ref-type="bibr">48</xref>,<xref rid="B62-vaccines-09-00917" ref-type="bibr">62</xref>,<xref rid="B63-vaccines-09-00917" ref-type="bibr">63</xref>,<xref rid="B66-vaccines-09-00917" ref-type="bibr">66</xref>,<xref rid="B67-vaccines-09-00917" ref-type="bibr">67</xref>,<xref rid="B68-vaccines-09-00917" ref-type="bibr">68</xref>]. Depletion of neutrophils abolished the protective role of c-di-GMP in the mouse model of <italic toggle="yes">Acinetobacter</italic> pneumonia, underscoring the importance of neutrophils as the critical effector cell in c-di-GMP-induced protection [<xref rid="B63-vaccines-09-00917" ref-type="bibr">63</xref>]. In addition, studies in a chicken model of <italic toggle="yes">C. perfringens</italic> infection have shown the promise of CDNs as an alternative to antibiotics without increasing the selection pressure for some &#946;-lactamase genes or altering the commensal bacterial population [<xref rid="B67-vaccines-09-00917" ref-type="bibr">67</xref>].</p><p>Recent studies have shown that systemic treatment of mice with cGAMP inhibited the replication of genital herpes simplex virus (HSV) 2 and improved the clinical outcome of infection [<xref rid="B64-vaccines-09-00917" ref-type="bibr">64</xref>]. More importantly, direct application of CDNs, but not TLR agonists, on the genital epithelial surface increased local IFN activity and conferred total protection against disease even in immunocompromised mice without causing overt systemic responses [<xref rid="B64-vaccines-09-00917" ref-type="bibr">64</xref>]. Moreover, therapeutic administration of encapsulated-cGAMP microparticles (MPs), but not soluble cGAMP, protected mice from the development and relapse of experimental allergic encephalomyelitis in an IFN-I-dependent and -independent mechanism, and the therapeutic outcome was more effective than recombinant IFN-&#946; [<xref rid="B69-vaccines-09-00917" ref-type="bibr">69</xref>]. In this regard, in vitro studies of PBMCs from relapsing-remitting multiple sclerosis patients showed that cGAMP MPs promoted both IFN-I and the immunoregulatory cytokines IL-27 and IL-10 responses [<xref rid="B69-vaccines-09-00917" ref-type="bibr">69</xref>].</p><p>The identification of the critical contribution of STING to antitumor immunity has generated a great enthusiasm to explore the intratumoral administration of STING agonists as standalone cancer immunotherapy or in combination with other cancer immunotherapeutic modalities such as immune checkpoint inhibitors and chimeric antigen receptor (CAR)-T-cell immunotherapies to enhance their efficacy (<xref ref-type="fig" rid="vaccines-09-00917-f005">Figure 5</xref>). Immunologically, intratumoral injection of mice with various soluble or encapsulated synthetic and natural CDNs (such as RR-CDG, the <italic toggle="yes">R</italic>,<italic toggle="yes">R</italic>-stereoisomer of the phosphorothioate analog c-di-GMP-S2 or RR-c-di-GMP-S2; RR-cyclic-di-guanine (CDG), <italic toggle="yes">R</italic>(P),R(P) dithio-c-di-GMP, ADU-S100, the <italic toggle="yes">R</italic>,<italic toggle="yes">R</italic>-stereoisomer of the phorphorothioate analog 2&#8242;3&#8242;-cAAMP-S2 or RR-2&#8242;3&#8242;-cAAMP or RR-CDA; c-di-GMP, and cGAMP-NPs) induced enhanced type I IFN signalling, potent local inflammatory responses (DCs, macrophages, NK cells, and CXCL10 and CCL5 responses), reprograming of macrophages from protumorigenic M2-like type toward M1-like type, and the activation of adaptive immunity (CD4 and CD8 T cells, and T-cell migration) to increase tumour immunogenicity [<xref rid="B70-vaccines-09-00917" ref-type="bibr">70</xref>,<xref rid="B71-vaccines-09-00917" ref-type="bibr">71</xref>,<xref rid="B72-vaccines-09-00917" ref-type="bibr">72</xref>,<xref rid="B73-vaccines-09-00917" ref-type="bibr">73</xref>,<xref rid="B74-vaccines-09-00917" ref-type="bibr">74</xref>,<xref rid="B75-vaccines-09-00917" ref-type="bibr">75</xref>,<xref rid="B76-vaccines-09-00917" ref-type="bibr">76</xref>]. As a result, the treatment reprogramed the tumor microenvironment toward a more immunogenic antitumor milieu and induced profound regression and necrosis of established tumours. In many cases, the treatment-induced substantial and durable systemic tumour-specific Th1 adaptive immunity is capable of rejecting distant metastases and providing long-lived immunologic memory [<xref rid="B72-vaccines-09-00917" ref-type="bibr">72</xref>,<xref rid="B73-vaccines-09-00917" ref-type="bibr">73</xref>,<xref rid="B74-vaccines-09-00917" ref-type="bibr">74</xref>,<xref rid="B76-vaccines-09-00917" ref-type="bibr">76</xref>]. The intratumoral CDN treatment also increased the response rate to T-cell receptor activation by checkpoint-modulating antibodies to CTLA-4, PD-1, 4-1BB, and OX40, resulting in significant increases in median survival time in animal models of melanoma (B16-F10 and YUMM1.7), breast adenocarcinoma (E0771), prostate cancer (TRAMP-C2), head and neck squamous cell cancers (SCCFVII) [<xref rid="B72-vaccines-09-00917" ref-type="bibr">72</xref>,<xref rid="B73-vaccines-09-00917" ref-type="bibr">73</xref>], HER-2<sup>+</sup> breast tumours [<xref rid="B76-vaccines-09-00917" ref-type="bibr">76</xref>], glioblastoma multiforme [<xref rid="B77-vaccines-09-00917" ref-type="bibr">77</xref>], glioma [<xref rid="B70-vaccines-09-00917" ref-type="bibr">70</xref>], neuroblastoma [<xref rid="B75-vaccines-09-00917" ref-type="bibr">75</xref>], and 4T1 breast tumour [<xref rid="B72-vaccines-09-00917" ref-type="bibr">72</xref>,<xref rid="B74-vaccines-09-00917" ref-type="bibr">74</xref>,<xref rid="B78-vaccines-09-00917" ref-type="bibr">78</xref>,<xref rid="B79-vaccines-09-00917" ref-type="bibr">79</xref>,<xref rid="B80-vaccines-09-00917" ref-type="bibr">80</xref>,<xref rid="B81-vaccines-09-00917" ref-type="bibr">81</xref>]. In this regard, a single dose of cGAMP-liposomal nanoparticles (cGAMP-NP) was sufficient to modulate the tumour microenvironment for effective control of programmed death-ligand 1 (PD-L1)-insensitive basal-like triple-negative breast cancer and melanoma and, more significantly, prevented the formation of secondary tumours in mice [<xref rid="B82-vaccines-09-00917" ref-type="bibr">82</xref>]. Moreover, coadministration of c-di-GMP with implantable biopolymer devices to deliver CAR T cells directly to the surfaces of solid tumours improved the effectiveness of CAR T-cell therapy and protected against the emergence of escape variants in immunocompetent orthotopic mouse models of pancreatic cancer and melanoma [<xref rid="B83-vaccines-09-00917" ref-type="bibr">83</xref>].</p><p>Studies in mouse models of breast cancer have shown that intratumoral administration of ADU-S100 (an analog of c-di-AMP) alone was able to induce durable tumour clearance in 100% of parental FVB/N mice that are able to mount potent immune responses to the implanted neu-positive tumour cells, but the treatment only resulted in tumour clearance in 10% of the FVB/N-derived neu/N transgenic mice that have well-established peripheral immune tolerance to the endogenous neu antigen [<xref rid="B76-vaccines-09-00917" ref-type="bibr">76</xref>,<xref rid="B81-vaccines-09-00917" ref-type="bibr">81</xref>]. Coadministration of ADU-S100 with anti-PD-L1 and anti-OX40 antibodies significantly enhanced the clearance rate to 40% of neu/N mice and also induced abscopal immunity [<xref rid="B76-vaccines-09-00917" ref-type="bibr">76</xref>,<xref rid="B81-vaccines-09-00917" ref-type="bibr">81</xref>]. The efficacy of combination treatment was well correlated with globally enhanced ratios of CD8<sup>+</sup> T cells to regulatory T cells, macrophages, and myeloid-derived suppressor cells, and downregulation of the M2 marker CD206 on tumour-associated macrophages in this model [<xref rid="B81-vaccines-09-00917" ref-type="bibr">81</xref>]. Unfortunately, ADU-S100 failed to demonstrate sufficient clinical benefit in clinical trials.</p><p>CDNs have also been used with other immunomodulators, such as CpG oligonucleotides (ODN) and monophosphoryl lipid A (MPLA), for cancer immunotherapy [<xref rid="B85-vaccines-09-00917" ref-type="bibr">85</xref>,<xref rid="B86-vaccines-09-00917" ref-type="bibr">86</xref>]. Systemic delivery of c-di-GMP/MPLA-encapsulated immuno-nanoparticles induced extensive upregulation of antigen-presenting cells (APCs) and NK cells in the blood and tumour tissue and resulted in significant therapeutic benefit in a mouse model of metastatic triple-negative breast cancer [<xref rid="B85-vaccines-09-00917" ref-type="bibr">85</xref>]. Compared with single treatments, intratumoral injection of both CpG ODN and cGAMP significantly reduced tumour size in mouse models of lymphoma and melanoma [<xref rid="B86-vaccines-09-00917" ref-type="bibr">86</xref>].</p><p>Although the precise events induced by CDNs in the tumour microenvironment remain to be determined, mechanistic studies using knockout and bone marrow chimeric mice suggest that both stromal and immune cells (bone marrow-derived TNF&#945;) and their crosstalk are essential to achieve CDN-induced tumour regression and clearance [<xref rid="B87-vaccines-09-00917" ref-type="bibr">87</xref>]. In this regard, cGAMP-induced STING activation promoted the polarization of tumour-associated macrophages into proinflammatory subtypes in spontaneous gastric cancer in p53(+/&#8722;) mice and cell line-based xenografts and induced apoptosis of gastric cancer cells through IL-6R-Janus kinase (JAK)-IL-24 pathway [<xref rid="B88-vaccines-09-00917" ref-type="bibr">88</xref>]. The potential role of macrophages in the CDN-induced antitumor activities has also been analyzed in detail. Intratumoral injection of cGAMP induced the transient accumulation of macrophages in the tumor tissue in mouse models of 4T1 breast cancer, squamous cell carcinomas, CT26 colon cancer, and B16F10 melanoma. Clodronate liposome-mediated macrophage depletion impaired the antitumor effect of cGAMP treatment [<xref rid="B89-vaccines-09-00917" ref-type="bibr">89</xref>]. It has also been reported that c-di-AMP-induced NK cell-mediated tumor rejection involved type I IFN-mediated activation of NK cells and the enhanced expression of IL-15 and IL-15 receptors [<xref rid="B90-vaccines-09-00917" ref-type="bibr">90</xref>].</p></sec></sec><sec id="sec6-vaccines-09-00917"><title>6. CDNs as Potent Vaccine Adjuvants for Systemic and Mucosal Immunization</title><p>The potential adjuvant function of CDNs was first demonstrated in mice with model antigens beta-galactosidase (beta-Gal) and ovalbumin (Ova). Subcutaneous immunization with c-di-GMP or c-di-AMP and beta-Gal or Ova elicited potent antigen-specific serum IgG titers, a balanced Th1/Th2 response, and strong in vivo cytotoxic T lymphocyte (CTL) responses (i.e., 30&#8211;60% of antigen-specific lysis) [<xref rid="B91-vaccines-09-00917" ref-type="bibr">91</xref>]. When immunized by mucosal routes (i.n. or sublingual), these vaccines also induced specific secretory IgA responses in multiple mucosal sites (such as lung and vagina) [<xref rid="B49-vaccines-09-00917" ref-type="bibr">49</xref>,<xref rid="B92-vaccines-09-00917" ref-type="bibr">92</xref>]. Similar results were also observed when bis-(3&#8242;,5&#8242;)-cyclic dimeric inosine monophosphate (c-di-IMP) or cGAMP was used [<xref rid="B93-vaccines-09-00917" ref-type="bibr">93</xref>,<xref rid="B94-vaccines-09-00917" ref-type="bibr">94</xref>].</p><p>Compared to other licensed and experimental adjuvants such as LPS, CpG ODN, and aluminum salt, c-di-GMP appears to be more potent in inducing both humoral and Th1 immune responses (higher IgG2a, IFN-&#947;, TNF-&#945;, and CXCL10 responses) in mice and in non-human primate PBMC cultures [<xref rid="B95-vaccines-09-00917" ref-type="bibr">95</xref>]. Mice immunized with c-di-GMP also showed a more predominant germinal centre formation, indicative of long-term memory, than the mice immunized with LPS or CpG [<xref rid="B95-vaccines-09-00917" ref-type="bibr">95</xref>]. Similarly, recent studies have shown that s.c. immunization of mice with c-di-AMP and Ova resulted in significantly higher levels of Ova-specific IgG and stronger Th1 and IFN&#947;-producing CD8<sup>+</sup> memory T-cell response than the mice immunized with poly(I:C)/CpG and Ova [<xref rid="B96-vaccines-09-00917" ref-type="bibr">96</xref>].</p><p>The potency and immune profiles induced by different CDNs and their derivatives have not been systemically compared in a head-to-head manner. Overall, it appears that all CDNs are capable of stimulating the host&#8217;s innate immune responses but often with subtle differences. Based on the antigen-specific IgG1 to IgG2a ratio and cytokine response profiles, earlier studies suggest that c-di-GMP induces a dominant Th1 response, cGAMP induces a balanced Th1/Th2 response, whereas c-di-AMP and c-di-IMP promotes a balanced Th1/Th2/Th17 response [<xref rid="B49-vaccines-09-00917" ref-type="bibr">49</xref>,<xref rid="B92-vaccines-09-00917" ref-type="bibr">92</xref>,<xref rid="B93-vaccines-09-00917" ref-type="bibr">93</xref>,<xref rid="B94-vaccines-09-00917" ref-type="bibr">94</xref>]. In murine BMDCs and human DCs, it has also been shown that cGAMP induced fewer IL-17 responses than c-di-AMP [<xref rid="B94-vaccines-09-00917" ref-type="bibr">94</xref>], but 3&#8242;3&#8242;-cGAMP stimulated stronger IFN gene activation than c-di-GMP [<xref rid="B97-vaccines-09-00917" ref-type="bibr">97</xref>]. Molecular dynamics simulation analysis showed that human STING binds more strongly to 3&#8242;3&#8242;-cGAMP than to c-di-GMP [<xref rid="B98-vaccines-09-00917" ref-type="bibr">98</xref>], although CDN derivatives capable of activating all human STING alleles and murine STING have been successfully synthesized [<xref rid="B71-vaccines-09-00917" ref-type="bibr">71</xref>]. In addition, Yan et al. have chemically synthesized several c-di-GMP analogs (mono- and bisphosphorothioate (c-di-GMP-S1 and -S2)) and the 2&#8242;-fluoro analog of c-di-GMP (2&#8242;-F-c-di-GMP) and compared their immunostimulatory properties in mice. Although the innate immune responses induced by these analogs were generally comparable to those induced by the parental c-di-GMP [<xref rid="B99-vaccines-09-00917" ref-type="bibr">99</xref>,<xref rid="B100-vaccines-09-00917" ref-type="bibr">100</xref>], the pulmonary inflammatory responses (neutrophils and chemokine CXCL1, CCL4, and CCL5) induced by the two phosphorothioate analogs (S1 and S2), particularly the c-di-GMP-S1, were much milder than the parent c-di-GMP [<xref rid="B99-vaccines-09-00917" ref-type="bibr">99</xref>]. On the other hand, 2&#8242;-F-c-di-GMP was effective when administered orally [<xref rid="B100-vaccines-09-00917" ref-type="bibr">100</xref>].</p><sec id="sec6dot1-vaccines-09-00917"><title>6.1. CDNs as Adjuvants for the Development of Vaccines against Infectious Diseases</title><p>The potential of CDNs as effective vaccine adjuvants for systemic and mucosal immunization against infectious diseases was first demonstrated in the development of vaccines against pneumococcal and <italic toggle="yes">S. aureus</italic> infections [<xref rid="B48-vaccines-09-00917" ref-type="bibr">48</xref>,<xref rid="B62-vaccines-09-00917" ref-type="bibr">62</xref>]. Intraperitoneal immunization of mice with c-di-GMP and pneumolysin toxoid (PdB) or pneumococcal surface protein A (PspA) induced significantly higher antigen-specific antibody responses and increased survival of mice after <italic toggle="yes">S. pneumoniae</italic> challenges, as compared to alum adjuvant [<xref rid="B62-vaccines-09-00917" ref-type="bibr">62</xref>]. Moreover, i.n. immunization of mice with pneumococcal surface adhesion A (PsaA) and c-di-GMP elicited strong antigen-specific serum IgG and secretory IgA responses at multiple mucosal surfaces and significantly reduced nasopharyngeal <italic toggle="yes">S. pneumoniae</italic> colonization in the immunized mice [<xref rid="B61-vaccines-09-00917" ref-type="bibr">61</xref>]. This study provided the first evidence of c-di-GMP as an effective mucosal adjuvant to induce protective immunity against mucosal bacterial infection. It appears that, in mice, c-di-GMP induces stronger immune responses and better protection against <italic toggle="yes">S. pneumoniae</italic> challenge than cGAMP-adjuvanted vaccine [<xref rid="B65-vaccines-09-00917" ref-type="bibr">65</xref>].</p><p>Many groups have subsequently explored the possibility of CDNs to improve the vaccine-induced immune profiles and the duration of immunity against a number of bacterial infections of human and veterinary importance (<xref rid="vaccines-09-00917-t001" ref-type="table">Table 1</xref>). Tuberculosis (TB), caused by <italic toggle="yes">Mycobacterium tuberculosis</italic>, remains a significant public health threat in many regions. <italic toggle="yes">Bacillus Calmette-Guerin</italic> (BCG), the live attenuated TB vaccine developed more than a century ago, is the most commonly used vaccine worldwide. However, BCG has varied protective efficiency in adults and safety concerns in the immunocompromised population. Several laboratories have attempted to use CDNs to enhance the current BCG vaccines or develop new, safe and effective subunit TB vaccines. Early efforts to introduce the c-di-GMP phosphodiesterase gene Rv1357c into BCG Pasteur failed to provide better protection against <italic toggle="yes">M. tuberculosis</italic> challenge than conventional BCG in mice [<xref rid="B101-vaccines-09-00917" ref-type="bibr">101</xref>]. Vaccination with another modified BCG strain (BCG&#916;BCG1419c) lacking the c-di-GMP phosphodiesterase gene BCG1419c induced a better activation of specific T lymphocytes, moderate protection, and improved resistance to infection reactivation in mice, as compared to vaccination with the conventional BCG vaccine [<xref rid="B102-vaccines-09-00917" ref-type="bibr">102</xref>]. Two groups have independently generated two recombinant BCG vaccines (rBCG-DisA), which overexpress the endogenous mycobacterial diadenylate cyclase (DisA) gene and produce high levels of c-di-AMP. Compared to conventional BCG vaccines, both rBCG-DisA vaccine candidates induced stronger immune responses, but one failed to provide additional protection against <italic toggle="yes">M. tuberculosis</italic> infection in mice [<xref rid="B103-vaccines-09-00917" ref-type="bibr">103</xref>], whereas the other showed significantly reduced lung weights, pathology scores, and <italic toggle="yes">M. tuberculosis</italic> burdens in guinea pigs [<xref rid="B104-vaccines-09-00917" ref-type="bibr">104</xref>].</p><p>When the CDN is used as an adjuvant for subunit TB vaccines, it enhances antigen-specific Th1 responses and elicits long-lasting protective immunity to <italic toggle="yes">M. tuberculosis</italic>. Immunization of mice with recombinant Rv3852 (H-NS) and cGAMP resulted in an enhanced antigen-specific IL-2 response by splenic lymphocytes, high serum levels of IL-2, IL-12p40, and TNF-&#945;, and better protective efficacy (reduced bacterial counts in the spleen, but not in the lung) in mice challenged with <italic toggle="yes">M. tuberculosis</italic> H37Rv [<xref rid="B133-vaccines-09-00917" ref-type="bibr">133</xref>]. Similarly, s.c. immunization of a subunit TB vaccine consisting of a five <italic toggle="yes">M. tuberculosis</italic> antigen (antigen-85B, ESAT-6, Rv1733c, Rv2626c, and RpfD) fusion protein and a synthetic CDN (RR-CDG) induced protection equivalent to that induced by BCG vaccine. Interestingly, the protection in this study was STING-dependent but type I IFN-independent and correlated with an increased frequency of a subset of CXCR3-expressing T cells in the lung tissue. More significantly, i.n. immunization of this vaccine candidate induced protection superior to that induced by the BCG vaccine and elicited both Th1 and Th17 immune responses, the latter of which was correlated with enhanced protection [<xref rid="B139-vaccines-09-00917" ref-type="bibr">139</xref>]. On the other hand, i.n. immunization of mice with ESAT-6 and c-di-AMP failed to reduce the bacterial burdens after an i.v. challenge as compared to the mice immunized with ESTA-6 alone [<xref rid="B119-vaccines-09-00917" ref-type="bibr">119</xref>].</p><p>Failure to induce potent Th1 immune responses and long-term immunity and protect against nasal colonization and transmission of <italic toggle="yes">Bordetella pertussis</italic> by the current acellular pertussis (aP) vaccines have contributed to the recent global resurgence of pertussis (whooping cough). Intranasal immunization of mice with an experimental aP vaccine formulated with c-di-GMP and LP1569, a TLR2 agonist from <italic toggle="yes">B. pertussis</italic> (LP-GMP), induced potent antigen-specific Th1 and Th17 responses and conferred long-lasting protection (for 10 months) against nasal colonization and lung infection with <italic toggle="yes">B. pertussis</italic> [<xref rid="B111-vaccines-09-00917" ref-type="bibr">111</xref>]. The long-term protection against nasal colonization was correlated to IL-17-secreting respiratory tissue-resident memory CD4 T cells. Others have studied the adjuvant activity of cGAMP for parenteral and mucosal immunization with recombinant <italic toggle="yes">Helicobacter pylori</italic> urease A, urease B, and neutrophil-activating protein [<xref rid="B132-vaccines-09-00917" ref-type="bibr">132</xref>]. The gastric mucosal <italic toggle="yes">H. pylori</italic> colonization was significantly reduced in mice immunized by i.n. and, to a lesser degree, s.c. route, but not by the i.m. route. The protection efficacy appeared to be associated with the level of antigen-specific Th1 and particularly Th17 responses [<xref rid="B132-vaccines-09-00917" ref-type="bibr">132</xref>]. Moreover, Li et al. have demonstrated the potential of 2&#8242;-Fluoro-c-di-GMP as an oral vaccine adjuvant. Oral immunization of mice with <italic toggle="yes">H. pylori</italic> cell-free sonicate extract or flagellin proteins from <italic toggle="yes">C. difficile</italic> and <italic toggle="yes">Listeria monocytogenes</italic> in combination with 2&#8242;-Fluoro-c-di-GMP induced antigen-specific serum IgG and mucosal IgA responses and showed a significant reduction in the gastric bacterial colonization when mice were orally challenged with <italic toggle="yes">H. pylori</italic> [<xref rid="B100-vaccines-09-00917" ref-type="bibr">100</xref>].</p><p>The adjuvant function of CDNs has also been demonstrated in experimental vaccines against other bacterial and parasitic infections, including bacteria of antimicrobial resistance and biodefense significance. Subcutaneous immunization of mice with c-di-GMP and <italic toggle="yes">S. aureus</italic> antigen, clumping factor A (ClfA), or a nontoxic mutant staphylococcal enterotoxin C (mSEC) significantly reduced the bacterial burdens in the spleen and liver and improved the day 7 survival rates (87.5%) than those of the non-immunized mice (33.3%) after i.v., challenge with methicillin-resistant <italic toggle="yes">S. aureus</italic> [<xref rid="B48-vaccines-09-00917" ref-type="bibr">48</xref>,<xref rid="B112-vaccines-09-00917" ref-type="bibr">112</xref>]. Similarly, sublingual immunization of mice with <italic toggle="yes">Bacillus anthracis</italic> protective antigen (PA) and 3&#8242;3&#8242;-cGAMP induced comparable levels of PA-specific serum IgG and saliva IgA responses to those induced after immunization with PA and cholera toxin (CT), the golden standard mucosal adjuvant [<xref rid="B138-vaccines-09-00917" ref-type="bibr">138</xref>]. A single dose immunization with F1-V antigens of <italic toggle="yes">Yersinia pestis</italic> and RR-CDG induced 95% protection against a lethal challenge with <italic toggle="yes">Y. pestis</italic> CO92 within 14 days post-immunization [<xref rid="B140-vaccines-09-00917" ref-type="bibr">140</xref>]. Encapsulation of F1-V within nanoparticles further improved the efficacy and duration of the protection at a high challenge dose (&#8805;7000 colony-forming units) in that 75% of immunized mice were protected from challenge at 182 days post-immunization [<xref rid="B140-vaccines-09-00917" ref-type="bibr">140</xref>]. Others have shown that the combination of the lipopeptide-based nano carrier system with c-di-AMP significantly reduced the antigen dose of a peptide vaccine and protected mice against a respiratory challenge with a lethal dose of a heterologous <italic toggle="yes">S. pyogenes</italic> strain [<xref rid="B120-vaccines-09-00917" ref-type="bibr">120</xref>]. Moreover, immunization of mice with several different recombinant antigens (a chimeric antigen Traspain, Tc52 or its N- and C-terminal domains) of <italic toggle="yes">Trypanosoma cruzi</italic> and c-di-AMP induced stronger protection against infection with higher survival rates, lower parasitemia, and reduced weight loss and chronic inflammation, compared to those immunized with other adjuvants [<xref rid="B123-vaccines-09-00917" ref-type="bibr">123</xref>,<xref rid="B124-vaccines-09-00917" ref-type="bibr">124</xref>,<xref rid="B125-vaccines-09-00917" ref-type="bibr">125</xref>]. Finally, c-di-GMP has also been explored for the development of live attenuated vaccines against salmonellosis (&#916;XIII) [<xref rid="B141-vaccines-09-00917" ref-type="bibr">141</xref>,<xref rid="B142-vaccines-09-00917" ref-type="bibr">142</xref>] and mycoplasmal infections [<xref rid="B126-vaccines-09-00917" ref-type="bibr">126</xref>]. Under these circumstances, the CDNs were either overexpressed in the live attenuated vaccine or delivered together with cationic liposomes [<xref rid="B126-vaccines-09-00917" ref-type="bibr">126</xref>].</p><p>The promise of CDNs as systemic and mucosal adjuvants for influenza vaccines has been extensively studied with different influenza vaccines and antigens, including hemagglutinin (HA), neuraminidase (NA), matrix protein 2 ectodomain (M2e), and inactivated viruses. Overall, these studies have demonstrated CDNs as effective adjuvants by promoting potent, long-lasting mucosal and systemic humoral (IgA, IgG, IgG isotypes, and hemagglutination inhibition (HI) titers) and cellular immune responses (high frequencies of virus-specific polyfunctional CD4<sup>+</sup> T cells producing one or more Th1 cytokines (IFN-&#947;, IL-2, TNF-&#945;), and protection against challenges with homologous and heterologous viral strains (H1N1, H5N1, H3N2, H5N1, H7N9, and H9N2) in mice and ferrets [<xref rid="B105-vaccines-09-00917" ref-type="bibr">105</xref>,<xref rid="B106-vaccines-09-00917" ref-type="bibr">106</xref>,<xref rid="B107-vaccines-09-00917" ref-type="bibr">107</xref>,<xref rid="B108-vaccines-09-00917" ref-type="bibr">108</xref>,<xref rid="B109-vaccines-09-00917" ref-type="bibr">109</xref>,<xref rid="B117-vaccines-09-00917" ref-type="bibr">117</xref>,<xref rid="B118-vaccines-09-00917" ref-type="bibr">118</xref>,<xref rid="B127-vaccines-09-00917" ref-type="bibr">127</xref>].</p><p>Several studies have shown that the combination of CDNs with other adjuvants and vaccine delivery systems (such as chitosan, silica nanoparticle, acetylated dextran microparticles, and microneedle) further enhanced the immunogenicity, dose-sparing, and cross-clade protection of the experimental or licensed influenza vaccines [<xref rid="B107-vaccines-09-00917" ref-type="bibr">107</xref>,<xref rid="B108-vaccines-09-00917" ref-type="bibr">108</xref>,<xref rid="B110-vaccines-09-00917" ref-type="bibr">110</xref>,<xref rid="B117-vaccines-09-00917" ref-type="bibr">117</xref>,<xref rid="B127-vaccines-09-00917" ref-type="bibr">127</xref>,<xref rid="B137-vaccines-09-00917" ref-type="bibr">137</xref>]. In this regard, formulation of an H1N1 vaccine with pulmonary surfactant-biomimetic liposomes encapsulating cGAMP elicited cross-protection against distant H1N1 and heterosubtypic H3N2, H5N1, and H7N9 viruses for at least 6 months [<xref rid="B130-vaccines-09-00917" ref-type="bibr">130</xref>]. Similarly, immunization of mice with cGAMP-adjuvanted inactivated H7N9 vaccine also provided effective cross-protection against H1N1, H3N2, and H9N2 influenza viruses, induced significantly higher nucleoprotein-specific CD4<sup>+</sup> and CD8<sup>+</sup> T-cell responses in immunized mice and upregulated the IFN-&#947; and granzyme B expression in the lung tissue of mice in the early stages post a heterosubtypic virus challenge [<xref rid="B127-vaccines-09-00917" ref-type="bibr">127</xref>]. The adjuvant effect and safety of cGAMP were further confirmed in a pig model of intradermal immunization with the H5N1 influenza vaccine [<xref rid="B129-vaccines-09-00917" ref-type="bibr">129</xref>]. The extensive studies of CDNs in influenza vaccine development have also demonstrated the broad application of CDNs in multiple animal species (mice, rats, guinea pigs, ferrets, cattle, pigs, and chickens) by different immunization routes (i.n., i.m. intratracheal, intradermal, and sublingual).</p><p>However, whether CDNs can effectively enhance specific immune responses in aged or newborns remains to be determined [<xref rid="B131-vaccines-09-00917" ref-type="bibr">131</xref>,<xref rid="B136-vaccines-09-00917" ref-type="bibr">136</xref>]. Borriello et al. found that although cGAMP induced a comparable expression of surface maturation markers in newborn and adult BMDCs, cGAMP adjuvantation alone failed to increase HA-specific antibody responses in newborn mice [<xref rid="B136-vaccines-09-00917" ref-type="bibr">136</xref>]. However, immunization of puppies with cGAMP formulated with alum (Alhydrogel)-adjuvanted trivalent recombinant HA influenza vaccine (Flublok) significantly enhanced HA-specific IgG2a/c titers by six weeks of age [<xref rid="B136-vaccines-09-00917" ref-type="bibr">136</xref>]. Immunization with cGAMP+alum also enhanced IFN&#947; production by CD4<sup>+</sup> T cells and increased both the absolute numbers and percentages of CD4<sup>+</sup>CXCR5<sup>+</sup>PD-1<sup>+</sup> T follicular helper cells and GL-7<sup>+</sup>CD138<sup>+</sup> germinal centre B cells. Similarly, immunization of an H1N1 influenza vaccine with cGAMP and saponin (Quil-A) significantly improved the survival (by 80&#8211;100%) of vaccinated 20-month-old mice, whereas cGAMP alone showed no significant improvement [<xref rid="B143-vaccines-09-00917" ref-type="bibr">143</xref>]. In this regard, recent studies found that targeting MoDCs with TNF fusion proteins restored the c-di-GMP adjuvantivity in aged mice [<xref rid="B144-vaccines-09-00917" ref-type="bibr">144</xref>].</p><p>The adjuvant activity of CDNs has also been demonstrated in vaccines against other viral infections, such as hepatitis B surface antigen (cGAMP) [<xref rid="B135-vaccines-09-00917" ref-type="bibr">135</xref>], HCV rE1E2 (c-di-AMP and archaeosomes) [<xref rid="B121-vaccines-09-00917" ref-type="bibr">121</xref>], HIV-1 reverse transcriptase (c-di-GMP) [<xref rid="B113-vaccines-09-00917" ref-type="bibr">113</xref>], mutant human papillomavirus (HPV) 16 E7 (E7GRG) protein (cGAMP and CpG-C ODN) [<xref rid="B134-vaccines-09-00917" ref-type="bibr">134</xref>], and foot and mouth disease vaccines in cattle and pigs [<xref rid="B114-vaccines-09-00917" ref-type="bibr">114</xref>]. In this regard, therapeutic immunization of female C57BL/6 mice with E7GRG formulated with cGAMP and CpG-C ODN induced significantly suppressed TC-1 tumour growth in mice [<xref rid="B134-vaccines-09-00917" ref-type="bibr">134</xref>].</p></sec><sec id="sec6dot2-vaccines-09-00917"><title>6.2. CDNs as Adjuvants for the Development of Cancer Vaccines</title><p>The potential of CDNs in the development of vaccines against chronic, non-communicable diseases, particularly cancer, has also been investigated. It has been well recognized that effective therapeutic cancer vaccines require potent adjuvants to induce robust type I IFN and proinflammatory cytokine responses in the tumour microenvironment. CDNs, such as c-di-GMP, c-di-AMP, and cGAMP, are excellent adjuvants for the development of cancer vaccines because they have the potential to provide &#8220;two punches&#8221; to eliminate the tumour: activating immunogenic tumour cell death directly and inducing type 1 IFN production to enhance tumour-specific Th1 and CTL responses (<xref ref-type="fig" rid="vaccines-09-00917-f005">Figure 5</xref>). Targeting both pathways is likely to result in a nearly complete local tumour regression and elimination of metastases [<xref rid="B145-vaccines-09-00917" ref-type="bibr">145</xref>]. Despite these rationales, relatively few studies have evaluated CDNs as a cancer vaccine adjuvant. This is perhaps due to the limited numbers of tumour-specific or associated antigens identified and available for cancer vaccine development. Chandra et al. reported that therapeutic immunization of metastatic breast cancer-bearing mice (4T1 model) with an attenuated <italic toggle="yes">L. monocytogenes</italic> (LM) expressing tumour-associated antigen MAGE-B (LM-Mb), followed by multiple low doses of c-di-GMP (0.2 &#956;mol/L) treatment, resulted in almost complete elimination of all metastases. In this model, it appears that low doses of c-di-GMP significantly increased the production of IL-12 by myeloid-derived suppressor cells and improved antigen-specific T-cell responses, while high doses of c-di-GMP (range: 0.3&#8211;3 mmol/L) killed the 4T1 tumour cells directly by activating the tumour cell caspase-3 pathway [<xref rid="B146-vaccines-09-00917" ref-type="bibr">146</xref>].</p><p>CDNs have also been evaluated with a number of other cancer antigens and cancer vaccines, including MUC1 glycopeptide [<xref rid="B147-vaccines-09-00917" ref-type="bibr">147</xref>], a B16 melanoma peptide [<xref rid="B148-vaccines-09-00917" ref-type="bibr">148</xref>], and a mouse model of glioma [<xref rid="B70-vaccines-09-00917" ref-type="bibr">70</xref>] and EG7-Ova tumour [<xref rid="B57-vaccines-09-00917" ref-type="bibr">57</xref>]. In these applications, c-di-GMP and cGAMP functioned as potent immunostimulants and induced robust antitumor immunity and tumour regression. Shae et al. have recently developed a synthetic cancer nanovaccine platform (nanoSTING-vax) for efficient co-delivery of tumour peptide antigens and cGAMP to the cytosol of APCs [<xref rid="B149-vaccines-09-00917" ref-type="bibr">149</xref>]. Therapeutic immunization with this platform, in combination with immune checkpoint blockade, induced significant suppression of tumour growth, even complete tumour rejection, and long-lasting antitumor immune memory in multiple murine tumor models.</p></sec></sec><sec id="sec7-vaccines-09-00917"><title>7. Novel Delivery Strategies to Enhance the Immunostimulatory and Adjuvant Function of CDNs</title><p>The in vivo efficacy of CDNs is limited by their physiochemical properties such as negative charges, hydrophilicity, short plasma half-life, and poor cellular targeting and membrane permeability. To overcome these challenges, researchers have developed several innovative strategies to transport CDNs more efficiently to the cell cytosol where STING is located (<xref rid="vaccines-09-00917-t002" ref-type="table">Table 2</xref>). These include in vivo synthesis of CDNs, nanoparticles, and microparticles and combination with other adjuvants and immunostimulators, etc. In this regard, the adjuvant activity of CDNs can be simply further enhanced or tailored by combination with other adjuvants and immunomodulators, particularly those that activate different immune signalling pathways, such as TLR agonists (CpG ODN, lipid A, and Pam<sub>3</sub>CSK), macrophage inducible C-type lectin (Mincle), saponin, and alum, etc. [<xref rid="B97-vaccines-09-00917" ref-type="bibr">97</xref>,<xref rid="B114-vaccines-09-00917" ref-type="bibr">114</xref>,<xref rid="B150-vaccines-09-00917" ref-type="bibr">150</xref>,<xref rid="B151-vaccines-09-00917" ref-type="bibr">151</xref>]. Others have attempted to synthesize c-di-GMP in vivo by transducing a diguanylate cyclase gene into the nonreplicating adenovirus serotype 5 (Ad5) vector, which produced enhanced amounts of c-di-GMP when expressed in mammalian cells in vivo [<xref rid="B152-vaccines-09-00917" ref-type="bibr">152</xref>,<xref rid="B153-vaccines-09-00917" ref-type="bibr">153</xref>]. Furthermore, cGAMP has been incorporated into viral particles such as lentivirus and herpesvirus virions [<xref rid="B154-vaccines-09-00917" ref-type="bibr">154</xref>]. The proof of concept of these approaches has been demonstrated in animal models with extracellular protein Ova, HIV-1 Gag peptides, or the <italic toggle="yes">C. difficile</italic> toxin B [<xref rid="B152-vaccines-09-00917" ref-type="bibr">152</xref>,<xref rid="B153-vaccines-09-00917" ref-type="bibr">153</xref>]. Quintana and colleagues have explored the feasibility to engineer a live <italic toggle="yes">Lactococcus lactis</italic> vector containing a single plasmid with both cdaA and tscf genes under different promoters, respectively, to simultaneously synthesize the adjuvant c-di-AMP as well as a heterologous vaccine antigen of interests in order to develop a simple and economical system for vaccine development [<xref rid="B155-vaccines-09-00917" ref-type="bibr">155</xref>]. However, control of the level and duration of the CDN expression by this approach can be a challenge since chronic STING activation has been involved and responsible for initiating certain inflammatory and autoimmune diseases due to type 1 IFN overproduction [<xref rid="B4-vaccines-09-00917" ref-type="bibr">4</xref>,<xref rid="B156-vaccines-09-00917" ref-type="bibr">156</xref>,<xref rid="B157-vaccines-09-00917" ref-type="bibr">157</xref>] In addition, sustained gene transcription is rigidly prevented by the host to avoid lethal STING-dependent proinflammatory disease by unknown mechanisms [<xref rid="B158-vaccines-09-00917" ref-type="bibr">158</xref>,<xref rid="B159-vaccines-09-00917" ref-type="bibr">159</xref>].</p><p>Substantial efforts have been made to develop novel delivery systems (such as different compositions of microparticles, liposomes, and nanoparticles, STINGel, and microneedles) to facilitate the efficient and targeted CDN delivery [<xref rid="B162-vaccines-09-00917" ref-type="bibr">162</xref>,<xref rid="B168-vaccines-09-00917" ref-type="bibr">168</xref>,<xref rid="B169-vaccines-09-00917" ref-type="bibr">169</xref>,<xref rid="B170-vaccines-09-00917" ref-type="bibr">170</xref>,<xref rid="B171-vaccines-09-00917" ref-type="bibr">171</xref>,<xref rid="B172-vaccines-09-00917" ref-type="bibr">172</xref>,<xref rid="B173-vaccines-09-00917" ref-type="bibr">173</xref>]. Compared with unformulated (free) CNDs, these formulations have a markedly prolonged half-life and local retention of CDNs within the tumour microenvironment, enhanced the local infiltration of CD11c<sup>+</sup> DCs, F4/80<sup>+</sup> macrophages, CD4<sup>+</sup> T cells, and CD8<sup>+</sup> T cells, stimulated APC activation (high expression of CD80, CD86 and MHC class I), induced the production of proinflammatory cytokines (type I and type II IFN, IL-1&#946;, and IL-6), dramatically increased expansion and function of antigen-specific CD8<sup>+</sup> T cells, and facilitated NK cell-mediated MHC-I non-restricted antitumor immunity [<xref rid="B74-vaccines-09-00917" ref-type="bibr">74</xref>,<xref rid="B77-vaccines-09-00917" ref-type="bibr">77</xref>,<xref rid="B78-vaccines-09-00917" ref-type="bibr">78</xref>,<xref rid="B79-vaccines-09-00917" ref-type="bibr">79</xref>,<xref rid="B160-vaccines-09-00917" ref-type="bibr">160</xref>,<xref rid="B161-vaccines-09-00917" ref-type="bibr">161</xref>,<xref rid="B174-vaccines-09-00917" ref-type="bibr">174</xref>].</p></sec><sec sec-type="conclusions" id="sec8-vaccines-09-00917"><title>8. Conclusions and Future Direction</title><p>Most of the recent research on the immunostimulatory and adjuvant function of CDNs has focused on the development of vaccines against bacterial and viral infections, particularly in influenza and tuberculosis. However, it is encouraging to note that CDNs have been increasingly used as vaccine adjuvants for some challenging infections and for their veterinary application. The identification of STING as a crucial pathway in cancer immunology generated a great interest in the research and development of CDNs for cancer immunotherapy and cancer vaccine adjuvants, which has led to several human clinical trials. As adjuvants for prophylactic vaccines for infectious diseases, CDNs induce potent humoral and cellular memory immune responses in the systemic and mucosal compartments. These immune responses often provide long-lasting immunity, cross-protection, and antigen dose-sparing, although more studies are needed to determine if CDNs are able to enhance the immunity in aged or newborns. As adjuvants for therapeutic cancer vaccines, CDNs induce potent antitumor immunity, including the activation of cytotoxic T cells, NK cells, and tumor-associated macrophages, and achieve durable regression in multiple mouse models of tumours.</p><p>Preclinical studies have shown that CDNs function in multiple animal species (mice, rats, guinea pigs, ferrets, chicken, pigs, and cattle). These studies also indicate that CDNs can be administered through different parenteral and mucosal routes to induce the desired systemic and local immune responses. Human cell culture and molecular modelling indicate that CDNs bind to human STING and function in vitro. CDNs have several inherent advantages as an ideal vaccine adjuvant, and these include the relative ease to synthesize and formulate, known mode of action, and a large amount of preclinical efficacy data. Several novel strategies and approaches, such as in vivo synthesis, chemical modifications, combination with other vaccine adjuvants and delivery systems, have been developed over the years to improve the cellular uptake of CDNs and facilitate their cytosolic delivery to further enhance their efficacy and application. In addition, several novel methods of enzymatic and microbiological synthesis of CDNs for scale-up have been developed. Among these, the delivery via in vivo synthesis is an attractive strategy, but appropriate control of their expression level and duration to prevent the development of autoimmune diseases will be a challenge.</p><p>Although an overwhelming number of studies have convincingly demonstrated the promise of CDNs as an effective and safe adjuvant for mucosal and systemic vaccination, a few studies have shown no or partial effect of CDNs. Intranasal immunization of mice with BtaF trimeric autotransporter of <italic toggle="yes">B. suis</italic> and c-di-AMP conferred significant protection against intragastric <italic toggle="yes">B. suis</italic> challenge but failed to protect against the respiratory challenge, despite the presence of vaccine-induced specific mucosal IgA and the production of high IFN-&#947; levels by lung cells [<xref rid="B122-vaccines-09-00917" ref-type="bibr">122</xref>]. Furthermore, immunization of pigs with c-di-AMP and naked self-amplifying replicon RNA (RepRNA) encoding influenza virus nucleoprotein and HA induced only low-level immune responses in 20% of pigs [<xref rid="B175-vaccines-09-00917" ref-type="bibr">175</xref>].</p><p>Despite the promising progress and more than 15 years of R&amp;D efforts by the biomedical research communities and pharm/biotech industries, the research on CDNs as vaccine adjuvants seems stalled at the preclinical development stage. To date, there are no licensed CDN products for human clinical use. Several clinical trials of the leading CDNs for cancer immunotherapy have been conducted with disappointing results. The reasons for this remain unknown, but it was suggested that the heterogeneity of the human STING gene and the potential immunocompromised status and immunosenescence in clinical trial participants are possible contributing factors [<xref rid="B176-vaccines-09-00917" ref-type="bibr">176</xref>]. In this regard, single nucleotide polymorphism analysis showed the common presence of STING variants and mutations in the human population (ranged from 1.5% in R293Q to 20.4% in R71H-G230A-R293Q (HAQ) [<xref rid="B177-vaccines-09-00917" ref-type="bibr">177</xref>]). Therefore, further studies should be directed to dissect the differences in immune responses induced by different CDNs and their mode of action between human and experimental animal cells. In addition, more stringent preclinical research and development in clinically relevant animal models will be needed to promote the clinical application of these promising molecules. Finally, strategies to design &#8220;pan-STING agonists&#8221; as prophylactic vaccine adjuvants should be considered to ensure their function in a majority of the population.</p></sec></body><back><ack><title>Acknowledgments</title><p>We thank Hongyan Zhou for her assistance in the literature search and the preparation of <xref rid="vaccines-09-00917-t001" ref-type="table">Table 1</xref> and <xref rid="vaccines-09-00917-t002" ref-type="table">Table 2</xref> in this manuscript.</p></ack><fn-group><fn><p><bold>Publisher&#8217;s Note:</bold> MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><app-group><app id="app1-vaccines-09-00917"><title>Supplementary Materials</title><p>The following are available online at <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.mdpi.com/article/10.3390/vaccines9080917/s1">https://www.mdpi.com/article/10.3390/vaccines9080917/s1</uri>, Figure S1: Selected CDNs containing 3&#8242;-5&#8242; internucleotide phosphate/phosphorothioate linkages reported in the literature, Figure S2: Selected CDNs containing 2&#8242;-5&#8242; and both 2&#8242;-5&#8242; and 3&#8242;-5&#8242; internucleotide phosphate/phosphorothioate linkages reported in the literature, Figure S3: Selected CDN analogs with internucleotide linkages that are not phosphorous based, and Figure S4: c-di-GMP conjugates reported.</p><supplementary-material content-type="local-data" id="vaccines-09-00917-s001" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="vaccines-09-00917-s001.zip" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>H.Y. and W.C. developed the concept, drafted the manuscript, and agreed to the published version of the manuscript. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Funding</title><p>This work was supported by the Natural Sciences and Engineering Research Council of Canada (RGPIN-2020-07040) and the National Research Council Canada (Vaccine Program and Vaccine and Immunotherapeutics Program). The view expressed here (W.C.) is solely the responsibility of the author and does not necessarily represent the official views of the National Research Council Canada.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>Not applicable.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors are inventors of U.S. Patent 10,092,644, which is owned by Brock University and the National Research Council Canada (Government of Canada).</p></notes><ref-list><title>References</title><ref id="B1-vaccines-09-00917"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahn</surname><given-names>J.</given-names></name><name name-style="western"><surname>Barber</surname><given-names>G.N.</given-names></name></person-group><article-title>STING signaling and host defense against microbial infection</article-title><source>Exp. Mol. Med.</source><year>2019</year><volume>51</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1038/s12276-019-0333-0</pub-id><pub-id pub-id-type="pmcid">PMC6906460</pub-id><pub-id pub-id-type="pmid">31827069</pub-id></element-citation></ref><ref id="B2-vaccines-09-00917"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burdette</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Monroe</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Sotelo-Troha</surname><given-names>K.</given-names></name><name name-style="western"><surname>Iwig</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Eckert</surname><given-names>B.</given-names></name><name name-style="western"><surname>Hyodo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hayakawa</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Vance</surname><given-names>R.E.</given-names></name></person-group><article-title>STING is a direct innate immune sensor of cyclic di-GMP</article-title><source>Nature</source><year>2011</year><volume>478</volume><fpage>515</fpage><lpage>518</lpage><pub-id pub-id-type="doi">10.1038/nature10429</pub-id><pub-id pub-id-type="pmid">21947006</pub-id><pub-id pub-id-type="pmcid">PMC3203314</pub-id></element-citation></ref><ref id="B3-vaccines-09-00917"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ouyang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Song</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ru</surname><given-names>H.</given-names></name><name name-style="western"><surname>Shaw</surname><given-names>N.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Niu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Parvatiyar</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Structural Analysis of the STING Adaptor Protein Reveals a Hydrophobic Dimer Interface and Mode of Cyclic di-GMP Binding</article-title><source>Immunity</source><year>2012</year><volume>36</volume><fpage>1073</fpage><lpage>1086</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2012.03.019</pub-id><pub-id pub-id-type="pmid">22579474</pub-id><pub-id pub-id-type="pmcid">PMC3654694</pub-id></element-citation></ref><ref id="B4-vaccines-09-00917"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barber</surname><given-names>G.N.</given-names></name></person-group><article-title>STING-dependent cytosolic DNA sensing pathways</article-title><source>Trends Immunol.</source><year>2014</year><volume>35</volume><fpage>88</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1016/j.it.2013.10.010</pub-id><pub-id pub-id-type="pmid">24309426</pub-id></element-citation></ref><ref id="B5-vaccines-09-00917"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>J.-J.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name></person-group><article-title>Agonists and inhibitors of the STING pathway: Potential agents for immunotherapy</article-title><source>Med. Res. Rev.</source><year>2020</year><volume>40</volume><fpage>1117</fpage><lpage>1141</lpage><pub-id pub-id-type="doi">10.1002/med.21649</pub-id><pub-id pub-id-type="pmid">31793026</pub-id></element-citation></ref><ref id="B6-vaccines-09-00917"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ross</surname><given-names>P.</given-names></name><name name-style="western"><surname>Aloni</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Weinhouse</surname><given-names>C.</given-names></name><name name-style="western"><surname>Michaeli</surname><given-names>D.</given-names></name><name name-style="western"><surname>Weinberger-Ohana</surname><given-names>P.</given-names></name><name name-style="western"><surname>Meyer</surname><given-names>R.</given-names></name><name name-style="western"><surname>Benziman</surname><given-names>M.</given-names></name></person-group><article-title>An unusual guanyl oligonucleotide regulates cellulose synthesis in Acetobacter xylinum</article-title><source>FEBS Lett.</source><year>1985</year><volume>186</volume><fpage>191</fpage><lpage>196</lpage><pub-id pub-id-type="doi">10.1016/0014-5793(85)80706-7</pub-id><pub-id pub-id-type="pmid">19160595</pub-id></element-citation></ref><ref id="B7-vaccines-09-00917"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ross</surname><given-names>P.</given-names></name><name name-style="western"><surname>Aloni</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Weinhouse</surname><given-names>H.</given-names></name><name name-style="western"><surname>Michaeli</surname><given-names>D.</given-names></name><name name-style="western"><surname>Weinberger-Ohana</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mayer</surname><given-names>R.</given-names></name><name name-style="western"><surname>Benziman</surname><given-names>M.</given-names></name></person-group><article-title>Control of cellulose synthesis Acetobacter xylinum. A unique guanyl oligonucleotide is the immediate activator of the cellulose synthase</article-title><source>Carbohydr. Res.</source><year>1986</year><volume>149</volume><fpage>101</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1016/S0008-6215(00)90372-0</pub-id></element-citation></ref><ref id="B8-vaccines-09-00917"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ross</surname><given-names>P.</given-names></name><name name-style="western"><surname>Weinhouse</surname><given-names>H.</given-names></name><name name-style="western"><surname>Aloni</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Michaeli</surname><given-names>D.</given-names></name><name name-style="western"><surname>Weinberger-Ohana</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mayer</surname><given-names>R.</given-names></name><name name-style="western"><surname>Braun</surname><given-names>S.</given-names></name><name name-style="western"><surname>de Vroom</surname><given-names>E.</given-names></name><name name-style="western"><surname>van der Marel</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>van Boom</surname><given-names>J.H.</given-names></name><etal/></person-group><article-title>Regulation of cellulose synthesis in Acetobacter xylinum by cyclic diguanylic acid</article-title><source>Nature</source><year>1987</year><volume>325</volume><fpage>279</fpage><lpage>281</lpage><pub-id pub-id-type="doi">10.1038/325279a0</pub-id><pub-id pub-id-type="pmid">18990795</pub-id></element-citation></ref><ref id="B9-vaccines-09-00917"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Egli</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gessner</surname><given-names>R.V.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>L.D.</given-names></name><name name-style="western"><surname>Quigley</surname><given-names>G.J.</given-names></name><name name-style="western"><surname>van der Marel</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>van Boom</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Rich</surname><given-names>A.</given-names></name><name name-style="western"><surname>Frederick</surname><given-names>C.A.</given-names></name></person-group><article-title>Atomic-resolution structure of the cellulose synthase regulator cyclic diguanylic acid</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>1990</year><volume>87</volume><fpage>3235</fpage><lpage>3239</lpage><pub-id pub-id-type="doi">10.1073/pnas.87.8.3235</pub-id><pub-id pub-id-type="pmid">2158107</pub-id><pub-id pub-id-type="pmcid">PMC53870</pub-id></element-citation></ref><ref id="B10-vaccines-09-00917"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Witte</surname><given-names>G.</given-names></name><name name-style="western"><surname>Hartung</surname><given-names>S.</given-names></name><name name-style="western"><surname>B&#252;ttner</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hopfner</surname><given-names>K.-P.</given-names></name></person-group><article-title>Structural Biochemistry of a Bacterial Checkpoint Protein Reveals Diadenylate Cyclase Activity Regulated by DNA Recombination Intermediates</article-title><source>Mol. Cell</source><year>2008</year><volume>30</volume><fpage>167</fpage><lpage>178</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2008.02.020</pub-id><pub-id pub-id-type="pmid">18439896</pub-id></element-citation></ref><ref id="B11-vaccines-09-00917"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>St&#252;lke</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kr&#252;ger</surname><given-names>L.</given-names></name></person-group><article-title>Cyclic di-AMP Signaling in Bacteria</article-title><source>Annu. Rev. Microbiol.</source><year>2020</year><volume>74</volume><fpage>159</fpage><lpage>179</lpage><pub-id pub-id-type="doi">10.1146/annurev-micro-020518-115943</pub-id><pub-id pub-id-type="pmid">32603625</pub-id></element-citation></ref><ref id="B12-vaccines-09-00917"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yin</surname><given-names>W.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chou</surname><given-names>S.-H.</given-names></name><name name-style="western"><surname>Galperin</surname><given-names>M.Y.</given-names></name><name name-style="western"><surname>He</surname><given-names>J.</given-names></name></person-group><article-title>A decade of research on the second messenger c-di-AMP</article-title><source>FEMS Microbiol. Rev.</source><year>2020</year><volume>44</volume><fpage>701</fpage><lpage>724</lpage><pub-id pub-id-type="doi">10.1093/femsre/fuaa019</pub-id><pub-id pub-id-type="pmid">32472931</pub-id><pub-id pub-id-type="pmcid">PMC7850090</pub-id></element-citation></ref><ref id="B13-vaccines-09-00917"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Davies</surname><given-names>B.</given-names></name><name name-style="western"><surname>Bogard</surname><given-names>R.W.</given-names></name><name name-style="western"><surname>Young</surname><given-names>T.S.</given-names></name><name name-style="western"><surname>Mekalanos</surname><given-names>J.J.</given-names></name></person-group><article-title>Coordinated Regulation of Accessory Genetic Elements Produces Cyclic Di-Nucleotides for V. cholerae Virulence</article-title><source>Cell</source><year>2012</year><volume>149</volume><fpage>358</fpage><lpage>370</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2012.01.053</pub-id><pub-id pub-id-type="pmid">22500802</pub-id><pub-id pub-id-type="pmcid">PMC3620040</pub-id></element-citation></ref><ref id="B14-vaccines-09-00917"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Du</surname><given-names>F.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z.J.</given-names></name></person-group><article-title>Cyclic GMP-AMP Synthase Is a Cytosolic DNA Sensor That Activates the Type I Interferon Pathway</article-title><source>Science</source><year>2013</year><volume>339</volume><fpage>786</fpage><lpage>791</lpage><pub-id pub-id-type="doi">10.1126/science.1232458</pub-id><pub-id pub-id-type="pmid">23258413</pub-id><pub-id pub-id-type="pmcid">PMC3863629</pub-id></element-citation></ref><ref id="B15-vaccines-09-00917"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Du</surname><given-names>F.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z.J.</given-names></name></person-group><article-title>Cyclic GMP-AMP Is an Endogenous Second Messenger in Innate Immune Signaling by Cytosolic DNA</article-title><source>Science</source><year>2013</year><volume>339</volume><fpage>826</fpage><lpage>830</lpage><pub-id pub-id-type="doi">10.1126/science.1229963</pub-id><pub-id pub-id-type="pmid">23258412</pub-id><pub-id pub-id-type="pmcid">PMC3855410</pub-id></element-citation></ref><ref id="B16-vaccines-09-00917"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z.J.</given-names></name></person-group><article-title>Cyclic GMP-AMP containing mixed phosphodiester linkages is an endogenous high-affinity ligand for STING</article-title><source>Mol. Cell.</source><year>2013</year><volume>51</volume><fpage>226</fpage><lpage>235</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2013.05.022</pub-id><pub-id pub-id-type="pmid">23747010</pub-id><pub-id pub-id-type="pmcid">PMC3808999</pub-id></element-citation></ref><ref id="B17-vaccines-09-00917"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dahlstrom</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>O&#8217;Toole</surname><given-names>G.A.</given-names></name></person-group><article-title>A Symphony of Cyclases: Specificity in Diguanylate Cyclase Signaling</article-title><source>Annu. Rev. Microbiol.</source><year>2017</year><volume>71</volume><fpage>179</fpage><lpage>195</lpage><pub-id pub-id-type="doi">10.1146/annurev-micro-090816-093325</pub-id><pub-id pub-id-type="pmid">28645224</pub-id><pub-id pub-id-type="pmcid">PMC5936083</pub-id></element-citation></ref><ref id="B18-vaccines-09-00917"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ross</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mayer</surname><given-names>R.</given-names></name><name name-style="western"><surname>Weinhouse</surname><given-names>H.</given-names></name><name name-style="western"><surname>Amikam</surname><given-names>D.</given-names></name><name name-style="western"><surname>Huggirat</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Benziman</surname><given-names>M.</given-names></name><name name-style="western"><surname>de Vroom</surname><given-names>E.</given-names></name><name name-style="western"><surname>Fidder</surname><given-names>A.</given-names></name><name name-style="western"><surname>de Paus</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sliedregt</surname><given-names>L.A.</given-names></name></person-group><article-title>The cyclic diguanylic acid regulatory system of cellulose synthesis in Acetobacter xylinum. Chemical synthesis and biological activity of cyclic nucleotide dimer, trimer, and phosphothioate derivatives</article-title><source>J. Biol. Chem.</source><year>1990</year><volume>265</volume><fpage>18933</fpage><lpage>18943</lpage><pub-id pub-id-type="doi">10.1016/S0021-9258(17)30606-3</pub-id><pub-id pub-id-type="pmid">2172238</pub-id></element-citation></ref><ref id="B19-vaccines-09-00917"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Amikam</surname><given-names>D.</given-names></name><name name-style="western"><surname>Galperin</surname><given-names>M.</given-names></name></person-group><article-title>PilZ domain is part of the bacterial c-di-GMP binding protein</article-title><source>Bioinformatics</source><year>2005</year><volume>22</volume><fpage>3</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bti739</pub-id><pub-id pub-id-type="pmid">16249258</pub-id></element-citation></ref><ref id="B20-vaccines-09-00917"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ryjenkov</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Simm</surname><given-names>R.</given-names></name><name name-style="western"><surname>Romling</surname><given-names>U.</given-names></name><name name-style="western"><surname>Gomelsky</surname><given-names>M.</given-names></name></person-group><article-title>The PilZ domain is a receptor for the second messenger c-di-GMP: The PilZ domain protein YcgR controls motility in enterobacteria</article-title><source>J. Biol. Chem.</source><year>2006</year><volume>281</volume><fpage>30310</fpage><lpage>30314</lpage><pub-id pub-id-type="doi">10.1074/jbc.C600179200</pub-id><pub-id pub-id-type="pmid">16920715</pub-id></element-citation></ref><ref id="B21-vaccines-09-00917"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alm</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Bodero</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Free</surname><given-names>P.D.</given-names></name><name name-style="western"><surname>Mattick</surname><given-names>J.</given-names></name></person-group><article-title>Identification of a novel gene, pilZ, essential for type 4 fimbrial biogenesis in Pseudomonas aeruginosa</article-title><source>J. Bacteriol.</source><year>1996</year><volume>178</volume><fpage>46</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1128/jb.178.1.46-53.1996</pub-id><pub-id pub-id-type="pmid">8550441</pub-id><pub-id pub-id-type="pmcid">PMC177619</pub-id></element-citation></ref><ref id="B22-vaccines-09-00917"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Christen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Christen</surname><given-names>B.</given-names></name><name name-style="western"><surname>Allan</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Folcher</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jen&#246;</surname><given-names>P.</given-names></name><name name-style="western"><surname>Grzesiek</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jenal</surname><given-names>U.</given-names></name></person-group><article-title>DgrA is a member of a new family of cyclic diguanosine monophosphate receptors and controls flagellar motor function in Caulobacter crescentus</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2007</year><volume>104</volume><fpage>4112</fpage><lpage>4117</lpage><pub-id pub-id-type="doi">10.1073/pnas.0607738104</pub-id><pub-id pub-id-type="pmid">17360486</pub-id><pub-id pub-id-type="pmcid">PMC1805490</pub-id></element-citation></ref><ref id="B23-vaccines-09-00917"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mart&#237;nez-Granero</surname><given-names>F.</given-names></name><name name-style="western"><surname>Navazo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Barahona</surname><given-names>E.</given-names></name><name name-style="western"><surname>Redondo-Nieto</surname><given-names>M.</given-names></name><name name-style="western"><surname>de Heredia</surname><given-names>E.G.</given-names></name><name name-style="western"><surname>Baena</surname><given-names>I.</given-names></name><name name-style="western"><surname>Mart&#237;n-Mart&#237;n</surname><given-names>I.</given-names></name><name name-style="western"><surname>Rivilla</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mart&#237;n</surname><given-names>M.</given-names></name></person-group><article-title>Identification of flgZ as a Flagellar Gene Encoding a PilZ Domain Protein That Regulates Swimming Motility and Biofilm Formation in Pseudomonas</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><elocation-id>e87608</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0087608</pub-id><pub-id pub-id-type="pmid">24504373</pub-id><pub-id pub-id-type="pmcid">PMC3913639</pub-id></element-citation></ref><ref id="B24-vaccines-09-00917"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pratt</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Tamayo</surname><given-names>R.</given-names></name><name name-style="western"><surname>Tischler</surname><given-names>A.</given-names></name><name name-style="western"><surname>Camilli</surname><given-names>A.</given-names></name></person-group><article-title>PilZ Domain Proteins Bind Cyclic Diguanylate and Regulate Diverse Processes in Vibrio cholerae</article-title><source>J. Biol. Chem.</source><year>2007</year><volume>282</volume><fpage>12860</fpage><lpage>12870</lpage><pub-id pub-id-type="doi">10.1074/jbc.M611593200</pub-id><pub-id pub-id-type="pmid">17307739</pub-id><pub-id pub-id-type="pmcid">PMC2790426</pub-id></element-citation></ref><ref id="B25-vaccines-09-00917"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.-H.</given-names></name><name name-style="western"><surname>Hao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Nair</surname><given-names>S.K.</given-names></name></person-group><article-title>Structures of the PelD Cyclic Diguanylate Effector Involved in Pellicle Formation in Pseudomonas aeruginosa PAO1</article-title><source>J. Biol. Chem.</source><year>2012</year><volume>287</volume><fpage>30191</fpage><lpage>30204</lpage><pub-id pub-id-type="doi">10.1074/jbc.M112.378273</pub-id><pub-id pub-id-type="pmid">22810222</pub-id><pub-id pub-id-type="pmcid">PMC3436273</pub-id></element-citation></ref><ref id="B26-vaccines-09-00917"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Newell</surname><given-names>P.D.</given-names></name><name name-style="western"><surname>Monds</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>O&#8217;Toole</surname><given-names>G.A.</given-names></name></person-group><article-title>LapD is a bis-(3&#8242;,5&#8242;)-cyclic dimeric GMP-binding protein that regulates surface attachment by Pseudomonas fluorescens Pf0-1</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2009</year><volume>106</volume><fpage>3461</fpage><lpage>3466</lpage><pub-id pub-id-type="doi">10.1073/pnas.0808933106</pub-id><pub-id pub-id-type="pmid">19218451</pub-id><pub-id pub-id-type="pmcid">PMC2651287</pub-id></element-citation></ref><ref id="B27-vaccines-09-00917"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hickman</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Harwood</surname><given-names>C.S.</given-names></name></person-group><article-title>Identification of FleQ from Pseudomonas aeruginosa as a c-di-GMP-responsive transcription factor</article-title><source>Mol. Microbiol.</source><year>2008</year><volume>69</volume><fpage>376</fpage><lpage>389</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2958.2008.06281.x</pub-id><pub-id pub-id-type="pmid">18485075</pub-id><pub-id pub-id-type="pmcid">PMC2612001</pub-id></element-citation></ref><ref id="B28-vaccines-09-00917"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fazli</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>O&#8217;Connell</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nilsson</surname><given-names>M.</given-names></name><name name-style="western"><surname>Niehaus</surname><given-names>K.</given-names></name><name name-style="western"><surname>Dow</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Givskov</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ryan</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>Tolker-Nielsen</surname><given-names>T.</given-names></name></person-group><article-title>The CRP/FNR family protein Bcam1349 is a c-di-GMP effector that regulates biofilm formation in the respiratory pathogen Burkholderia cenocepacia</article-title><source>Mol. Microbiol.</source><year>2011</year><volume>82</volume><fpage>327</fpage><lpage>341</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2958.2011.07814.x</pub-id><pub-id pub-id-type="pmid">21883527</pub-id></element-citation></ref><ref id="B29-vaccines-09-00917"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>K.D.</given-names></name><name name-style="western"><surname>Shanahan</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Moore</surname><given-names>E.L.</given-names></name><name name-style="western"><surname>Simon</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Strobel</surname><given-names>S.A.</given-names></name></person-group><article-title>Structural basis of differential ligand recognition by two classes of bis-(3&#8242;-5&#8242;)-cyclic dimeric guanosine monophosphate-binding riboswitches</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2011</year><volume>108</volume><fpage>7757</fpage><lpage>7762</lpage><pub-id pub-id-type="doi">10.1073/pnas.1018857108</pub-id><pub-id pub-id-type="pmid">21518891</pub-id><pub-id pub-id-type="pmcid">PMC3093532</pub-id></element-citation></ref><ref id="B30-vaccines-09-00917"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sudarsan</surname><given-names>N.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>E.R.</given-names></name><name name-style="western"><surname>Weinberg</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Moy</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.N.</given-names></name><name name-style="western"><surname>Link</surname><given-names>K.H.</given-names></name><name name-style="western"><surname>Breaker</surname><given-names>R.R.</given-names></name></person-group><article-title>Riboswitches in Eubacteria Sense the Second Messenger Cyclic Di-GMP</article-title><source>Science</source><year>2008</year><volume>321</volume><fpage>411</fpage><lpage>413</lpage><pub-id pub-id-type="doi">10.1126/science.1159519</pub-id><pub-id pub-id-type="pmid">18635805</pub-id><pub-id pub-id-type="pmcid">PMC5304454</pub-id></element-citation></ref><ref id="B31-vaccines-09-00917"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>E.R.</given-names></name><name name-style="western"><surname>Baker</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Weinberg</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Sudarsan</surname><given-names>N.</given-names></name><name name-style="western"><surname>Breaker</surname><given-names>R.R.</given-names></name></person-group><article-title>An Allosteric Self-Splicing Ribozyme Triggered by a Bacterial Second Messenger</article-title><source>Science</source><year>2010</year><volume>329</volume><fpage>845</fpage><lpage>848</lpage><pub-id pub-id-type="doi">10.1126/science.1190713</pub-id><pub-id pub-id-type="pmid">20705859</pub-id><pub-id pub-id-type="pmcid">PMC4538695</pub-id></element-citation></ref><ref id="B32-vaccines-09-00917"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roy</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Petrova</surname><given-names>O.E.</given-names></name><name name-style="western"><surname>Sauer</surname><given-names>K.</given-names></name></person-group><article-title>Extraction and Quantification of Cyclic Di-GMP from P. aeruginosa</article-title><source>Bio Protoc.</source><year>2013</year><volume>3</volume><fpage>e828</fpage><pub-id pub-id-type="doi">10.21769/BioProtoc.828</pub-id><pub-id pub-id-type="pmcid">PMC4241849</pub-id><pub-id pub-id-type="pmid">25429368</pub-id></element-citation></ref><ref id="B33-vaccines-09-00917"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Sinn</surname><given-names>M.</given-names></name><name name-style="western"><surname>Stifel</surname><given-names>J.</given-names></name><name name-style="western"><surname>Heiler</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Sommershof</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hartig</surname><given-names>J.S.</given-names></name></person-group><article-title>Synthesis of All Possible Canonical (3&#8242;-5&#8242;-Linked) Cyclic Di-nucleotides and Evaluation of Riboswitch Interactions and Immune-Stimulatory Effects</article-title><source>J. Am. Chem. Soc.</source><year>2017</year><volume>139</volume><fpage>16154</fpage><lpage>16160</lpage><pub-id pub-id-type="doi">10.1021/jacs.7b06141</pub-id><pub-id pub-id-type="pmid">29056046</pub-id></element-citation></ref><ref id="B34-vaccines-09-00917"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rao</surname><given-names>F.</given-names></name><name name-style="western"><surname>Pasunooti</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhuo</surname><given-names>W.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>A.W.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>Z.-X.</given-names></name></person-group><article-title>Enzymatic synthesis of c-di-GMP using a thermophilic diguanylate cyclase</article-title><source>Anal. Biochem.</source><year>2009</year><volume>389</volume><fpage>138</fpage><lpage>142</lpage><pub-id pub-id-type="doi">10.1016/j.ab.2009.03.031</pub-id><pub-id pub-id-type="pmid">19328769</pub-id></element-citation></ref><ref id="B35-vaccines-09-00917"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Korovashkina</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Rymko</surname><given-names>A.N.</given-names></name><name name-style="western"><surname>Kvach</surname><given-names>S.V.</given-names></name><name name-style="western"><surname>Zinchenko</surname><given-names>A.</given-names></name></person-group><article-title>Enzymatic synthesis of c-di-GMP using inclusion bodies of Ther-motoga maritima full-length diguanylate cyclase</article-title><source>J. Biotechnol.</source><year>2012</year><volume>164</volume><fpage>276</fpage><lpage>280</lpage><pub-id pub-id-type="doi">10.1016/j.jbiotec.2012.12.006</pub-id><pub-id pub-id-type="pmid">23274918</pub-id></element-citation></ref><ref id="B36-vaccines-09-00917"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shchokolova</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Rymko</surname><given-names>A.N.</given-names></name><name name-style="western"><surname>Kvach</surname><given-names>S.V.</given-names></name><name name-style="western"><surname>Shabunya</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Fatykhava</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Zinchenko</surname><given-names>A.I.</given-names></name></person-group><article-title>Enzymatic synthesis of 2&#8242;-ara and 2&#8242;-deoxy analogues of c-di-GMP</article-title><source>Nucleosides Nucleotides Nucleic Acids</source><year>2015</year><volume>34</volume><fpage>416</fpage><lpage>423</lpage><pub-id pub-id-type="doi">10.1080/15257770.2015.1006775</pub-id><pub-id pub-id-type="pmid">25965330</pub-id></element-citation></ref><ref id="B37-vaccines-09-00917"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Launer-Felty</surname><given-names>K.D.</given-names></name><name name-style="western"><surname>Strobel</surname><given-names>S.A.</given-names></name></person-group><article-title>Enzymatic synthesis of cyclic dinucleotide analogs by a promiscuous cyclic-AMP-GMP syn-thetase and analysis of cyclic dinucleotide responsive riboswitches</article-title><source>Nucleic Acids Res.</source><year>2018</year><volume>46</volume><fpage>2765</fpage><lpage>2776</lpage><pub-id pub-id-type="doi">10.1093/nar/gky137</pub-id><pub-id pub-id-type="pmid">29514227</pub-id><pub-id pub-id-type="pmcid">PMC5888326</pub-id></element-citation></ref><ref id="B38-vaccines-09-00917"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Becker</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nikel</surname><given-names>P.</given-names></name><name name-style="western"><surname>Andexer</surname><given-names>J.</given-names></name><name name-style="western"><surname>L&#252;tz</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rosenthal</surname><given-names>K.</given-names></name></person-group><article-title>A Multi-Enzyme Cascade Reaction for the Production of 2&#8242;3&#8242;-cGAMP</article-title><source>Biomolecules</source><year>2021</year><volume>11</volume><elocation-id>590</elocation-id><pub-id pub-id-type="doi">10.3390/biom11040590</pub-id><pub-id pub-id-type="pmid">33923845</pub-id><pub-id pub-id-type="pmcid">PMC8073963</pub-id></element-citation></ref><ref id="B39-vaccines-09-00917"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Kuss</surname><given-names>P.</given-names></name><name name-style="western"><surname>Maliga</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Millan</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Mitchison</surname><given-names>T.J.</given-names></name></person-group><article-title>Hydrolysis of 2&#8242;3&#8242;-cGAMP by ENPP1 and design of nonhydrolyzable analogs</article-title><source>Nat. Chem. Biol.</source><year>2014</year><volume>10</volume><fpage>1043</fpage><lpage>1048</lpage><pub-id pub-id-type="doi">10.1038/nchembio.1661</pub-id><pub-id pub-id-type="pmid">25344812</pub-id><pub-id pub-id-type="pmcid">PMC4232468</pub-id></element-citation></ref><ref id="B40-vaccines-09-00917"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosenthal</surname><given-names>K.</given-names></name><name name-style="western"><surname>Becker</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rolf</surname><given-names>J.</given-names></name><name name-style="western"><surname>Siedentop</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hillen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nett</surname><given-names>M.</given-names></name><name name-style="western"><surname>L&#252;tz</surname><given-names>S.</given-names></name></person-group><article-title>Catalytic promiscuity of cGAS: A facile enzymatic synthesis of 2&#8242;-3&#8242;-Linked cyclic dinucleotides</article-title><source>Chembiochem Eur. J. Chem. Biol.</source><year>2020</year><volume>21</volume><fpage>3225</fpage><lpage>3228</lpage><pub-id pub-id-type="doi">10.1002/cbic.202000433</pub-id><pub-id pub-id-type="pmcid">PMC7754487</pub-id><pub-id pub-id-type="pmid">32633874</pub-id></element-citation></ref><ref id="B41-vaccines-09-00917"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dubensky</surname><given-names>J.T.W.</given-names></name><name name-style="western"><surname>Kanne</surname><given-names>D.B.</given-names></name><name name-style="western"><surname>Leong</surname><given-names>M.L.</given-names></name></person-group><article-title>Rationale, progress and development of vaccines utilizing STING-activating cyclic dinucleotide adjuvants</article-title><source>Ther. Adv. Vaccines</source><year>2013</year><volume>1</volume><fpage>131</fpage><lpage>143</lpage><pub-id pub-id-type="doi">10.1177/2051013613501988</pub-id><pub-id pub-id-type="pmid">24757520</pub-id><pub-id pub-id-type="pmcid">PMC3991150</pub-id></element-citation></ref><ref id="B42-vaccines-09-00917"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parvatiyar</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Teles</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ouyang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Iyer</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Zaver</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Schenk</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>W.</given-names></name><etal/></person-group><article-title>The helicase DDX41 recognizes the bacterial secondary messengers cyclic di-GMP and cyclic di-AMP to activate a type I interferon immune response</article-title><source>Nat. Immunol.</source><year>2012</year><volume>13</volume><fpage>1155</fpage><lpage>1161</lpage><pub-id pub-id-type="doi">10.1038/ni.2460</pub-id><pub-id pub-id-type="pmid">23142775</pub-id><pub-id pub-id-type="pmcid">PMC3501571</pub-id></element-citation></ref><ref id="B43-vaccines-09-00917"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McFarland</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ahmed-Qadri</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zuck</surname><given-names>M.</given-names></name><name name-style="western"><surname>Thayer</surname><given-names>E.F.</given-names></name><name name-style="western"><surname>Goo</surname><given-names>Y.A.</given-names></name><name name-style="western"><surname>Hybiske</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tong</surname><given-names>L.</given-names></name><name name-style="western"><surname>Woodward</surname><given-names>J.J.</given-names></name></person-group><article-title>Sensing of Bacterial Cyclic Dinucleotides by the Oxidoreductase RECON Promotes NF-kappaB Activation and Shapes a Proinflammatory Antibacterial State</article-title><source>Immunity</source><year>2017</year><volume>46</volume><fpage>433</fpage><lpage>445</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2017.02.014</pub-id><pub-id pub-id-type="pmid">28329705</pub-id><pub-id pub-id-type="pmcid">PMC5404390</pub-id></element-citation></ref><ref id="B44-vaccines-09-00917"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blaauboer</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Gabrielle</surname><given-names>V.D.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>L.</given-names></name></person-group><article-title>MPYS/STING-Mediated TNF-&#945;, Not Type I IFN, Is Essential for the Mucosal Adjuvant Activity of (3&#8242;&#8211;5&#8242;)-Cyclic-Di-Guanosine-Monophosphate In Vivo</article-title><source>J. Immunol.</source><year>2013</year><volume>192</volume><fpage>492</fpage><lpage>502</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1301812</pub-id><pub-id pub-id-type="pmid">24307739</pub-id><pub-id pub-id-type="pmcid">PMC6195764</pub-id></element-citation></ref><ref id="B45-vaccines-09-00917"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Whiteley</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Gwilt</surname><given-names>K.B.</given-names></name><name name-style="western"><surname>Lencer</surname><given-names>W.I.</given-names></name><name name-style="western"><surname>Mekalanos</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Thiagarajah</surname><given-names>J.R.</given-names></name></person-group><article-title>Extracellular cyclic dinucleotides induce polarized responses in barrier epithelial cells by adenosine signaling</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2020</year><volume>117</volume><fpage>27502</fpage><lpage>27508</lpage><pub-id pub-id-type="doi">10.1073/pnas.2015919117</pub-id><pub-id pub-id-type="pmid">33087577</pub-id><pub-id pub-id-type="pmcid">PMC7959571</pub-id></element-citation></ref><ref id="B46-vaccines-09-00917"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>P.</given-names></name></person-group><article-title>The mechanism of double-stranded DNA sensing through the cGAS-STING pathway</article-title><source>Cytokine Growth Factor Rev.</source><year>2014</year><volume>25</volume><fpage>641</fpage><lpage>648</lpage><pub-id pub-id-type="doi">10.1016/j.cytogfr.2014.06.006</pub-id><pub-id pub-id-type="pmid">25007740</pub-id><pub-id pub-id-type="pmcid">PMC4254336</pub-id></element-citation></ref><ref id="B47-vaccines-09-00917"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>&#352;krnjug</surname><given-names>I.</given-names></name><name name-style="western"><surname>Rueckert</surname><given-names>C.</given-names></name><name name-style="western"><surname>Libanova</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lienenklaus</surname><given-names>S.</given-names></name><name name-style="western"><surname>Weiss</surname><given-names>S.</given-names></name><name name-style="western"><surname>Guzm&#225;n</surname><given-names>C.</given-names></name></person-group><article-title>The Mucosal Adjuvant Cyclic di-AMP Exerts Immune Stimulatory Effects on Dendritic Cells and Macrophages</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><elocation-id>e95728</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0095728</pub-id><pub-id pub-id-type="pmid">24755640</pub-id><pub-id pub-id-type="pmcid">PMC3996008</pub-id></element-citation></ref><ref id="B48-vaccines-09-00917"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karaolis</surname><given-names>D.K.R.</given-names></name><name name-style="western"><surname>Means</surname><given-names>T.K.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yoshimura</surname><given-names>T.</given-names></name><name name-style="western"><surname>Muraille</surname><given-names>E.</given-names></name><name name-style="western"><surname>Philpott</surname><given-names>D.</given-names></name><name name-style="western"><surname>Schroeder</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Hyodo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hayakawa</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Bacterial c-di-GMP Is an Immunostimulatory Molecule</article-title><source>J. Immunol.</source><year>2007</year><volume>178</volume><fpage>2171</fpage><lpage>2181</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.178.4.2171</pub-id><pub-id pub-id-type="pmid">17277122</pub-id></element-citation></ref><ref id="B49-vaccines-09-00917"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ebensen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Libanova</surname><given-names>R.</given-names></name><name name-style="western"><surname>Schulze</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yevsa</surname><given-names>T.</given-names></name><name name-style="western"><surname>Morr</surname><given-names>M.</given-names></name><name name-style="western"><surname>Guzman</surname><given-names>C.A.</given-names></name></person-group><article-title>Bis-(3&#8242;,5&#8242;)-cyclic dimeric adenosine monophosphate: Strong Th1/Th2/Th17 promoting mucosal adjuvant</article-title><source>Vaccine</source><year>2011</year><volume>29</volume><fpage>5210</fpage><lpage>5220</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2011.05.026</pub-id><pub-id pub-id-type="pmid">21619907</pub-id></element-citation></ref><ref id="B50-vaccines-09-00917"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hill</surname><given-names>K.K.</given-names></name><name name-style="western"><surname>Filak</surname><given-names>H.</given-names></name><name name-style="western"><surname>Mogan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Knowles</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Perraud</surname><given-names>A.-L.</given-names></name><name name-style="western"><surname>Cambier</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Lenz</surname><given-names>L.L.</given-names></name></person-group><article-title>MPYS Is Required for IFN Response Factor 3 Activation and Type I IFN Production in the Response of Cultured Phagocytes to Bacterial Second Messengers Cyclic-di-AMP and Cyclic-di-GMP</article-title><source>J. Immunol.</source><year>2011</year><volume>187</volume><fpage>2595</fpage><lpage>2601</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1100088</pub-id><pub-id pub-id-type="pmid">21813776</pub-id><pub-id pub-id-type="pmcid">PMC3159690</pub-id></element-citation></ref><ref id="B51-vaccines-09-00917"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martin</surname><given-names>G.R.</given-names></name><name name-style="western"><surname>Blomquist</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Henare</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Jirik</surname><given-names>F.R.</given-names></name></person-group><article-title>Stimulator of interferon genes (STING) activation exacerbates experimental colitis in mice</article-title><source>Sci. Rep.</source><year>2019</year><volume>9</volume><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1038/s41598-019-50656-5</pub-id><pub-id pub-id-type="pmid">31582793</pub-id><pub-id pub-id-type="pmcid">PMC6776661</pub-id></element-citation></ref><ref id="B52-vaccines-09-00917"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Darling</surname><given-names>R.</given-names></name><name name-style="western"><surname>Senapati</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kelly</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Kohut</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Narasimhan</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wannemuehler</surname><given-names>M.J.</given-names></name></person-group><article-title>STING pathway stimulation results in a differentially activated innate immune phenotype associated with low nitric oxide and enhanced antibody titers in young and aged mice</article-title><source>Vaccine</source><year>2019</year><volume>37</volume><fpage>2721</fpage><lpage>2730</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2019.04.004</pub-id><pub-id pub-id-type="pmid">30987850</pub-id><pub-id pub-id-type="pmcid">PMC6499688</pub-id></element-citation></ref><ref id="B53-vaccines-09-00917"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mansouri</surname><given-names>S.</given-names></name><name name-style="western"><surname>Katikaneni</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Gogoi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>L.</given-names></name></person-group><article-title>Monocyte-Derived Dendritic Cells (moDCs) Differentiate into Bcl6+ Mature moDCs to Promote Cyclic di-GMP Vaccine Adjuvant&#8211;Induced Memory TH Cells in the Lung</article-title><source>J. Immunol.</source><year>2021</year><volume>206</volume><fpage>2233</fpage><lpage>2245</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.2001347</pub-id><pub-id pub-id-type="pmid">33879579</pub-id><pub-id pub-id-type="pmcid">PMC8063211</pub-id></element-citation></ref><ref id="B54-vaccines-09-00917"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abdul-Sater</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Tattoli</surname><given-names>I.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Grajkowski</surname><given-names>A.</given-names></name><name name-style="western"><surname>Levi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Koller</surname><given-names>B.H.</given-names></name><name name-style="western"><surname>Allen</surname><given-names>I.C.</given-names></name><name name-style="western"><surname>Beaucage</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Fitzgerald</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Ting</surname><given-names>J.P.Y.</given-names></name><etal/></person-group><article-title>Cyclic-di-GMP and cyclic-di-AMP activate the NLRP3 inflammasome</article-title><source>EMBO Rep.</source><year>2013</year><volume>14</volume><fpage>900</fpage><lpage>906</lpage><pub-id pub-id-type="doi">10.1038/embor.2013.132</pub-id><pub-id pub-id-type="pmid">24008845</pub-id><pub-id pub-id-type="pmcid">PMC3807221</pub-id></element-citation></ref><ref id="B55-vaccines-09-00917"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walker</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Crute</surname><given-names>B.W.</given-names></name><name name-style="western"><surname>Cambier</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Getahun</surname><given-names>A.</given-names></name></person-group><article-title>B Cell&#8211;Intrinsic STING Signaling Triggers Cell Activation, Synergizes with B Cell Receptor Signals, and Promotes Antibody Responses</article-title><source>J. Immunol.</source><year>2018</year><volume>201</volume><fpage>2641</fpage><lpage>2653</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1701405</pub-id><pub-id pub-id-type="pmid">30282750</pub-id><pub-id pub-id-type="pmcid">PMC6497520</pub-id></element-citation></ref><ref id="B56-vaccines-09-00917"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Imanishi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Unno</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kobayashi</surname><given-names>W.</given-names></name><name name-style="western"><surname>Yoneda</surname><given-names>N.</given-names></name><name name-style="western"><surname>Matsuda</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ikeda</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hoshii</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hirao</surname><given-names>A.</given-names></name><name name-style="western"><surname>Miyake</surname><given-names>K.</given-names></name><name name-style="western"><surname>Barber</surname><given-names>G.N.</given-names></name><etal/></person-group><article-title>Reciprocal regulation of STING and TCR signaling by mTORC1 for T-cell activation and function</article-title><source>Life Sci. Alliance</source><year>2019</year><volume>2</volume><fpage>e201800282</fpage><pub-id pub-id-type="doi">10.26508/lsa.201800282</pub-id><pub-id pub-id-type="pmid">30683688</pub-id><pub-id pub-id-type="pmcid">PMC6348487</pub-id></element-citation></ref><ref id="B57-vaccines-09-00917"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gutjahr</surname><given-names>A.</given-names></name><name name-style="western"><surname>Papagno</surname><given-names>L.</given-names></name><name name-style="western"><surname>Nicoli</surname><given-names>F.</given-names></name><name name-style="western"><surname>Kanuma</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kuse</surname><given-names>N.</given-names></name><name name-style="western"><surname>Cabral-Piccin</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Rochereau</surname><given-names>N.</given-names></name><name name-style="western"><surname>Gostick</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lioux</surname><given-names>T.</given-names></name><name name-style="western"><surname>Perouzel</surname><given-names>E.</given-names></name><etal/></person-group><article-title>The STING ligand cGAMP potentiates the efficacy of vaccine-induced CD8+ T cells</article-title><source>JCI Insight</source><year>2019</year><volume>4</volume><pub-id pub-id-type="doi">10.1172/jci.insight.125107</pub-id><pub-id pub-id-type="pmid">30944257</pub-id><pub-id pub-id-type="pmcid">PMC6483644</pub-id></element-citation></ref><ref id="B58-vaccines-09-00917"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuse</surname><given-names>N.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X.</given-names></name><name name-style="western"><surname>Akahoshi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Lissina</surname><given-names>A.</given-names></name><name name-style="western"><surname>Yamamoto</surname><given-names>T.</given-names></name><name name-style="western"><surname>Appay</surname><given-names>V.</given-names></name><name name-style="western"><surname>Takiguchi</surname><given-names>M.</given-names></name></person-group><article-title>Priming of HIV-1-specific CD8+ T cells with strong functional properties from na&#239;ve T cells</article-title><source>EBioMedicine</source><year>2019</year><volume>42</volume><fpage>109</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1016/j.ebiom.2019.03.078</pub-id><pub-id pub-id-type="pmid">30956171</pub-id><pub-id pub-id-type="pmcid">PMC6491959</pub-id></element-citation></ref><ref id="B59-vaccines-09-00917"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yamamoto</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kanuma</surname><given-names>T.</given-names></name><name name-style="western"><surname>Takahama</surname><given-names>S.</given-names></name><name name-style="western"><surname>Okamura</surname><given-names>T.</given-names></name><name name-style="western"><surname>Moriishi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ishii</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Terahara</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yasutomi</surname><given-names>Y.</given-names></name></person-group><article-title>STING agonists activate latently infected cells and enhance SIV-specific responses ex vivo in naturally SIV controlled cynomolgus macaques</article-title><source>Sci. Rep.</source><year>2019</year><volume>9</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1038/s41598-019-42253-3</pub-id><pub-id pub-id-type="pmid">30976083</pub-id><pub-id pub-id-type="pmcid">PMC6459902</pub-id></element-citation></ref><ref id="B60-vaccines-09-00917"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elmanfi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sintim</surname><given-names>H.O.</given-names></name><name name-style="western"><surname>K&#246;n&#246;nen</surname><given-names>E.</given-names></name><name name-style="western"><surname>G&#252;rsoy</surname><given-names>M.</given-names></name><name name-style="western"><surname>G&#252;rsoy</surname><given-names>U.K.</given-names></name></person-group><article-title>Regulation of gingival epithelial cytokine response by bacterial cyclic dinucleotides</article-title><source>J. Oral Microbiol.</source><year>2018</year><volume>11</volume><fpage>1538927</fpage><pub-id pub-id-type="doi">10.1080/20002297.2018.1538927</pub-id><pub-id pub-id-type="pmid">30598733</pub-id><pub-id pub-id-type="pmcid">PMC6263105</pub-id></element-citation></ref><ref id="B61-vaccines-09-00917"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yan</surname><given-names>H.</given-names></name><name name-style="western"><surname>KuoLee</surname><given-names>R.</given-names></name><name name-style="western"><surname>Tram</surname><given-names>K.</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>G.B.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W.</given-names></name></person-group><article-title>3&#8242;,5&#8242;-Cyclic diguanylic acid elicits mucosal immunity against bacterial infection</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2009</year><volume>387</volume><fpage>581</fpage><lpage>584</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2009.07.061</pub-id><pub-id pub-id-type="pmid">19615973</pub-id></element-citation></ref><ref id="B62-vaccines-09-00917"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ogunniyi</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Paton</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Kirby</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>McCullers</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Cook</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hyodo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hayakawa</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Karaolis</surname><given-names>D.K.</given-names></name></person-group><article-title>c-di-GMP is an effective immunomodulator and vaccine adjuvant against pneumococcal infection</article-title><source>Vaccine</source><year>2008</year><volume>26</volume><fpage>4676</fpage><lpage>4685</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2008.06.099</pub-id><pub-id pub-id-type="pmid">18640167</pub-id><pub-id pub-id-type="pmcid">PMC2647696</pub-id></element-citation></ref><ref id="B63-vaccines-09-00917"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>L.</given-names></name><name name-style="western"><surname>KuoLee</surname><given-names>R.</given-names></name><name name-style="western"><surname>Harris</surname><given-names>G.</given-names></name><name name-style="western"><surname>Tram</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W.</given-names></name></person-group><article-title>c-di-GMP protects against intranasal Acinetobacter baumannii infection in mice by chemokine induction and enhanced neutrophil recruitment</article-title><source>Int. Immunopharmacol.</source><year>2011</year><volume>11</volume><fpage>1378</fpage><lpage>1383</lpage><pub-id pub-id-type="doi">10.1016/j.intimp.2011.03.024</pub-id><pub-id pub-id-type="pmid">21496497</pub-id></element-citation></ref><ref id="B64-vaccines-09-00917"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Skouboe</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Knudsen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Reinert</surname><given-names>L.</given-names></name><name name-style="western"><surname>Boularan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lioux</surname><given-names>T.</given-names></name><name name-style="western"><surname>P&#233;rouzel</surname><given-names>E.</given-names></name><name name-style="western"><surname>Thomsen</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Paludan</surname><given-names>S.R.</given-names></name></person-group><article-title>STING agonists enable antiviral cross-talk between human cells and confer protection against genital herpes in mice</article-title><source>PLoS Pathog.</source><year>2018</year><volume>14</volume><elocation-id>e1006976</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1006976</pub-id><pub-id pub-id-type="pmid">29608601</pub-id><pub-id pub-id-type="pmcid">PMC5897032</pub-id></element-citation></ref><ref id="B65-vaccines-09-00917"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blaauboer</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Mansouri</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tucker</surname><given-names>H.R.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.L.</given-names></name><name name-style="western"><surname>Gabrielle</surname><given-names>V.D.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>L.</given-names></name></person-group><article-title>The mucosal adjuvant cyclic di-GMP enhances antigen uptake and selectively activates pinocytosis-efficient cells in vivo</article-title><source>eLife</source><year>2015</year><volume>4</volume><fpage>e06670</fpage><pub-id pub-id-type="doi">10.7554/eLife.06670</pub-id><pub-id pub-id-type="pmcid">PMC4428110</pub-id><pub-id pub-id-type="pmid">25898005</pub-id></element-citation></ref><ref id="B66-vaccines-09-00917"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elahi</surname><given-names>S.</given-names></name><name name-style="western"><surname>van Kessel</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kiros</surname><given-names>T.G.</given-names></name><name name-style="western"><surname>Strom</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hayakawa</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hyodo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Babiuk</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Gerdts</surname><given-names>V.</given-names></name></person-group><article-title>c-di-GMP Enhances Protective Innate Immunity in a Murine Model of Pertussis</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><elocation-id>e109778</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0109778</pub-id><pub-id pub-id-type="pmid">25333720</pub-id><pub-id pub-id-type="pmcid">PMC4198122</pub-id></element-citation></ref><ref id="B67-vaccines-09-00917"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fatima</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rempel</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kuang</surname><given-names>X.T.</given-names></name><name name-style="western"><surname>Allen</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Malouin</surname><given-names>F.</given-names></name><name name-style="western"><surname>Diarra</surname><given-names>M.S.</given-names></name></person-group><article-title>Effect of 3&#8217;,5&#8217;-cyclic diguanylic acid in a broiler Clostridium perfringens infection model</article-title><source>Poult. Sci.</source><year>2013</year><volume>92</volume><fpage>2644</fpage><lpage>2650</lpage><pub-id pub-id-type="doi">10.3382/ps.2013-03143</pub-id><pub-id pub-id-type="pmid">24046411</pub-id></element-citation></ref><ref id="B68-vaccines-09-00917"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karaolis</surname><given-names>D.K.R.</given-names></name><name name-style="western"><surname>Newstead</surname><given-names>M.W.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Hyodo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hayakawa</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Bhan</surname><given-names>U.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Standiford</surname><given-names>T.J.</given-names></name></person-group><article-title>Cyclic Di-GMP Stimulates Protective Innate Immunity in Bacterial Pneumonia</article-title><source>Infect. Immun.</source><year>2007</year><volume>75</volume><fpage>4942</fpage><lpage>4950</lpage><pub-id pub-id-type="doi">10.1128/IAI.01762-06</pub-id><pub-id pub-id-type="pmid">17646358</pub-id><pub-id pub-id-type="pmcid">PMC2044534</pub-id></element-citation></ref><ref id="B69-vaccines-09-00917"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johnson</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Uchimura</surname><given-names>T.</given-names></name><name name-style="western"><surname>Gallovic</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Thamilarasan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chou</surname><given-names>W.-C.</given-names></name><name name-style="western"><surname>Gibson</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tam</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Batty</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>J.</given-names></name><etal/></person-group><article-title>STING Agonist Mitigates Experimental Autoimmune Encephalomyelitis by Stimulating Type I IFN&#8211;Dependent and &#8211;Independent Immune-Regulatory Pathways</article-title><source>J. Immunol.</source><year>2021</year><volume>206</volume><fpage>2015</fpage><lpage>2028</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.2001317</pub-id><pub-id pub-id-type="pmid">33820855</pub-id><pub-id pub-id-type="pmcid">PMC8406342</pub-id></element-citation></ref><ref id="B70-vaccines-09-00917"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ohkuri</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ghosh</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kosaka</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ikeura</surname><given-names>M.</given-names></name><name name-style="western"><surname>David</surname><given-names>M.</given-names></name><name name-style="western"><surname>Watkins</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Sarkar</surname><given-names>S.N.</given-names></name><name name-style="western"><surname>Okada</surname><given-names>H.</given-names></name></person-group><article-title>STING contributes to antiglioma immunity via triggering type I IFN signals in the tumor microenvironment</article-title><source>Cancer Immunol. Res.</source><year>2014</year><volume>2</volume><fpage>1199</fpage><lpage>1208</lpage><pub-id pub-id-type="doi">10.1158/2326-6066.CIR-14-0099</pub-id><pub-id pub-id-type="pmid">25300859</pub-id><pub-id pub-id-type="pmcid">PMC4258479</pub-id></element-citation></ref><ref id="B71-vaccines-09-00917"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Corrales</surname><given-names>L.</given-names></name><name name-style="western"><surname>Glickman</surname><given-names>L.H.</given-names></name><name name-style="western"><surname>McWhirter</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Kanne</surname><given-names>D.B.</given-names></name><name name-style="western"><surname>Sivick</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Katibah</surname><given-names>G.E.</given-names></name><name name-style="western"><surname>Woo</surname><given-names>S.-R.</given-names></name><name name-style="western"><surname>Lemmens</surname><given-names>E.</given-names></name><name name-style="western"><surname>Banda</surname><given-names>T.</given-names></name><name name-style="western"><surname>Leong</surname><given-names>J.J.</given-names></name><etal/></person-group><article-title>Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity</article-title><source>Cell Rep.</source><year>2015</year><volume>11</volume><fpage>1018</fpage><lpage>1030</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2015.04.031</pub-id><pub-id pub-id-type="pmid">25959818</pub-id><pub-id pub-id-type="pmcid">PMC4440852</pub-id></element-citation></ref><ref id="B72-vaccines-09-00917"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gadkaree</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sen</surname><given-names>R.</given-names></name><name name-style="western"><surname>Korrer</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Allen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y.J.</given-names></name></person-group><article-title>Induction of tumor regression by intratumoral STING agonists combined with anti-programmed death-L1 blocking antibody in a preclinical squamous cell carcinoma model</article-title><source>Head Neck</source><year>2017</year><volume>39</volume><fpage>1086</fpage><lpage>1094</lpage><pub-id pub-id-type="doi">10.1002/hed.24704</pub-id><pub-id pub-id-type="pmid">28323387</pub-id></element-citation></ref><ref id="B73-vaccines-09-00917"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moore</surname><given-names>E.</given-names></name><name name-style="western"><surname>Clavijo</surname><given-names>P.E.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>R.</given-names></name><name name-style="western"><surname>Cash</surname><given-names>H.</given-names></name><name name-style="western"><surname>van Waes</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Allen</surname><given-names>C.</given-names></name></person-group><article-title>Established T Cell&#8211;Inflamed Tumors Rejected after Adaptive Resistance Was Reversed by Combination STING Activation and PD-1 Pathway Blockade</article-title><source>Cancer Immunol. Res.</source><year>2016</year><volume>4</volume><fpage>1061</fpage><lpage>1071</lpage><pub-id pub-id-type="doi">10.1158/2326-6066.CIR-16-0104</pub-id><pub-id pub-id-type="pmid">27821498</pub-id><pub-id pub-id-type="pmcid">PMC5134907</pub-id></element-citation></ref><ref id="B74-vaccines-09-00917"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wehbe</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wang-Bishop</surname><given-names>L.</given-names></name><name name-style="western"><surname>Becker</surname><given-names>K.W.</given-names></name><name name-style="western"><surname>Shae</surname><given-names>D.</given-names></name><name name-style="western"><surname>Baljon</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>He</surname><given-names>X.</given-names></name><name name-style="western"><surname>Christov</surname><given-names>P.</given-names></name><name name-style="western"><surname>Boyd</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Balko</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>J.T.</given-names></name></person-group><article-title>Nanoparticle delivery improves the pharmacokinetic properties of cyclic dinucleotide STING agonists to open a therapeutic window for intravenous administration</article-title><source>J. Control. Release</source><year>2021</year><volume>330</volume><fpage>1118</fpage><lpage>1129</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2020.11.017</pub-id><pub-id pub-id-type="pmid">33189789</pub-id><pub-id pub-id-type="pmcid">PMC9008741</pub-id></element-citation></ref><ref id="B75-vaccines-09-00917"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang-Bishop</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wehbe</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shae</surname><given-names>D.</given-names></name><name name-style="western"><surname>James</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hacker</surname><given-names>B.C.</given-names></name><name name-style="western"><surname>Garland</surname><given-names>K.</given-names></name><name name-style="western"><surname>Chistov</surname><given-names>P.P.</given-names></name><name name-style="western"><surname>Rafat</surname><given-names>M.</given-names></name><name name-style="western"><surname>Balko</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>J.T.</given-names></name></person-group><article-title>Potent STING activation stimulates immunogenic cell death to enhance antitumor immunity in neuroblastoma</article-title><source>J. Immunother. Cancer</source><year>2019</year><volume>8</volume><fpage>e000282</fpage><pub-id pub-id-type="doi">10.1136/jitc-2019-000282</pub-id><pub-id pub-id-type="pmcid">PMC7069313</pub-id><pub-id pub-id-type="pmid">32169869</pub-id></element-citation></ref><ref id="B76-vaccines-09-00917"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Foote</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Kok</surname><given-names>M.</given-names></name><name name-style="western"><surname>Leatherman</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Armstrong</surname><given-names>T.D.</given-names></name><name name-style="western"><surname>Marcinkowski</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ojalvo</surname><given-names>L.S.</given-names></name><name name-style="western"><surname>Kanne</surname><given-names>D.B.</given-names></name><name name-style="western"><surname>Jaffee</surname><given-names>E.</given-names></name><name name-style="western"><surname>Dubensky</surname><given-names>T.W.</given-names></name><name name-style="western"><surname>Emens</surname><given-names>L.A.</given-names></name></person-group><article-title>A STING Agonist Given with OX40 Receptor and PD-L1 Modulators Primes Immunity and Reduces Tumor Growth in Tolerized Mice</article-title><source>Cancer Immunol. Res.</source><year>2017</year><volume>5</volume><fpage>468</fpage><lpage>479</lpage><pub-id pub-id-type="doi">10.1158/2326-6066.CIR-16-0284</pub-id><pub-id pub-id-type="pmid">28483787</pub-id><pub-id pub-id-type="pmcid">PMC5550830</pub-id></element-citation></ref><ref id="B77-vaccines-09-00917"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bielecki</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Lorkowski</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Becicka</surname><given-names>W.M.</given-names></name><name name-style="western"><surname>Atukorale</surname><given-names>P.U.</given-names></name><name name-style="western"><surname>Moon</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wiese</surname><given-names>M.</given-names></name><name name-style="western"><surname>Covarrubias</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ravichandran</surname><given-names>S.</given-names></name><name name-style="western"><surname>Karathanasis</surname><given-names>E.</given-names></name></person-group><article-title>Immunostimulatory silica nanoparticle boosts innate immunity in brain tumors</article-title><source>Nanoscale Horiz.</source><year>2021</year><volume>6</volume><fpage>156</fpage><lpage>167</lpage><pub-id pub-id-type="doi">10.1039/D0NH00446D</pub-id><pub-id pub-id-type="pmid">33400743</pub-id><pub-id pub-id-type="pmcid">PMC7878432</pub-id></element-citation></ref><ref id="B78-vaccines-09-00917"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Y.P.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>T.W.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Q.H.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>T.P.</given-names></name><name name-style="western"><surname>Mou</surname><given-names>C.Y.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>S.H.</given-names></name></person-group><article-title>STING Activator c-di-GMP-Loaded Mesoporous Silica Nano-particles Enhance Immunotherapy Against Breast Cancer</article-title><source>ACS Appl. Mater. Interfaces</source><year>2020</year><volume>12</volume><fpage>56741</fpage><lpage>56752</lpage><pub-id pub-id-type="doi">10.1021/acsami.0c16728</pub-id><pub-id pub-id-type="pmid">33305564</pub-id></element-citation></ref><ref id="B79-vaccines-09-00917"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>An</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Xi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Reyes</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mao</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>W.Z.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name></person-group><article-title>Induction of necrotic cell death and activation of STING in the tumor mi-croenvironment via cationic silica nanoparticles leading to enhanced antitumor immunity</article-title><source>Nanoscale</source><year>2018</year><volume>10</volume><fpage>9311</fpage><lpage>9319</lpage><pub-id pub-id-type="doi">10.1039/C8NR01376D</pub-id><pub-id pub-id-type="pmid">29737353</pub-id><pub-id pub-id-type="pmcid">PMC5969905</pub-id></element-citation></ref><ref id="B80-vaccines-09-00917"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilson</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Sen</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sunshine</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pardoll</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Green</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y.J.</given-names></name></person-group><article-title>Biodegradable STING agonist nanoparticles for enhanced cancer immunotherapy</article-title><source>Nanomed. Nanotechnol. Biol. Med.</source><year>2018</year><volume>14</volume><fpage>237</fpage><lpage>246</lpage><pub-id pub-id-type="doi">10.1016/j.nano.2017.10.013</pub-id><pub-id pub-id-type="pmid">29127039</pub-id><pub-id pub-id-type="pmcid">PMC6035751</pub-id></element-citation></ref><ref id="B81-vaccines-09-00917"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ager</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Reilley</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Nicholas</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bartkowiak</surname><given-names>T.</given-names></name><name name-style="western"><surname>Jaiswal</surname><given-names>A.</given-names></name><name name-style="western"><surname>Curran</surname><given-names>M.A.</given-names></name></person-group><article-title>Intratumoral STING Activation with T-cell Checkpoint Modulation Generates Systemic Antitumor Immunity</article-title><source>Cancer Immunol. Res.</source><year>2017</year><volume>5</volume><fpage>676</fpage><lpage>684</lpage><pub-id pub-id-type="doi">10.1158/2326-6066.CIR-17-0049</pub-id><pub-id pub-id-type="pmid">28674082</pub-id><pub-id pub-id-type="pmcid">PMC5547907</pub-id></element-citation></ref><ref id="B82-vaccines-09-00917"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>N.</given-names></name><name name-style="western"><surname>Watkins-Schulz</surname><given-names>R.</given-names></name><name name-style="western"><surname>Junkins</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>David</surname><given-names>C.N.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Montgomery</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Peine</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Darr</surname><given-names>D.B.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>H.</given-names></name><name name-style="western"><surname>McKinnon</surname><given-names>K.P.</given-names></name><etal/></person-group><article-title>A nanoparticle-incorporated STING activator enhances antitumor immunity in PD-L1&#8211;insensitive models of triple-negative breast cancer</article-title><source>JCI Insight</source><year>2018</year><volume>3</volume><pub-id pub-id-type="doi">10.1172/jci.insight.120638</pub-id><pub-id pub-id-type="pmid">30429378</pub-id><pub-id pub-id-type="pmcid">PMC6302949</pub-id></element-citation></ref><ref id="B83-vaccines-09-00917"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>T.T.</given-names></name><name name-style="western"><surname>Moffett</surname><given-names>H.</given-names></name><name name-style="western"><surname>Stephan</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Opel</surname><given-names>C.F.</given-names></name><name name-style="western"><surname>Dumigan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Pillarisetty</surname><given-names>V.G.</given-names></name><name name-style="western"><surname>Pillai</surname><given-names>S.P.S.</given-names></name><name name-style="western"><surname>Wittrup</surname><given-names>K.D.</given-names></name><name name-style="western"><surname>Stephan</surname><given-names>M.</given-names></name></person-group><article-title>Biopolymers codelivering engineered T cells and STING agonists can eliminate heterogeneous tumors</article-title><source>J. Clin. Investig.</source><year>2017</year><volume>127</volume><fpage>2176</fpage><lpage>2191</lpage><pub-id pub-id-type="doi">10.1172/JCI87624</pub-id><pub-id pub-id-type="pmid">28436934</pub-id><pub-id pub-id-type="pmcid">PMC5451231</pub-id></element-citation></ref><ref id="B84-vaccines-09-00917"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>An</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Qiao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>T.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name></person-group><article-title>STING: A master regulator in the cancer-immunity cycle</article-title><source>Mol. Cancer</source><year>2019</year><volume>18</volume><fpage>1</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1186/s12943-019-1087-y</pub-id><pub-id pub-id-type="pmid">31679519</pub-id><pub-id pub-id-type="pmcid">PMC6827255</pub-id></element-citation></ref><ref id="B85-vaccines-09-00917"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Atukorale</surname><given-names>P.U.</given-names></name><name name-style="western"><surname>Raghunathan</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Raguveer</surname><given-names>V.</given-names></name><name name-style="western"><surname>Moon</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bielecki</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Wiese</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Goldberg</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Covarrubias</surname><given-names>G.</given-names></name><name name-style="western"><surname>Hoimes</surname><given-names>C.J.</given-names></name><etal/></person-group><article-title>Nanoparticle Encapsulation of Synergistic Immune Agonists Enables Systemic Codelivery to Tumor Sites and IFNbeta-Driven Antitumor Immunity</article-title><source>Cancer Res.</source><year>2019</year><volume>79</volume><fpage>5394</fpage><lpage>5406</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-19-0381</pub-id><pub-id pub-id-type="pmid">31431457</pub-id><pub-id pub-id-type="pmcid">PMC6801091</pub-id></element-citation></ref><ref id="B86-vaccines-09-00917"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Temizoz</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kuroda</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ohata</surname><given-names>K.</given-names></name><name name-style="western"><surname>Jounai</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ozasa</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kobiyama</surname><given-names>K.</given-names></name><name name-style="western"><surname>Aoshi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ishii</surname><given-names>K.J.</given-names></name></person-group><article-title>TLR9 and STING agonists synergistically induce innate and adaptive type-II IFN</article-title><source>Eur. J. Immunol.</source><year>2015</year><volume>45</volume><fpage>1159</fpage><lpage>1169</lpage><pub-id pub-id-type="doi">10.1002/eji.201445132</pub-id><pub-id pub-id-type="pmid">25529558</pub-id><pub-id pub-id-type="pmcid">PMC4671267</pub-id></element-citation></ref><ref id="B87-vaccines-09-00917"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Francica</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Ghasemzadeh</surname><given-names>A.</given-names></name><name name-style="western"><surname>Desbien</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Theodros</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sivick</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Reiner</surname><given-names>G.L.</given-names></name><name name-style="western"><surname>Glickman</surname><given-names>L.H.</given-names></name><name name-style="western"><surname>Marciscano</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Sharabi</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Leong</surname><given-names>M.L.</given-names></name><etal/></person-group><article-title>TNFalpha and Radioresistant Stromal Cells Are Essential for Therapeutic Efficacy of Cyclic Dinucleotide STING Agonists in Nonimmunogenic Tumors</article-title><source>Cancer Immunol. Res.</source><year>2018</year><volume>6</volume><fpage>422</fpage><lpage>433</lpage><pub-id pub-id-type="doi">10.1158/2326-6066.CIR-17-0263</pub-id><pub-id pub-id-type="pmid">29472271</pub-id><pub-id pub-id-type="pmcid">PMC6215542</pub-id></element-citation></ref><ref id="B88-vaccines-09-00917"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Qi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Q.-N.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>D.-L.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>X.-L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>Z.-L.</given-names></name><name name-style="western"><surname>Ju</surname><given-names>H.-Q.</given-names></name><etal/></person-group><article-title>Targeting the STING pathway in tumor-associated macrophages regulates innate immune sensing of gastric cancer cells</article-title><source>Theranostics</source><year>2020</year><volume>10</volume><fpage>498</fpage><lpage>515</lpage><pub-id pub-id-type="doi">10.7150/thno.37745</pub-id><pub-id pub-id-type="pmid">31903134</pub-id><pub-id pub-id-type="pmcid">PMC6929973</pub-id></element-citation></ref><ref id="B89-vaccines-09-00917"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ohkuri</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kosaka</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ishibashi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kumai</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hirata</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ohara</surname><given-names>K.</given-names></name><name name-style="western"><surname>Nagato</surname><given-names>T.</given-names></name><name name-style="western"><surname>Oikawa</surname><given-names>K.</given-names></name><name name-style="western"><surname>Aoki</surname><given-names>N.</given-names></name><name name-style="western"><surname>Harabuchi</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Intratumoral administration of cGAMP transiently ac-cumulates potent macrophages for anti-tumor immunity at a mouse tumor site</article-title><source>Cancer Immunol. Immunother.</source><year>2017</year><volume>66</volume><fpage>705</fpage><lpage>716</lpage><pub-id pub-id-type="doi">10.1007/s00262-017-1975-1</pub-id><pub-id pub-id-type="pmid">28243692</pub-id><pub-id pub-id-type="pmcid">PMC11028681</pub-id></element-citation></ref><ref id="B90-vaccines-09-00917"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nicolai</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Wolf</surname><given-names>N.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>I.-C.</given-names></name><name name-style="western"><surname>Kirn</surname><given-names>G.</given-names></name><name name-style="western"><surname>Marcus</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ndubaku</surname><given-names>C.O.</given-names></name><name name-style="western"><surname>McWhirter</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Raulet</surname><given-names>D.H.</given-names></name></person-group><article-title>NK cells mediate clearance of CD8+ T cell&#8211;resistant tumors in response to STING agonists</article-title><source>Sci. Immunol.</source><year>2020</year><volume>5</volume><fpage>eaaz2738</fpage><pub-id pub-id-type="doi">10.1126/sciimmunol.aaz2738</pub-id><pub-id pub-id-type="pmid">32198222</pub-id><pub-id pub-id-type="pmcid">PMC7228660</pub-id></element-citation></ref><ref id="B91-vaccines-09-00917"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ebensen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Schulze</surname><given-names>K.</given-names></name><name name-style="western"><surname>Riese</surname><given-names>P.</given-names></name><name name-style="western"><surname>Link</surname><given-names>C.</given-names></name><name name-style="western"><surname>Morr</surname><given-names>M.</given-names></name><name name-style="western"><surname>Guzm&#225;n</surname><given-names>C.A.</given-names></name></person-group><article-title>The bacterial second messenger cyclic diGMP exhibits potent adjuvant properties</article-title><source>Vaccine</source><year>2007</year><volume>25</volume><fpage>1464</fpage><lpage>1469</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2006.10.033</pub-id><pub-id pub-id-type="pmid">17187906</pub-id></element-citation></ref><ref id="B92-vaccines-09-00917"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ebensen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Schulze</surname><given-names>K.</given-names></name><name name-style="western"><surname>Riese</surname><given-names>P.</given-names></name><name name-style="western"><surname>Morr</surname><given-names>M.</given-names></name><name name-style="western"><surname>Guzm&#225;n</surname><given-names>C.A.</given-names></name></person-group><article-title>The Bacterial Second Messenger cdiGMP Exhibits Promising Activity as a Mucosal Adjuvant</article-title><source>Clin. Vaccine Immunol.</source><year>2007</year><volume>14</volume><fpage>952</fpage><lpage>958</lpage><pub-id pub-id-type="doi">10.1128/CVI.00119-07</pub-id><pub-id pub-id-type="pmid">17567766</pub-id><pub-id pub-id-type="pmcid">PMC2044480</pub-id></element-citation></ref><ref id="B93-vaccines-09-00917"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Libanova</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ebensen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Schulze</surname><given-names>K.</given-names></name><name name-style="western"><surname>Bruhn</surname><given-names>D.</given-names></name><name name-style="western"><surname>N&#246;rder</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yevsa</surname><given-names>T.</given-names></name><name name-style="western"><surname>Morr</surname><given-names>M.</given-names></name><name name-style="western"><surname>Guzm&#225;n</surname><given-names>C.A.</given-names></name></person-group><article-title>The member of the cyclic di-nucleotide family bis-(3&#8242;, 5&#8242;)-cyclic dimeric inosine monophosphate exerts potent activity as mucosal adjuvant</article-title><source>Vaccine</source><year>2010</year><volume>28</volume><fpage>2249</fpage><lpage>2258</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2009.12.045</pub-id><pub-id pub-id-type="pmid">20060510</pub-id></element-citation></ref><ref id="B94-vaccines-09-00917"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>&#352;krnjug</surname><given-names>I.</given-names></name><name name-style="western"><surname>Guzm&#225;n</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ruecker</surname><given-names>C.</given-names></name></person-group><article-title>Cyclic GMP-AMP Displays Mucosal Adjuvant Activity in Mice</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><elocation-id>e110150</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0110150</pub-id><pub-id pub-id-type="pmid">25295996</pub-id><pub-id pub-id-type="pmcid">PMC4190368</pub-id></element-citation></ref><ref id="B95-vaccines-09-00917"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gray</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Forrest</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wisniewski</surname><given-names>T.</given-names></name><name name-style="western"><surname>Porter</surname><given-names>G.</given-names></name><name name-style="western"><surname>Freed</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>DeMartino</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Zaller</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Leone</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>T.-M.</given-names></name><etal/></person-group><article-title>Evidence for cyclic diguanylate as a vaccine adjuvant with novel immunostimulatory activities</article-title><source>Cell. Immunol.</source><year>2012</year><volume>278</volume><fpage>113</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1016/j.cellimm.2012.07.006</pub-id><pub-id pub-id-type="pmid">23121983</pub-id></element-citation></ref><ref id="B96-vaccines-09-00917"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Volckmar</surname><given-names>J.</given-names></name><name name-style="western"><surname>Knop</surname><given-names>L.</given-names></name><name name-style="western"><surname>Stegemann-Koniszewski</surname><given-names>S.</given-names></name><name name-style="western"><surname>Schulze</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ebensen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Guzman</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Bruder</surname><given-names>D.</given-names></name></person-group><article-title>The STING activator c-di-AMP exerts superior adjuvant properties than the formulation poly(I:C)/CpG after subcutaneous vaccination with soluble protein antigen or DEC-205-mediated antigen targeting to dendritic cells</article-title><source>Vaccine</source><year>2019</year><volume>37</volume><fpage>4963</fpage><lpage>4974</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2019.07.019</pub-id><pub-id pub-id-type="pmid">31320219</pub-id></element-citation></ref><ref id="B97-vaccines-09-00917"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yildiz</surname><given-names>S.</given-names></name><name name-style="western"><surname>Alpdundar</surname><given-names>E.</given-names></name><name name-style="western"><surname>Gungor</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kahraman</surname><given-names>T.</given-names></name><name name-style="western"><surname>Bayyurt</surname><given-names>B.</given-names></name><name name-style="western"><surname>Gursel</surname><given-names>I.</given-names></name><name name-style="western"><surname>Gursel</surname><given-names>M.</given-names></name></person-group><article-title>Enhanced immunostimulatory activity of cyclic dinucleotides on mouse cells when complexed with a cell-penetrating peptide or combined with CpG</article-title><source>Eur. J. Immunol.</source><year>2015</year><volume>45</volume><fpage>1170</fpage><lpage>1179</lpage><pub-id pub-id-type="doi">10.1002/eji.201445133</pub-id><pub-id pub-id-type="pmid">25581346</pub-id></element-citation></ref><ref id="B98-vaccines-09-00917"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>W.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C.P.</given-names></name></person-group><article-title>Distinct Dynamic and Conformational Features of Human STING in Re-sponse to 2&#8242;3&#8242;-cGAMP and c-di-GMP</article-title><source>Chembiochem Eur. J. Chem. Biol.</source><year>2019</year><volume>20</volume><fpage>1838</fpage><lpage>1847</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cbic.201900051</pub-id><pub-id pub-id-type="pmid">30895657</pub-id></element-citation></ref><ref id="B99-vaccines-09-00917"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>KuoLee</surname><given-names>R.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W.</given-names></name></person-group><article-title>Synthesis and immunostimulatory properties of the phosphorothioate analogues of cdiGMP</article-title><source>Bioorganic Med. Chem. Lett.</source><year>2008</year><volume>18</volume><fpage>5631</fpage><lpage>5634</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2008.08.088</pub-id><pub-id pub-id-type="pmid">18799311</pub-id></element-citation></ref><ref id="B100-vaccines-09-00917"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>H.</given-names></name></person-group><article-title>2&#8242;-Fluoro-c-di-GMP as an oral vaccine adjuvant</article-title><source>RSC Adv.</source><year>2019</year><volume>9</volume><fpage>41481</fpage><lpage>41489</lpage><pub-id pub-id-type="doi">10.1039/C9RA08310C</pub-id><pub-id pub-id-type="pmcid">PMC9076492</pub-id><pub-id pub-id-type="pmid">35541605</pub-id></element-citation></ref><ref id="B101-vaccines-09-00917"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Flores-Valdez</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Aceves-S&#225;nchez</surname><given-names>M.D.J.</given-names></name><name name-style="western"><surname>Montero-P&#233;rez</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>S&#225;nchez-L&#243;pez</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Guti&#233;rrez-Pabello</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Hern&#225;ndez-Pando</surname><given-names>R.</given-names></name></person-group><article-title>Vaccination of mice with recombinant bacille Calmette-Gu&#233;rin harboring Rv1357c protects similarly to native BCG</article-title><source>Int. J. Tuberc. Lung Dis.</source><year>2012</year><volume>16</volume><fpage>774</fpage><lpage>776</lpage><pub-id pub-id-type="doi">10.5588/ijtld.11.0735</pub-id><pub-id pub-id-type="pmid">22507759</pub-id></element-citation></ref><ref id="B102-vaccines-09-00917"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pedroza-Roldan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Guapillo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Barrios-Pay&#225;n</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mata-Espinosa</surname><given-names>D.</given-names></name><name name-style="western"><surname>Aceves-S&#225;nchez</surname><given-names>M.D.J.</given-names></name><name name-style="western"><surname>Marquina-Castillo</surname><given-names>B.</given-names></name><name name-style="western"><surname>Hern&#225;ndez-Pando</surname><given-names>R.</given-names></name><name name-style="western"><surname>Flores-Valdez</surname><given-names>M.A.</given-names></name></person-group><article-title>The BCG&#916;BCG1419c strain, which produces more pellicle in vitro, improves control of chronic tuberculosis in vivo</article-title><source>Vaccine</source><year>2016</year><volume>34</volume><fpage>4763</fpage><lpage>4770</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2016.08.035</pub-id><pub-id pub-id-type="pmid">27546876</pub-id></element-citation></ref><ref id="B103-vaccines-09-00917"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ning</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>T.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Bai</surname><given-names>Y.</given-names></name></person-group><article-title>Recombinant BCG With Bacterial Signaling Molecule Cyclic di-AMP as Endogenous Adjuvant Induces Elevated Immune Responses After Mycobacterium tuberculosis Infection</article-title><source>Front. Immunol.</source><year>2019</year><volume>10</volume><fpage>1519</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2019.01519</pub-id><pub-id pub-id-type="pmid">31333655</pub-id><pub-id pub-id-type="pmcid">PMC6618344</pub-id></element-citation></ref><ref id="B104-vaccines-09-00917"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dey</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Dey</surname><given-names>B.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Praharaj</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bishai</surname><given-names>W.</given-names></name></person-group><article-title>Bacillus Calmette-Gu&#233;rin Overexpressing an Endogenous Stimulator of Interferon Genes Agonist Provides Enhanced Protection Against Pulmonary Tuberculosis</article-title><source>J. Infect. Dis.</source><year>2020</year><volume>221</volume><fpage>1048</fpage><lpage>1056</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiz116</pub-id><pub-id pub-id-type="pmid">30901058</pub-id><pub-id pub-id-type="pmcid">PMC7931846</pub-id></element-citation></ref><ref id="B105-vaccines-09-00917"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Madhun</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Haaheim</surname><given-names>L.R.</given-names></name><name name-style="western"><surname>Nostbakken</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Ebensen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Chichester</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yusibov</surname><given-names>V.</given-names></name><name name-style="western"><surname>Guzm&#225;n</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Cox</surname><given-names>R.J.</given-names></name></person-group><article-title>Intranasal c-di-GMP-adjuvanted plant-derived H5 influenza vaccine induces multifunctional Th1 CD4+ cells and strong mucosal and systemic antibody re-sponses in mice</article-title><source>Vaccine</source><year>2011</year><volume>29</volume><fpage>4973</fpage><lpage>4982</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2011.04.094</pub-id><pub-id pub-id-type="pmid">21600260</pub-id></element-citation></ref><ref id="B106-vaccines-09-00917"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pedersen</surname><given-names>G.K.</given-names></name><name name-style="western"><surname>Ebensen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Gjeraker</surname><given-names>I.H.</given-names></name><name name-style="western"><surname>Svindland</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bredholt</surname><given-names>G.</given-names></name><name name-style="western"><surname>Guzm&#225;n</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Cox</surname><given-names>R.J.</given-names></name></person-group><article-title>Evaluation of the Sublingual Route for Administration of Influenza H5N1 Virosomes in Combination with the Bacterial Second Messenger c-di-GMP</article-title><source>PLoS ONE</source><year>2011</year><volume>6</volume><elocation-id>e26973</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0026973</pub-id><pub-id pub-id-type="pmid">22069479</pub-id><pub-id pub-id-type="pmcid">PMC3206068</pub-id></element-citation></ref><ref id="B107-vaccines-09-00917"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Svindland</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Pedersen</surname><given-names>G.</given-names></name><name name-style="western"><surname>Pathirana</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Bredholt</surname><given-names>G.</given-names></name><name name-style="western"><surname>N&#248;stbakken</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Jul-Larsen</surname><given-names>&#197;.</given-names></name><name name-style="western"><surname>Guzm&#225;n</surname><given-names>C.</given-names></name><name name-style="western"><surname>Montomoli</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lapini</surname><given-names>G.</given-names></name><name name-style="western"><surname>Piccirella</surname><given-names>S.</given-names></name><etal/></person-group><article-title>A study of Chitosan and c-di-GMP as mucosal adjuvants for intranasal influenza H5N1 vaccine</article-title><source>Influenza Other Respir. Viruses</source><year>2012</year><volume>7</volume><fpage>1181</fpage><lpage>1193</lpage><pub-id pub-id-type="doi">10.1111/irv.12056</pub-id><pub-id pub-id-type="pmid">23170900</pub-id><pub-id pub-id-type="pmcid">PMC4634239</pub-id></element-citation></ref><ref id="B108-vaccines-09-00917"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Neuhaus</surname><given-names>V.</given-names></name><name name-style="western"><surname>Chichester</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Ebensen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Schwarz</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hartman</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Shoji</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Guzm&#225;n</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Yusibov</surname><given-names>V.</given-names></name><name name-style="western"><surname>Sewald</surname><given-names>K.</given-names></name><name name-style="western"><surname>Braun</surname><given-names>A.</given-names></name></person-group><article-title>A new adjuvanted nanoparticle-based H1N1 influenza vaccine induced antigen-specific local mucosal and systemic immune responses after administration into the lung</article-title><source>Vaccine</source><year>2014</year><volume>32</volume><fpage>3216</fpage><lpage>3222</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2014.04.011</pub-id><pub-id pub-id-type="pmid">24731807</pub-id></element-citation></ref><ref id="B109-vaccines-09-00917"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Major</surname><given-names>D.</given-names></name><name name-style="western"><surname>Chichester</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Pathirana</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Guilfoyle</surname><given-names>K.</given-names></name><name name-style="western"><surname>Shoji</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Guzm&#225;n</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yusibov</surname><given-names>V.</given-names></name><name name-style="western"><surname>Cox</surname><given-names>R.J.</given-names></name></person-group><article-title>Intranasal vaccination with a plant-derived H5 HA vaccine protects mice and ferrets against highly pathogenic avian influenza virus challenge</article-title><source>Hum. Vaccines Immunother.</source><year>2015</year><volume>11</volume><fpage>1235</fpage><lpage>1243</lpage><pub-id pub-id-type="doi">10.4161/21645515.2014.988554</pub-id><pub-id pub-id-type="pmcid">PMC4514375</pub-id><pub-id pub-id-type="pmid">25714901</pub-id></element-citation></ref><ref id="B110-vaccines-09-00917"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shin</surname><given-names>J.-H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.-H.</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Noh</surname><given-names>J.-Y.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H.W.</given-names></name><name name-style="western"><surname>Song</surname><given-names>C.-S.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y.-C.</given-names></name></person-group><article-title>C-di-GMP with influenza vaccine showed enhanced and shifted immune responses in microneedle vaccination in the skin</article-title><source>Drug Deliv. Transl. Res.</source><year>2020</year><volume>10</volume><fpage>815</fpage><lpage>825</lpage><pub-id pub-id-type="doi">10.1007/s13346-020-00728-1</pub-id><pub-id pub-id-type="pmid">32141036</pub-id></element-citation></ref><ref id="B111-vaccines-09-00917"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Allen</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Wilk</surname><given-names>M.</given-names></name><name name-style="western"><surname>Misiak</surname><given-names>A.</given-names></name><name name-style="western"><surname>Borkner</surname><given-names>L.</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>D.</given-names></name><name name-style="western"><surname>Mills</surname><given-names>K.H.G.</given-names></name></person-group><article-title>Sustained protective immunity against Bordetella pertussis nasal colonization by intranasal immunization with a vaccine-adjuvant combination that induces IL-17-secreting TRM cells</article-title><source>Mucosal Immunol.</source><year>2018</year><volume>11</volume><fpage>1763</fpage><lpage>1776</lpage><pub-id pub-id-type="doi">10.1038/s41385-018-0080-x</pub-id><pub-id pub-id-type="pmid">30127384</pub-id></element-citation></ref><ref id="B112-vaccines-09-00917"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>D.-L.</given-names></name><name name-style="western"><surname>Narita</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hyodo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hayakawa</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Nakane</surname><given-names>A.</given-names></name><name name-style="western"><surname>Karaolis</surname><given-names>D.K.</given-names></name></person-group><article-title>c-di-GMP as a vaccine adjuvant enhances protection against systemic methicillin-resistant Staphylococcus aureus (MRSA) infection</article-title><source>Vaccine</source><year>2009</year><volume>27</volume><fpage>4867</fpage><lpage>4873</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2009.04.053</pub-id><pub-id pub-id-type="pmid">19406185</pub-id></element-citation></ref><ref id="B113-vaccines-09-00917"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Latanova</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Petkov</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kilpelainen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jansons</surname><given-names>J.</given-names></name><name name-style="western"><surname>Latyshev</surname><given-names>O.E.</given-names></name><name name-style="western"><surname>Kuzmenko</surname><given-names>Y.V.</given-names></name><name name-style="western"><surname>Hinkula</surname><given-names>J.</given-names></name><name name-style="western"><surname>Abakumov</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Valuev-Eliston</surname><given-names>V.T.</given-names></name><name name-style="western"><surname>Gomelsy</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Codon optimization and improved delivery/immunization regimen enhance the immune response against wild-type and drug-resistant HIV-1 reverse tran-scriptase, preserving its Th2-polarity</article-title><source>Sci. Rep.</source><year>2018</year><volume>8</volume><fpage>8078</fpage><pub-id pub-id-type="doi">10.1038/s41598-018-26281-z</pub-id><pub-id pub-id-type="pmid">29799015</pub-id><pub-id pub-id-type="pmcid">PMC5967322</pub-id></element-citation></ref><ref id="B114-vaccines-09-00917"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Jo</surname><given-names>H.</given-names></name><name name-style="western"><surname>Shin</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>B.</given-names></name><name name-style="western"><surname>Shim</surname><given-names>H.S.</given-names></name><name name-style="western"><surname>Park</surname><given-names>J.H.</given-names></name></person-group><article-title>Mincle and STING-Stimulating Adjuvants Elicit Robust Cellular Immunity and Drive Long-Lasting Memory Responses in a Foot-and-Mouth Disease Vaccine</article-title><source>Front. Immunol.</source><year>2019</year><volume>10</volume><fpage>2509</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2019.02509</pub-id><pub-id pub-id-type="pmid">31736952</pub-id><pub-id pub-id-type="pmcid">PMC6828931</pub-id></element-citation></ref><ref id="B115-vaccines-09-00917"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Azegami</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yuki</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sawada</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mejima</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ishige</surname><given-names>K.</given-names></name><name name-style="western"><surname>Akiyoshi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Itoh</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kiyono</surname><given-names>H.</given-names></name></person-group><article-title>Nanogel-based nasal ghrelin vaccine prevents obesity</article-title><source>Mucosal Immunol.</source><year>2017</year><volume>10</volume><fpage>1351</fpage><lpage>1360</lpage><pub-id pub-id-type="doi">10.1038/mi.2016.137</pub-id><pub-id pub-id-type="pmid">28120848</pub-id></element-citation></ref><ref id="B116-vaccines-09-00917"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Azegami</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yuki</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hayashi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hishikawa</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sawada</surname><given-names>S.-I.</given-names></name><name name-style="western"><surname>Ishige</surname><given-names>K.</given-names></name><name name-style="western"><surname>Akiyoshi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kiyono</surname><given-names>H.</given-names></name><name name-style="western"><surname>Itoh</surname><given-names>H.</given-names></name></person-group><article-title>Intranasal vaccination against angiotensin II type 1 receptor and pneumococcal surface protein A attenuates hypertension and pneumococcal infection in rodents</article-title><source>J. Hypertens.</source><year>2018</year><volume>36</volume><fpage>387</fpage><lpage>394</lpage><pub-id pub-id-type="doi">10.1097/HJH.0000000000001519</pub-id><pub-id pub-id-type="pmid">28832363</pub-id></element-citation></ref><ref id="B117-vaccines-09-00917"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ebensen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Debarry</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pedersen</surname><given-names>G.K.</given-names></name><name name-style="western"><surname>Blazejewska</surname><given-names>P.</given-names></name><name name-style="western"><surname>Weissmann</surname><given-names>S.</given-names></name><name name-style="western"><surname>Schulze</surname><given-names>K.</given-names></name><name name-style="western"><surname>McCullough</surname><given-names>K.C.</given-names></name><name name-style="western"><surname>Cox</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Guzman</surname><given-names>C.A.</given-names></name></person-group><article-title>Mucosal Administration of Cy-cle-Di-Nucleotide-Adjuvanted Virosomes Efficiently Induces Protection against Influenza H5N1 in Mice</article-title><source>Front. Immunol.</source><year>2017</year><volume>8</volume><fpage>1223</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2017.01223</pub-id><pub-id pub-id-type="pmid">29033942</pub-id><pub-id pub-id-type="pmcid">PMC5624999</pub-id></element-citation></ref><ref id="B118-vaccines-09-00917"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sanchez</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ebensen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Schulze</surname><given-names>K.</given-names></name><name name-style="western"><surname>Cargnelutti</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Blazejewska</surname><given-names>P.</given-names></name><name name-style="western"><surname>Scodeller</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Guzm&#225;n</surname><given-names>C.A.</given-names></name></person-group><article-title>Intranasal Delivery of Influenza rNP Adjuvanted with c-di-AMP Induces Strong Humoral and Cellular Immune Responses and Provides Protection against Virus Challenge</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><elocation-id>e104824</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0104824</pub-id><pub-id pub-id-type="pmid">25140692</pub-id><pub-id pub-id-type="pmcid">PMC4139298</pub-id></element-citation></ref><ref id="B119-vaccines-09-00917"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ning</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>T.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Bai</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Subunit Vaccine ESAT-6:c-di-AMP Delivered by Intranasal Route Elicits Immune Responses and Protects Against Mycobacterium tuberculosis Infection</article-title><source>Front. Cell. Infect. Microbiol.</source><year>2021</year><volume>11</volume><pub-id pub-id-type="doi">10.3389/fcimb.2021.647220</pub-id><pub-id pub-id-type="pmid">33829000</pub-id><pub-id pub-id-type="pmcid">PMC8019782</pub-id></element-citation></ref><ref id="B120-vaccines-09-00917"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schulze</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ebensen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Chandrudu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Skwarczynski</surname><given-names>M.</given-names></name><name name-style="western"><surname>Toth</surname><given-names>I.</given-names></name><name name-style="western"><surname>Olive</surname><given-names>C.</given-names></name><name name-style="western"><surname>Guzman</surname><given-names>C.A.</given-names></name></person-group><article-title>Bivalent mucosal peptide vaccines administered using the LCP carrier system stimulate protective immune responses against Streptococcus pyogenes infection</article-title><source>Nanomed. Nanotechnol. Biol. Med.</source><year>2017</year><volume>13</volume><fpage>2463</fpage><lpage>2474</lpage><pub-id pub-id-type="doi">10.1016/j.nano.2017.08.015</pub-id><pub-id pub-id-type="pmid">28887213</pub-id></element-citation></ref><ref id="B121-vaccines-09-00917"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Landi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Law</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hockman</surname><given-names>D.</given-names></name><name name-style="western"><surname>Logan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Crawford</surname><given-names>K.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kundu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ebensen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Guzman</surname><given-names>C.</given-names></name><name name-style="western"><surname>Deschatelets</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Superior immunogenicity of HCV envelope glycoproteins when adjuvanted with cyclic-di-AMP, a STING activator or archaeosomes</article-title><source>Vaccine</source><year>2017</year><volume>35</volume><fpage>6949</fpage><lpage>6956</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2017.10.072</pub-id><pub-id pub-id-type="pmid">29089195</pub-id></element-citation></ref><ref id="B122-vaccines-09-00917"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Munoz Gonzalez</surname><given-names>F.</given-names></name><name name-style="western"><surname>Sycz</surname><given-names>G.</given-names></name><name name-style="western"><surname>Alonso Paiva</surname><given-names>I.M.</given-names></name><name name-style="western"><surname>Linke</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zorreguieta</surname><given-names>A.</given-names></name><name name-style="western"><surname>Baldi</surname><given-names>P.C.</given-names></name><name name-style="western"><surname>Ferero</surname><given-names>M.C.</given-names></name></person-group><article-title>The BtaF Adhesin Is Necessary for Full Virulence during Respiratory Infection by Brucella suis and Is a Novel Immunogen for Nasal Vaccination Against Brucella Infection</article-title><source>Front. Immunol.</source><year>2019</year><volume>10</volume><fpage>1775</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2019.01775</pub-id><pub-id pub-id-type="pmid">31402921</pub-id><pub-id pub-id-type="pmcid">PMC6676368</pub-id></element-citation></ref><ref id="B123-vaccines-09-00917"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matos</surname><given-names>M.N.</given-names></name><name name-style="western"><surname>Cazorla</surname><given-names>S.I.</given-names></name><name name-style="western"><surname>Schulze</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ebensen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Guzm&#225;n</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Malchiodi</surname><given-names>E.</given-names></name></person-group><article-title>Immunization with Tc52 or its amino terminal domain adjuvanted with c-di-AMP induces Th17+Th1 specific immune responses and confers protection against Trypanosoma cruzi</article-title><source>PLoS Negl. Trop. Dis.</source><year>2017</year><volume>11</volume><elocation-id>e0005300</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0005300</pub-id><pub-id pub-id-type="pmid">28234897</pub-id><pub-id pub-id-type="pmcid">PMC5342303</pub-id></element-citation></ref><ref id="B124-vaccines-09-00917"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sanchez Alberti</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bivona</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Cerny</surname><given-names>N.</given-names></name><name name-style="western"><surname>Schulze</surname><given-names>K.</given-names></name><name name-style="western"><surname>Weissmann</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ebensen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Morales</surname><given-names>C.</given-names></name><name name-style="western"><surname>Padilla</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Cazorla</surname><given-names>S.I.</given-names></name><name name-style="western"><surname>Tarleton</surname><given-names>R.L.</given-names></name><etal/></person-group><article-title>Engineered trivalent immunogen adju-vanted with a STING agonist confers protection against Trypanosoma cruzi infection</article-title><source>NPJ Vaccines</source><year>2017</year><volume>2</volume><fpage>9</fpage><pub-id pub-id-type="doi">10.1038/s41541-017-0010-z</pub-id><pub-id pub-id-type="pmid">29263868</pub-id><pub-id pub-id-type="pmcid">PMC5604744</pub-id></element-citation></ref><ref id="B125-vaccines-09-00917"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sanchez Alberti</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bivona</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Matos</surname><given-names>M.N.</given-names></name><name name-style="western"><surname>Cerny</surname><given-names>N.</given-names></name><name name-style="western"><surname>Schulze</surname><given-names>K.</given-names></name><name name-style="western"><surname>Weissmann</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ebensen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Gonzalez</surname><given-names>G.</given-names></name><name name-style="western"><surname>Morales</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cardoso</surname><given-names>A.C.</given-names></name><etal/></person-group><article-title>Mucosal Heterologous Prime/Boost Vaccination Induces Polyfunctional Systemic Immunity, Improving Protection Against Trypanosoma cruzi</article-title><source>Front. Immunol.</source><year>2020</year><volume>11</volume><fpage>128</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2020.00128</pub-id><pub-id pub-id-type="pmid">32153562</pub-id><pub-id pub-id-type="pmcid">PMC7047160</pub-id></element-citation></ref><ref id="B126-vaccines-09-00917"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matthijs</surname><given-names>A.M.F.</given-names></name><name name-style="western"><surname>Auray</surname><given-names>G.</given-names></name><name name-style="western"><surname>Jakob</surname><given-names>V.</given-names></name><name name-style="western"><surname>Garc&#237;a-Nicol&#225;s</surname><given-names>O.</given-names></name><name name-style="western"><surname>Braun</surname><given-names>R.O.</given-names></name><name name-style="western"><surname>Keller</surname><given-names>I.</given-names></name><name name-style="western"><surname>Bruggman</surname><given-names>R.</given-names></name><name name-style="western"><surname>Devriendt</surname><given-names>B.</given-names></name><name name-style="western"><surname>Boyen</surname><given-names>F.</given-names></name><name name-style="western"><surname>Guzman</surname><given-names>C.A.</given-names></name><etal/></person-group><article-title>Systems Immunology Characterization of Novel Vaccine Formulations for Mycoplasma hyopneumoniae Bacterins</article-title><source>Front. Immunol.</source><year>2019</year><volume>10</volume><fpage>1087</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2019.01087</pub-id><pub-id pub-id-type="pmid">31178860</pub-id><pub-id pub-id-type="pmcid">PMC6543460</pub-id></element-citation></ref><ref id="B127-vaccines-09-00917"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.-P.</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>F.-F.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>F.-X.</given-names></name><name name-style="western"><surname>Yi</surname><given-names>Y.-L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>W.-S.</given-names></name></person-group><article-title>Enhancing Immune Response and Heterosubtypic Protection Ability of Inactivated H7N9 Vaccine by Using STING Agonist as a Mucosal Adjuvant</article-title><source>Front. Immunol.</source><year>2019</year><volume>10</volume><fpage>2274</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2019.02274</pub-id><pub-id pub-id-type="pmid">31611875</pub-id><pub-id pub-id-type="pmcid">PMC6777483</pub-id></element-citation></ref><ref id="B128-vaccines-09-00917"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Takaki</surname><given-names>H.</given-names></name><name name-style="western"><surname>Takashima</surname><given-names>K.</given-names></name><name name-style="western"><surname>Oshiumi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ainai</surname><given-names>A.</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hasegawa</surname><given-names>H.</given-names></name><name name-style="western"><surname>Matsumoto</surname><given-names>M.</given-names></name><name name-style="western"><surname>Seya</surname><given-names>T.</given-names></name></person-group><article-title>cGAMP Promotes Germinal Center Formation and Production of IgA in Nasal-Associated Lymphoid Tissue</article-title><source>Med. Sci.</source><year>2017</year><volume>5</volume><elocation-id>35</elocation-id><pub-id pub-id-type="doi">10.3390/medsci5040035</pub-id><pub-id pub-id-type="pmcid">PMC5753664</pub-id><pub-id pub-id-type="pmid">29258267</pub-id></element-citation></ref><ref id="B129-vaccines-09-00917"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>M.X.</given-names></name></person-group><article-title>Natural STING Agonist as an &#8220;Ideal&#8221; Adjuvant for Cutaneous Vaccination</article-title><source>J. Investig. Dermatol.</source><year>2016</year><volume>136</volume><fpage>2183</fpage><lpage>2191</lpage><pub-id pub-id-type="doi">10.1016/j.jid.2016.05.105</pub-id><pub-id pub-id-type="pmid">27287182</pub-id><pub-id pub-id-type="pmcid">PMC6091668</pub-id></element-citation></ref><ref id="B130-vaccines-09-00917"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>P.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>M.X.</given-names></name></person-group><article-title>Pulmonary surfactant&#8211;biomimetic nanoparticles potentiate heterosubtypic influenza immunity</article-title><source>Science</source><year>2020</year><volume>367</volume><fpage>eaau0810</fpage><pub-id pub-id-type="doi">10.1126/science.aau0810</pub-id><pub-id pub-id-type="pmid">32079747</pub-id><pub-id pub-id-type="pmcid">PMC7432993</pub-id></element-citation></ref><ref id="B131-vaccines-09-00917"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vassilieva</surname><given-names>E.V.</given-names></name><name name-style="western"><surname>Li</surname><given-names>S.</given-names></name><name name-style="western"><surname>Korniychuk</surname><given-names>H.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Prausnitz</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Compans</surname><given-names>R.W.</given-names></name></person-group><article-title>cGAMP/Saponin Adjuvant Combination Improves Protective Response to Influenza Vaccination by Microneedle Patch in an Aged Mouse Model</article-title><source>Front. Immunol.</source><year>2021</year><volume>11</volume><fpage>583251</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2020.583251</pub-id><pub-id pub-id-type="pmid">33603732</pub-id><pub-id pub-id-type="pmcid">PMC7884748</pub-id></element-citation></ref><ref id="B132-vaccines-09-00917"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>B.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M.</given-names></name></person-group><article-title>Parenteral immunization with a cyclic guanosine monophos-phate-adenosine monophosphate (cGAMP) adjuvanted Helicobacter pylori vaccine induces protective immunity against H. pylori infection in mice</article-title><source>Hum. Vaccines Immunother.</source><year>2020</year><volume>16</volume><fpage>2849</fpage><lpage>2854</lpage><pub-id pub-id-type="doi">10.1080/21645515.2020.1744364</pub-id><pub-id pub-id-type="pmcid">PMC7733891</pub-id><pub-id pub-id-type="pmid">32298215</pub-id></element-citation></ref><ref id="B133-vaccines-09-00917"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>B.</given-names></name><name name-style="western"><surname>Guan</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Duan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>H.</given-names></name></person-group><article-title>A subunit vaccine based on rH-NS induces protection against Mycobac-terium tuberculosis infection by inducing the Th1 immune response and activating macrophages</article-title><source>Acta Biochim. Biophys. Sin.</source><year>2016</year><volume>48</volume><fpage>909</fpage><lpage>922</lpage><pub-id pub-id-type="doi">10.1093/abbs/gmw078</pub-id><pub-id pub-id-type="pmid">27563010</pub-id></element-citation></ref><ref id="B134-vaccines-09-00917"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dorostkar</surname><given-names>F.</given-names></name><name name-style="western"><surname>Arashkia</surname><given-names>A.</given-names></name><name name-style="western"><surname>Roohvand</surname><given-names>F.</given-names></name><name name-style="western"><surname>Shoja</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Navari</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mashhadi Abolghasem Shirazi</surname><given-names>M.</given-names></name></person-group><article-title>Co-administration of 2&#8217;3&#8217;-cGAMP STING activator and CpG-C adjuvants with a mutated form of HPV 16 E7 protein leads to tumor growth inhibition in the mouse model</article-title><source>Infect. Agents Cancer</source><year>2021</year><volume>16</volume><fpage>7</fpage><pub-id pub-id-type="doi">10.1186/s13027-021-00346-7</pub-id><pub-id pub-id-type="pmid">33499895</pub-id><pub-id pub-id-type="pmcid">PMC7836183</pub-id></element-citation></ref><ref id="B135-vaccines-09-00917"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ito</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kanbe</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hara</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ishikawa</surname><given-names>T.</given-names></name></person-group><article-title>Induction of humoral and cellular immune response to HBV vaccine can be up-regulated by STING ligand</article-title><source>Virology</source><year>2019</year><volume>531</volume><fpage>233</fpage><lpage>239</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2019.03.013</pub-id><pub-id pub-id-type="pmid">30928701</pub-id></element-citation></ref><ref id="B136-vaccines-09-00917"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Borriello</surname><given-names>F.</given-names></name><name name-style="western"><surname>Pietrasanta</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>J.C.Y.</given-names></name><name name-style="western"><surname>Walsh</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>P.</given-names></name><name name-style="western"><surname>O&#8217;Driscoll</surname><given-names>D.N.</given-names></name><name name-style="western"><surname>Ramirez</surname><given-names>J.</given-names></name><name name-style="western"><surname>Brightman</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pugni</surname><given-names>L.</given-names></name><name name-style="western"><surname>Mosca</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Identification and Characterization of Stimulator of Interferon Genes as a Robust Adjuvant Target for Early Life Immunization</article-title><source>Front. Immunol.</source><year>2017</year><volume>8</volume><fpage>1772</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2017.01772</pub-id><pub-id pub-id-type="pmid">29312305</pub-id><pub-id pub-id-type="pmcid">PMC5732947</pub-id></element-citation></ref><ref id="B137-vaccines-09-00917"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>N.</given-names></name><name name-style="western"><surname>Gallovic</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Tiet</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ting</surname><given-names>J.P.-Y.</given-names></name><name name-style="western"><surname>Ainslie</surname><given-names>K.</given-names></name><name name-style="western"><surname>Bachelder</surname><given-names>E.M.</given-names></name></person-group><article-title>Investigation of tunable acetalated dextran microparticle platform to optimize M2e-based influenza vaccine efficacy</article-title><source>J. Control. Release</source><year>2018</year><volume>289</volume><fpage>114</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2018.09.020</pub-id><pub-id pub-id-type="pmid">30261204</pub-id><pub-id pub-id-type="pmcid">PMC6365168</pub-id></element-citation></ref><ref id="B138-vaccines-09-00917"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martin</surname><given-names>T.</given-names></name><name name-style="western"><surname>Jee</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>E.</given-names></name><name name-style="western"><surname>Steiner</surname><given-names>H.E.</given-names></name><name name-style="western"><surname>Cormet-Boyaka</surname><given-names>E.</given-names></name><name name-style="western"><surname>Boyaka</surname><given-names>P.N.</given-names></name></person-group><article-title>Sublingual targeting of STING with 3&#8242;3&#8242;-cGAMP promotes systemic and mucosal immunity against anthrax toxins</article-title><source>Vaccine</source><year>2017</year><volume>35</volume><fpage>2511</fpage><lpage>2519</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2017.02.064</pub-id><pub-id pub-id-type="pmid">28343781</pub-id><pub-id pub-id-type="pmcid">PMC5719503</pub-id></element-citation></ref><ref id="B139-vaccines-09-00917"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Dis</surname><given-names>E.</given-names></name><name name-style="western"><surname>Sogi</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Rae</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Sivick</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Surh</surname><given-names>N.H.</given-names></name><name name-style="western"><surname>Leong</surname><given-names>M.L.</given-names></name></person-group><article-title>Faculty Opinions recommendation of STING-Activating Adjuvants Elicit a Th17 Immune Response and Protect against Mycobacterium tuberculosis Infection</article-title><source>Fac. Opin.</source><year>2018</year><volume>23</volume><fpage>1435</fpage><lpage>1447</lpage><pub-id pub-id-type="doi">10.3410/f.733156534.793562003</pub-id><pub-id pub-id-type="pmcid">PMC6003617</pub-id><pub-id pub-id-type="pmid">29719256</pub-id></element-citation></ref><ref id="B140-vaccines-09-00917"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wagner</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Kelly</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Petersen</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Peroutka-Bigus</surname><given-names>N.</given-names></name><name name-style="western"><surname>Darling</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bellaire</surname><given-names>B.H.</given-names></name><name name-style="western"><surname>Wannemuehler</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Narasimhan</surname><given-names>B.</given-names></name></person-group><article-title>Single-dose combination nanovaccine induces both rapid and long-lived protection against pneumonic plague</article-title><source>Acta Biomater.</source><year>2019</year><volume>100</volume><fpage>326</fpage><lpage>337</lpage><pub-id pub-id-type="doi">10.1016/j.actbio.2019.10.016</pub-id><pub-id pub-id-type="pmid">31610342</pub-id><pub-id pub-id-type="pmcid">PMC7012387</pub-id></element-citation></ref><ref id="B141-vaccines-09-00917"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Latasa</surname><given-names>C.</given-names></name><name name-style="western"><surname>Echeverz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Garcia</surname><given-names>B.</given-names></name><name name-style="western"><surname>Gil</surname><given-names>C.</given-names></name><name name-style="western"><surname>Garc&#237;a-Ona</surname><given-names>E.</given-names></name><name name-style="western"><surname>Burgui</surname><given-names>S.</given-names></name><name name-style="western"><surname>Casares</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hervas-Stubbs</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lasarte</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Lasa</surname><given-names>I.</given-names></name><etal/></person-group><article-title>Evaluation of a Salmonella Strain Lacking the Secondary Messenger C-di-GMP and RpoS as a Live Oral Vaccine</article-title><source>PLoS ONE</source><year>2016</year><volume>11</volume><elocation-id>e0161216</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0161216</pub-id><pub-id pub-id-type="pmid">27537839</pub-id><pub-id pub-id-type="pmcid">PMC4990191</pub-id></element-citation></ref><ref id="B142-vaccines-09-00917"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gil</surname><given-names>C.</given-names></name><name name-style="western"><surname>Latasa</surname><given-names>C.</given-names></name><name name-style="western"><surname>Garc&#237;a-Ona</surname><given-names>E.</given-names></name><name name-style="western"><surname>L&#225;zaro</surname><given-names>I.</given-names></name><name name-style="western"><surname>Labairu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Echeverz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Burgui</surname><given-names>S.</given-names></name><name name-style="western"><surname>Garc&#237;a</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lasa</surname><given-names>I.</given-names></name><name name-style="western"><surname>Solano</surname><given-names>C.</given-names></name></person-group><article-title>A DIVA vaccine strain lacking RpoS and the secondary messenger c-di-GMP for protection against salmonellosis in pigs</article-title><source>Veter. Res.</source><year>2020</year><volume>51</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1186/s13567-019-0730-3</pub-id><pub-id pub-id-type="pmcid">PMC6954585</pub-id><pub-id pub-id-type="pmid">31924274</pub-id></element-citation></ref><ref id="B143-vaccines-09-00917"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vassilieva</surname><given-names>E.V.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>D.W.</given-names></name><name name-style="western"><surname>Compans</surname><given-names>R.W.</given-names></name></person-group><article-title>Combination of STING Pathway Agonist with Saponin Is an Effective Adjuvant in Immunosenescent Mice</article-title><source>Front. Immunol.</source><year>2019</year><volume>10</volume><fpage>3006</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2019.03006</pub-id><pub-id pub-id-type="pmid">31921219</pub-id><pub-id pub-id-type="pmcid">PMC6935580</pub-id></element-citation></ref><ref id="B144-vaccines-09-00917"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gogoi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Mansouri</surname><given-names>S.</given-names></name><name name-style="western"><surname>Katikaneni</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>L.</given-names></name></person-group><article-title>New MoDC-Targeting TNF Fusion Proteins Enhance Cyclic Di-GMP Vaccine Adjuvanticity in Middle-Aged and Aged Mice</article-title><source>Front. Immunol.</source><year>2020</year><volume>11</volume><fpage>1674</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2020.01674</pub-id><pub-id pub-id-type="pmid">32849581</pub-id><pub-id pub-id-type="pmcid">PMC7427090</pub-id></element-citation></ref><ref id="B145-vaccines-09-00917"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gravekamp</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chandra</surname><given-names>D.</given-names></name></person-group><article-title>Targeting STING pathways for the treatment of cancer</article-title><source>OncoImmunology</source><year>2015</year><volume>4</volume><fpage>e988463</fpage><pub-id pub-id-type="doi">10.4161/2162402X.2014.988463</pub-id><pub-id pub-id-type="pmid">26587334</pub-id><pub-id pub-id-type="pmcid">PMC4635943</pub-id></element-citation></ref><ref id="B146-vaccines-09-00917"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chandra</surname><given-names>D.</given-names></name><name name-style="western"><surname>Quispe-Tintaya</surname><given-names>W.</given-names></name><name name-style="western"><surname>Jahangir</surname><given-names>A.</given-names></name><name name-style="western"><surname>Asafu-Adjei</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ramos</surname><given-names>I.</given-names></name><name name-style="western"><surname>Sintim</surname><given-names>H.O.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hayakawa</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Karaolis</surname><given-names>D.K.</given-names></name><name name-style="western"><surname>Gravekamp</surname><given-names>C.</given-names></name></person-group><article-title>STING Ligand c-di-GMP Improves Cancer Vaccination against Metastatic Breast Cancer</article-title><source>Cancer Immunol. Res.</source><year>2014</year><volume>2</volume><fpage>901</fpage><lpage>910</lpage><pub-id pub-id-type="doi">10.1158/2326-6066.CIR-13-0123</pub-id><pub-id pub-id-type="pmid">24913717</pub-id><pub-id pub-id-type="pmcid">PMC4264585</pub-id></element-citation></ref><ref id="B147-vaccines-09-00917"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>J.-J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.-H.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>P.-G.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>B.-D.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>H.-G.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q.-Q.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.-X.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y.-F.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.-M.</given-names></name></person-group><article-title>Targeting STING with cyclic di-GMP greatly augmented immune responses of glycopeptide cancer vaccines</article-title><source>Chem. Commun.</source><year>2018</year><volume>54</volume><fpage>9655</fpage><lpage>9658</lpage><pub-id pub-id-type="doi">10.1039/C8CC04860F</pub-id><pub-id pub-id-type="pmid">30101273</pub-id></element-citation></ref><ref id="B148-vaccines-09-00917"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Celis</surname><given-names>E.</given-names></name></person-group><article-title>STING activator c-di-GMP enhances the anti-tumor effects of peptide vaccines in melanoma-bearing mice</article-title><source>Cancer Immunol. Immunother.</source><year>2015</year><volume>64</volume><fpage>1057</fpage><lpage>1066</lpage><pub-id pub-id-type="doi">10.1007/s00262-015-1713-5</pub-id><pub-id pub-id-type="pmid">25986168</pub-id><pub-id pub-id-type="pmcid">PMC4648249</pub-id></element-citation></ref><ref id="B149-vaccines-09-00917"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shae</surname><given-names>D.</given-names></name><name name-style="western"><surname>Baljon</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Wehbe</surname><given-names>M.</given-names></name><name name-style="western"><surname>Christov</surname><given-names>P.P.</given-names></name><name name-style="western"><surname>Becker</surname><given-names>K.W.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Suryadevara</surname><given-names>N.</given-names></name><name name-style="western"><surname>Carson</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Palmer</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Knight</surname><given-names>F.C.</given-names></name><etal/></person-group><article-title>Co-delivery of Peptide Neoantigens and Stimulator of Interferon Genes Agonists Enhances Response to Cancer Vaccines</article-title><source>ACS Nano</source><year>2020</year><volume>14</volume><fpage>9904</fpage><lpage>9916</lpage><pub-id pub-id-type="doi">10.1021/acsnano.0c02765</pub-id><pub-id pub-id-type="pmid">32701257</pub-id><pub-id pub-id-type="pmcid">PMC7775800</pub-id></element-citation></ref><ref id="B150-vaccines-09-00917"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ebensen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Delandre</surname><given-names>S.</given-names></name><name name-style="western"><surname>Prochnow</surname><given-names>B.</given-names></name><name name-style="western"><surname>Guzm&#225;n</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Schulze</surname><given-names>K.</given-names></name></person-group><article-title>The Combination Vaccine Adjuvant System Alum/c-di-AMP Results in Quantitative and Qualitative Enhanced Immune Responses Post Immunization</article-title><source>Front. Cell. Infect. Microbiol.</source><year>2019</year><volume>9</volume><fpage>31</fpage><pub-id pub-id-type="doi">10.3389/fcimb.2019.00031</pub-id><pub-id pub-id-type="pmid">30838180</pub-id><pub-id pub-id-type="pmcid">PMC6390046</pub-id></element-citation></ref><ref id="B151-vaccines-09-00917"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>H.G.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>B.D.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.M.</given-names></name></person-group><article-title>Pam3CSK4-CDG(SF) Augments Antitumor Immunotherapy by Synergistically Activating TLR1/2 and STING</article-title><source>Bioconjug. Chem.</source><year>2020</year><volume>31</volume><fpage>2499</fpage><lpage>2503</lpage><pub-id pub-id-type="doi">10.1021/acs.bioconjchem.0c00522</pub-id><pub-id pub-id-type="pmid">33147965</pub-id></element-citation></ref><ref id="B152-vaccines-09-00917"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alyaqoub</surname><given-names>F.S.</given-names></name><name name-style="western"><surname>Aldhamen</surname><given-names>Y.A.</given-names></name><name name-style="western"><surname>Koestler</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Bruger</surname><given-names>E.L.</given-names></name><name name-style="western"><surname>Seregin</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Pereira-Hicks</surname><given-names>C.</given-names></name><name name-style="western"><surname>Godbehere</surname><given-names>S.</given-names></name><name name-style="western"><surname>Waters</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Amalfitano</surname><given-names>A.</given-names></name></person-group><article-title>In Vivo Synthesis of Cyclic-di-GMP Using a Recombinant Adenovirus Preferentially Improves Adaptive Immune Responses against Extracellular Antigens</article-title><source>J. Immunol.</source><year>2016</year><volume>196</volume><fpage>1741</fpage><lpage>1752</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1501272</pub-id><pub-id pub-id-type="pmid">26792800</pub-id><pub-id pub-id-type="pmcid">PMC5523134</pub-id></element-citation></ref><ref id="B153-vaccines-09-00917"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koestler</surname><given-names>B.</given-names></name><name name-style="western"><surname>Seregin</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Rastall</surname><given-names>D.P.W.</given-names></name><name name-style="western"><surname>Aldhamen</surname><given-names>Y.A.</given-names></name><name name-style="western"><surname>Godbehere</surname><given-names>S.</given-names></name><name name-style="western"><surname>Amalfitano</surname><given-names>A.</given-names></name><name name-style="western"><surname>Waters</surname><given-names>C.M.</given-names></name></person-group><article-title>Stimulation of Innate Immunity byIn VivoCyclic di-GMP Synthesis Using Adenovirus</article-title><source>Clin. Vaccine Immunol.</source><year>2014</year><volume>21</volume><fpage>1550</fpage><lpage>1559</lpage><pub-id pub-id-type="doi">10.1128/CVI.00471-14</pub-id><pub-id pub-id-type="pmid">25230938</pub-id><pub-id pub-id-type="pmcid">PMC4248757</pub-id></element-citation></ref><ref id="B154-vaccines-09-00917"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bridgeman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Maelfait</surname><given-names>J.</given-names></name><name name-style="western"><surname>Davenne</surname><given-names>T.</given-names></name><name name-style="western"><surname>Partridge</surname><given-names>T.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Mayer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kaever</surname><given-names>V.</given-names></name><name name-style="western"><surname>Borrow</surname><given-names>P.</given-names></name><name name-style="western"><surname>Rehwinkel</surname><given-names>J.</given-names></name></person-group><article-title>Viruses transfer the antiviral second messenger cGAMP between cells</article-title><source>Science</source><year>2015</year><volume>349</volume><fpage>1228</fpage><lpage>1232</lpage><pub-id pub-id-type="doi">10.1126/science.aab3632</pub-id><pub-id pub-id-type="pmid">26229117</pub-id><pub-id pub-id-type="pmcid">PMC4617605</pub-id></element-citation></ref><ref id="B155-vaccines-09-00917"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Quintana</surname><given-names>I.</given-names></name><name name-style="western"><surname>Espariz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Villar</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Gonzalez</surname><given-names>F.B.</given-names></name><name name-style="western"><surname>Pacini</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Cabrera</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bontempi</surname><given-names>I.</given-names></name><name name-style="western"><surname>Prochetto</surname><given-names>E.</given-names></name><name name-style="western"><surname>Stulke</surname><given-names>J.</given-names></name><name name-style="western"><surname>Perez</surname><given-names>A.R.</given-names></name><etal/></person-group><article-title>Genetic Engineering of Lactococcus lactis Co-producing Antigen and the Mucosal Adjuvant 3&#8242; 5&#8242;- cyclic di Adenosine Monophosphate (c-di-AMP) as a Design Strategy to Develop a Mucosal Vaccine Prototype</article-title><source>Front. Microbiol.</source><year>2018</year><volume>9</volume><fpage>2100</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2018.02100</pub-id><pub-id pub-id-type="pmid">30258417</pub-id><pub-id pub-id-type="pmcid">PMC6143824</pub-id></element-citation></ref><ref id="B156-vaccines-09-00917"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Konno</surname><given-names>H.</given-names></name><name name-style="western"><surname>Chinn</surname><given-names>I.K.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>D.</given-names></name><name name-style="western"><surname>Orange</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Lupski</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Mendoza</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pedroza</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Barber</surname><given-names>G.N.</given-names></name></person-group><article-title>Pro-inflammation Associated with a Gain-of-Function Mutation (R284S) in the Innate Immune Sensor STING</article-title><source>Cell Rep.</source><year>2018</year><volume>23</volume><fpage>1112</fpage><lpage>1123</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2018.03.115</pub-id><pub-id pub-id-type="pmid">29694889</pub-id><pub-id pub-id-type="pmcid">PMC6092751</pub-id></element-citation></ref><ref id="B157-vaccines-09-00917"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ozasa</surname><given-names>K.</given-names></name><name name-style="western"><surname>Temizoz</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kusakabe</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kobari</surname><given-names>S.</given-names></name><name name-style="western"><surname>Momota</surname><given-names>M.</given-names></name><name name-style="western"><surname>Coban</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ito</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kobiyama</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kuroda</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ishii</surname><given-names>K.J.</given-names></name></person-group><article-title>Cyclic GMP-AMP Triggers Asthma in an IL-33-Dependent Manner That Is Blocked by Amlexanox, a TBK1 Inhibitor</article-title><source>Front. Immunol.</source><year>2019</year><volume>10</volume><pub-id pub-id-type="doi">10.3389/fimmu.2019.02212</pub-id><pub-id pub-id-type="pmid">31616416</pub-id><pub-id pub-id-type="pmcid">PMC6775192</pub-id></element-citation></ref><ref id="B158-vaccines-09-00917"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Konno</surname><given-names>H.</given-names></name><name name-style="western"><surname>Konno</surname><given-names>K.</given-names></name><name name-style="western"><surname>Barber</surname><given-names>G.N.</given-names></name></person-group><article-title>Cyclic Dinucleotides Trigger ULK1 (ATG1) Phosphorylation of STING to Prevent Sustained Innate Immune Signaling</article-title><source>Cell</source><year>2013</year><volume>155</volume><fpage>688</fpage><lpage>698</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2013.09.049</pub-id><pub-id pub-id-type="pmid">24119841</pub-id><pub-id pub-id-type="pmcid">PMC3881181</pub-id></element-citation></ref><ref id="B159-vaccines-09-00917"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rueckert</surname><given-names>C.</given-names></name><name name-style="western"><surname>Rand</surname><given-names>U.</given-names></name><name name-style="western"><surname>Roy</surname><given-names>U.</given-names></name><name name-style="western"><surname>Kasmapour</surname><given-names>B.</given-names></name><name name-style="western"><surname>Strowig</surname><given-names>T.</given-names></name><name name-style="western"><surname>Guzm&#225;n</surname><given-names>C.A.</given-names></name></person-group><article-title>Cyclic dinucleotides modulate induced type I IFN responses in innate immune cells by degradation of STING</article-title><source>FASEB J.</source><year>2017</year><volume>31</volume><fpage>3107</fpage><lpage>3115</lpage><pub-id pub-id-type="doi">10.1096/fj.201601093R</pub-id><pub-id pub-id-type="pmid">28396343</pub-id></element-citation></ref><ref id="B160-vaccines-09-00917"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miyabe</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hyodo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nakamura</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sato</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hayakawa</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Harashima</surname><given-names>H.</given-names></name></person-group><article-title>A new adjuvant delivery system &#8216;cyclic di-GMP/YSK05 liposome&#8217; for cancer immunotherapy</article-title><source>J. Control. Release</source><year>2014</year><volume>184</volume><fpage>20</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2014.04.004</pub-id><pub-id pub-id-type="pmid">24727060</pub-id></element-citation></ref><ref id="B161-vaccines-09-00917"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kocabas</surname><given-names>B.B.</given-names></name><name name-style="western"><surname>Almacioglu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Bulut</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Gucluler</surname><given-names>G.</given-names></name><name name-style="western"><surname>Tincer</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bayik</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gursel</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gursel</surname><given-names>I.</given-names></name></person-group><article-title>Dual-adjuvant effect of pH-sensitive liposomes loaded with STING and TLR9 agonists regress tumor development by enhancing Th1 immune response</article-title><source>J. Control. Release</source><year>2020</year><volume>328</volume><fpage>587</fpage><lpage>595</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2020.09.040</pub-id><pub-id pub-id-type="pmid">32971199</pub-id></element-citation></ref><ref id="B162-vaccines-09-00917"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hanson</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Crespo</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Abraham</surname><given-names>W.</given-names></name><name name-style="western"><surname>Moynihan</surname><given-names>K.D.</given-names></name><name name-style="western"><surname>Szeto</surname><given-names>G.L.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Melo</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Mueller</surname><given-names>S.</given-names></name><name name-style="western"><surname>Irvine</surname><given-names>D.J.</given-names></name></person-group><article-title>Nanoparticulate STING agonists are potent lymph node&#8211;targeted vaccine adjuvants</article-title><source>J. Clin. Investig.</source><year>2015</year><volume>125</volume><fpage>2532</fpage><lpage>2546</lpage><pub-id pub-id-type="doi">10.1172/JCI79915</pub-id><pub-id pub-id-type="pmid">25938786</pub-id><pub-id pub-id-type="pmcid">PMC4497758</pub-id></element-citation></ref><ref id="B163-vaccines-09-00917"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shakya</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Uddin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gill</surname><given-names>H.S.</given-names></name></person-group><article-title>Assessment of Th1/Th2 Bias of STING Agonists Coated on Microneedles for Possible Use in Skin Allergen Immunotherapy</article-title><source>Mol. Pharm.</source><year>2018</year><volume>15</volume><fpage>5437</fpage><lpage>5443</lpage><pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.8b00768</pub-id><pub-id pub-id-type="pmid">30299105</pub-id><pub-id pub-id-type="pmcid">PMC6857785</pub-id></element-citation></ref><ref id="B164-vaccines-09-00917"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mittal</surname><given-names>A.</given-names></name><name name-style="western"><surname>Schulze</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ebensen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Weissmann</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hansen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Guzm&#225;n</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Lehr</surname><given-names>C.-M.</given-names></name></person-group><article-title>Inverse micellar sugar glass (IMSG) nanoparticles for transfollicular vaccination</article-title><source>J. Control. Release</source><year>2015</year><volume>206</volume><fpage>140</fpage><lpage>152</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2015.03.017</pub-id><pub-id pub-id-type="pmid">25795506</pub-id></element-citation></ref><ref id="B165-vaccines-09-00917"><label>165.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>E.</given-names></name><name name-style="western"><surname>Jang</surname><given-names>H.-E.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>Y.Y.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ahn</surname><given-names>J.-H.</given-names></name><name name-style="western"><surname>Mok</surname><given-names>H.</given-names></name></person-group><article-title>Submicron-sized hydrogels incorporating cyclic dinucleotides for selective delivery and elevated cytokine release in macrophages</article-title><source>Acta Biomater.</source><year>2016</year><volume>29</volume><fpage>271</fpage><lpage>281</lpage><pub-id pub-id-type="doi">10.1016/j.actbio.2015.10.025</pub-id><pub-id pub-id-type="pmid">26485167</pub-id></element-citation></ref><ref id="B166-vaccines-09-00917"><label>166.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koshy</surname><given-names>S.T.</given-names></name><name name-style="western"><surname>Cheung</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Graveline</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mooney</surname><given-names>D.J.</given-names></name></person-group><article-title>Liposomal Delivery Enhances Immune Activation by STING Agonists for Cancer Immunotherapy</article-title><source>Adv. Biosyst.</source><year>2017</year><volume>1</volume><pub-id pub-id-type="doi">10.1002/adbi.201600013</pub-id><pub-id pub-id-type="pmid">30258983</pub-id><pub-id pub-id-type="pmcid">PMC6152940</pub-id></element-citation></ref><ref id="B167-vaccines-09-00917"><label>167.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Nyalile</surname><given-names>T.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Glass</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Q.</given-names></name></person-group><article-title>In situ cancer vaccination using lipidoid nanoparticles</article-title><source>Sci. Adv.</source><year>2021</year><volume>7</volume><fpage>eabf1244</fpage><pub-id pub-id-type="doi">10.1126/sciadv.abf1244</pub-id><pub-id pub-id-type="pmid">33952519</pub-id><pub-id pub-id-type="pmcid">PMC8099179</pub-id></element-citation></ref><ref id="B168-vaccines-09-00917"><label>168.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Collier</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Junkins</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Gallovic</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Macintyre</surname><given-names>A.N.</given-names></name><name name-style="western"><surname>Sempowski</surname><given-names>G.D.</given-names></name><name name-style="western"><surname>Bachelder</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Ting</surname><given-names>J.P.Y.</given-names></name><name name-style="western"><surname>Ainslie</surname><given-names>K.M.</given-names></name></person-group><article-title>Acetalated Dextran Microparticles for Codelivery of STING and TLR7/8 Agonists</article-title><source>Mol. Pharm.</source><year>2018</year><volume>15</volume><fpage>4933</fpage><lpage>4946</lpage><pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.8b00579</pub-id><pub-id pub-id-type="pmid">30281314</pub-id><pub-id pub-id-type="pmcid">PMC6261357</pub-id></element-citation></ref><ref id="B169-vaccines-09-00917"><label>169.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Junkins</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Gallovic</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Collier</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Watkins-Schulz</surname><given-names>R.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>N.</given-names></name><name name-style="western"><surname>David</surname><given-names>C.N.</given-names></name><name name-style="western"><surname>McGee</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Sempowski</surname><given-names>G.D.</given-names></name><name name-style="western"><surname>Shterev</surname><given-names>I.</given-names></name><etal/></person-group><article-title>A robust microparticle platform for a STING-targeted adjuvant that enhances both humoral and cellular immunity during vaccination</article-title><source>J. Control. Release</source><year>2018</year><volume>270</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2017.11.030</pub-id><pub-id pub-id-type="pmid">29170142</pub-id><pub-id pub-id-type="pmcid">PMC5808851</pub-id></element-citation></ref><ref id="B170-vaccines-09-00917"><label>170.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kelly</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Cossette</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Varadhan</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Collier</surname><given-names>J.H.</given-names></name></person-group><article-title>Titrating Polyarginine into Nanofibers Enhances Cyclic-Dinucleotide Adjuvanticity in Vitro and after Sublingual Immunization</article-title><source>ACS Biomater. Sci. Eng.</source><year>2021</year><volume>7</volume><fpage>1876</fpage><lpage>1888</lpage><pub-id pub-id-type="doi">10.1021/acsbiomaterials.0c01429</pub-id><pub-id pub-id-type="pmid">33775089</pub-id><pub-id pub-id-type="pmcid">PMC8822437</pub-id></element-citation></ref><ref id="B171-vaccines-09-00917"><label>171.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shae</surname><given-names>D.</given-names></name><name name-style="western"><surname>Becker</surname><given-names>K.W.</given-names></name><name name-style="western"><surname>Christov</surname><given-names>P.</given-names></name><name name-style="western"><surname>Yun</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Lytton-Jean</surname><given-names>A.K.R.</given-names></name><name name-style="western"><surname>Sevimli</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ascano</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kelley</surname><given-names>M.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>D.B.</given-names></name><name name-style="western"><surname>Balko</surname><given-names>J.M.</given-names></name><etal/></person-group><article-title>Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy</article-title><source>Nat. Nanotechnol.</source><year>2019</year><volume>14</volume><fpage>269</fpage><lpage>278</lpage><pub-id pub-id-type="doi">10.1038/s41565-018-0342-5</pub-id><pub-id pub-id-type="pmid">30664751</pub-id><pub-id pub-id-type="pmcid">PMC6402974</pub-id></element-citation></ref><ref id="B172-vaccines-09-00917"><label>172.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schulze</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ebensen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Babiuk</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Gerdts</surname><given-names>V.</given-names></name><name name-style="western"><surname>Guzman</surname><given-names>C.A.</given-names></name></person-group><article-title>Intranasal vaccination with an adjuvanted polyphosphazenes na-noparticle-based vaccine formulation stimulates protective immune responses in mice</article-title><source>Nanomed. Nanotechnol. Biol. Med.</source><year>2017</year><volume>13</volume><fpage>2169</fpage><lpage>2178</lpage><pub-id pub-id-type="doi">10.1016/j.nano.2017.05.012</pub-id><pub-id pub-id-type="pmid">28579436</pub-id></element-citation></ref><ref id="B173-vaccines-09-00917"><label>173.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leach</surname><given-names>D.G.</given-names></name><name name-style="western"><surname>Dharmaraj</surname><given-names>N.</given-names></name><name name-style="western"><surname>Piotrowski</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Lopez-Silva</surname><given-names>T.L.</given-names></name><name name-style="western"><surname>Lei</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sikora</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Young</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hartgerink</surname><given-names>J.D.</given-names></name></person-group><article-title>STINGel: Controlled release of a cyclic dinucleotide for enhanced cancer immunotherapy</article-title><source>Biomaterials</source><year>2018</year><volume>163</volume><fpage>67</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2018.01.035</pub-id><pub-id pub-id-type="pmid">29454236</pub-id><pub-id pub-id-type="pmcid">PMC5840037</pub-id></element-citation></ref><ref id="B174-vaccines-09-00917"><label>174.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nakamura</surname><given-names>T.</given-names></name><name name-style="western"><surname>Miyabe</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hyodo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sato</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hayakawa</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Harashima</surname><given-names>H.</given-names></name></person-group><article-title>Liposomes loaded with a STING pathway ligand, cyclic di-GMP, enhance cancer immunotherapy against metastatic melanoma</article-title><source>J. Control. Release</source><year>2015</year><volume>216</volume><fpage>149</fpage><lpage>157</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2015.08.026</pub-id><pub-id pub-id-type="pmid">26282097</pub-id></element-citation></ref><ref id="B175-vaccines-09-00917"><label>175.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Demoulins</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ruggli</surname><given-names>N.</given-names></name><name name-style="western"><surname>Gerber</surname><given-names>M.</given-names></name><name name-style="western"><surname>Thomann-Harwood</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Ebensen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Schulze</surname><given-names>K.</given-names></name><name name-style="western"><surname>Guzman</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>McCullough</surname><given-names>K.C.</given-names></name></person-group><article-title>Self-Amplifying Pestivirus Replicon RNA Encoding Influenza Virus Nucleoprotein and Hemagglutinin Promote Humoral and Cellular Immune Responses in Pigs</article-title><source>Front. Immunol.</source><year>2020</year><volume>11</volume><fpage>622385</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2020.622385</pub-id><pub-id pub-id-type="pmid">33584723</pub-id><pub-id pub-id-type="pmcid">PMC7877248</pub-id></element-citation></ref><ref id="B176-vaccines-09-00917"><label>176.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gogoi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Mansouri</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>L.</given-names></name></person-group><article-title>The Age of Cyclic Dinucleotide Vaccine Adjuvants</article-title><source>Vaccines</source><year>2020</year><volume>8</volume><elocation-id>453</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines8030453</pub-id><pub-id pub-id-type="pmid">32823563</pub-id><pub-id pub-id-type="pmcid">PMC7563944</pub-id></element-citation></ref><ref id="B177-vaccines-09-00917"><label>177.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Brendel</surname><given-names>V.P.</given-names></name><name name-style="western"><surname>Shu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Li</surname><given-names>P.</given-names></name><name name-style="western"><surname>Palanathan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kao</surname><given-names>C.C.</given-names></name></person-group><article-title>Single Nucleotide Polymorphisms of Human STING Can Affect Innate Immune Response to Cyclic Dinucleotides</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><elocation-id>e77846</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0077846</pub-id><pub-id pub-id-type="pmid">24204993</pub-id><pub-id pub-id-type="pmcid">PMC3804601</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="vaccines-09-00917-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Chemical structures of naturally occurring cyclic dinucleotides known to date. The structure of 2&#8242;3&#8242;-cGAMP was originally misassigned as 2&#8242;2&#8242;-cGAMP shown in brackets.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="vaccines-09-00917-g001.jpg"/></fig><fig id="vaccines-09-00917-f002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>The number of published records on c-di-GMP and analogs retrieved (as of 20 May 2021) from the Web of Sciences with either topic or title containing one of the following terms: c-diGMP, c-di-GMP, cyclic di-GMP, cyclic diguanylic acid, c-GAMP, cGAMP, c-di-AMP, c-di-AMP, cyclic GMP-AMP, or cyclic dinucleotide, with duplicates removed.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="vaccines-09-00917-g002.jpg"/></fig><fig id="vaccines-09-00917-f003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Processes regulated by c-di-GMP signalling networks.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="vaccines-09-00917-g003.jpg"/></fig><fig id="vaccines-09-00917-f004" orientation="portrait" position="float"><label>Figure 4</label><caption><p>Innate immune sensing of bacterial cyclic dinucleotides and microbial DNA through the cGAS-STING pathway. Reproduced from Figure 1 of the work of [<xref rid="B46-vaccines-09-00917" ref-type="bibr">46</xref>] with permission from Copyright Clearance Center, Inc. ER: endoplasmic reticulum; TBK-1: TANK-binding kinase 1; IRF3: interferon regulatory factor 3; NF-&#954;B: nuclear factor kappa B; IFN-&#946;: interferon-&#946;.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="vaccines-09-00917-g004.jpg"/></fig><fig id="vaccines-09-00917-f005" orientation="portrait" position="float"><label>Figure 5</label><caption><p>Activation of STING positively regulates each step of the cancer immunity cycle. Reproduced from Figure 2 of [<xref rid="B84-vaccines-09-00917" ref-type="bibr">84</xref>] with permission under the terms of the Creative Commons Attribution 4.0 International Licence (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</uri>, accessed on 5 August 2021).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="vaccines-09-00917-g005.jpg"/></fig><table-wrap id="vaccines-09-00917-t001" orientation="portrait" position="float"><object-id pub-id-type="pii">vaccines-09-00917-t001_Table 1</object-id><label>Table 1</label><caption><p>Selected application of cyclic dinucleotides (CDNs) as adjuvants in the development of vaccines against infectious diseases and cancers.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">CDNs</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Others</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Species</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Immunization Route</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Antigens</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Immunogenicity</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Efficacy</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">c-di-GMP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Beta-gal</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Serum IgG, Th1/Th2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B91-vaccines-09-00917" ref-type="bibr">91</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">c-di-GMP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IN</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Beta-gal, Ova</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Serum IgG, mucosal IgA, Th1, CTL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B92-vaccines-09-00917" ref-type="bibr">92</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">c-di-GMP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IN, IM</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Influenza H5N1 (A/Anhui/1/05)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mucosal IgA, serum IgG, balanced Th1/Th2, high frequencies of multifunctional Th1 CD4<sup>+</sup> cells. IN &gt; IM</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B105-vaccines-09-00917" ref-type="bibr">105</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">c-di-GMP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IN, sublingual, IM</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Influenza H5N1 (A/Anhui/1/05)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mucosal IgA, serum IgG, balanced Th1/Th2, high frequencies of splenic H5N1-specific multifunctional (IL-2<sup>+</sup>TNF-&#945;<sup>+</sup>) CD4<sup>+</sup> T cells.<break/>IN or SL &gt; IM</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B106-vaccines-09-00917" ref-type="bibr">106</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">c-di-GMP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chitosan</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IN</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NIBRG-14 (H5N1) HA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Serum and local antibody responses, HI antibody, higher frequencies of virus-specific polyfunctional CD4<sup>+</sup> T cells, more Th1 cytokines (IFN-&#947;, IL-2, TNF-&#945;). 7.5 &#956;g &gt; 1.5 or 0.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B107-vaccines-09-00917" ref-type="bibr">107</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">c-di-GMP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Silica nanoparticles (SiO<sub>2</sub>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intratracheal</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Plant-produced H1N1 influenza HA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High systemic antibody responses, local IgG and IgA responses, local T-cell response (IL-2 and IFN-&#947;)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B108-vaccines-09-00917" ref-type="bibr">108</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">c-di-GMP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice, ferrets</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IN</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HA A/Indonesia/05/05 (H5N1)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IgG and IgA antibodies</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Survived the viral challenge</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B109-vaccines-09-00917" ref-type="bibr">109</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">c-di-GMP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">microneedle</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Microneedle skin patches</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Influenza microneedle vaccine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Enhanced IgG, IgG subtypes, and cellular immune responses</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100% survival rate and rapid weight recovery</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B110-vaccines-09-00917" ref-type="bibr">110</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">c-di-GMP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">B. pertussis</italic> LP1569 (a TLR2 agonist)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SC, IP, IN</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Acellular pertussis vaccine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IFN-&#946;, IL-12 and IL-23 responses, maturation of dendritic cells; IN: Th1 and Th17 responses; Th17 response and IL-17-secreting T<sub>RM</sub> cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IN: protection against nasal colonization and lung infection (sustained for at least 10 months)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B111-vaccines-09-00917" ref-type="bibr">111</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">c-di-GMP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ClfA or mSEC<break/>(<italic toggle="yes">S. aureus</italic>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High titers of IgG1, IgG2a, IgG2b and IgG3 compared to alum adjuvant<break/>mSEC &gt; ClfA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Higher survival rates at day 7 with <italic toggle="yes">S. aureus</italic> challenge</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B112-vaccines-09-00917" ref-type="bibr">112</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">c-di-GMP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IN, IP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S. pneumoniae</italic> PdB or PspA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IP induced higher antigen-specific antibodies</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Significant decrease in bacterial load in lungs and blood; IP: increased survival compared to that with alum adjuvant</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B62-vaccines-09-00917" ref-type="bibr">62</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">c-di-GMP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IN</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S. pneumonia</italic> PsaA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Strong IgG and IgA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Significantly reduced nasopharyngeal colonization</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B61-vaccines-09-00917" ref-type="bibr">61</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">c-di-GMP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DNA vaccine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ID</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HIV-1 reverse transcriptase</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Transient increase in IFN-&#947; production</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B113-vaccines-09-00917" ref-type="bibr">113</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">c-di-GMP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice,<break/>cattle,<break/>pigs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IM</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Foot and mouth disease vaccine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Early onset of high neutralizing antibody titers; long-lasting immune memory response</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B114-vaccines-09-00917" ref-type="bibr">114</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">c-di-GMP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IN</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ghrelin-PspA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Specific antibody responses</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reduced body weight gain in diet-induced obesity mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B115-vaccines-09-00917" ref-type="bibr">115</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">c-di-GMP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rats, mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IN</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Angiotensin II type 1 receptor (AT1R) peptide conjugated with PspA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Specific antibody responses</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prevented the development of hypertension in spontaneously hypertensive rats; Sera protected mice against lethal pneumococcal infection</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B116-vaccines-09-00917" ref-type="bibr">116</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">c-di-GMP and c-di-AMP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IN, sublingual</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">H5N1 virosomes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Local and systemic humoral and cellular immune responses; long-lasting immunity; dose-sparing</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Effective protection against influenza H5N1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B117-vaccines-09-00917" ref-type="bibr">117</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">c-di-AMP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ova (soluble or DC targeted)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Serum IgG, Th1, CTL, and IFN&#947;-producing CD8 memory T-cell response, better than PolyI:C/CpG</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B96-vaccines-09-00917" ref-type="bibr">96</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">c-di-AMP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IN</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Influenza nucleoprotein</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IgG and IgA responses, strong Th1 response (IFN-&#947; and IL-2)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Protection against A/Puerto Rico/8/34 (H1N1) virus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B118-vaccines-09-00917" ref-type="bibr">118</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">c-di-AMP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IN</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ESAT-6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Innate and adaptive immune responses and regulated autophagy of macrophages</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Protection against i.v. challenge similar to antigen alone group</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B119-vaccines-09-00917" ref-type="bibr">119</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">c-di-AMP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lipopeptide-based nano carrier systems</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IN</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">T and B cell epitopes of <italic toggle="yes">S. pyogenes</italic> M protein</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antigen dose-sparing</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> [<xref rid="B120-vaccines-09-00917" ref-type="bibr">120</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">c-di-AMP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Archaeosomes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IN-IN-IN,<break/>IM-IN-IN, or<break/>IM-IM-IM</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HCV rE1E2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Induced more robust polyfunctional CD4<sup>+</sup> T-cell responses</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B121-vaccines-09-00917" ref-type="bibr">121</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">c-di-AMP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IN</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BtaF trimeric autotransporter</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Local and systemic antibody responses, central memory CD4<sup>+</sup> T cells, and strong Th1 responses</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Protection against intragastric, but not respiratory, challenge with <italic toggle="yes">B. suis</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B122-vaccines-09-00917" ref-type="bibr">122</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">c-di-AMP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Conjugated at N-terminal of target antigen</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IN</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">T. cruzi</italic> recombinant Tc52</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Predominantly Th17 and Th1 immune responses</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Better protection against infection with lower parasitemia and weight loss, and higher survival rates</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B123-vaccines-09-00917" ref-type="bibr">123</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">c-di-AMP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IN</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Traspain (trivalent <italic toggle="yes">T. cruzi</italic> antigen)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Primed Th1/Th17 immune response</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reduced parasite load and chronic inflammation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B124-vaccines-09-00917" ref-type="bibr">124</xref>,<xref rid="B125-vaccines-09-00917" ref-type="bibr">125</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">c-di-AMP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Poly(lactic-co-glycolic acid (PLGA) microparticles</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Piglets</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IM</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inactivated <italic toggle="yes">M. hyopneumoniae</italic> field isolate BA 2940-99</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Strong innate immune responses and robust Th1 or Th17 responses</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B126-vaccines-09-00917" ref-type="bibr">126</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">c-di-AMP or c-di-IMP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IN</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Beta-gal, Ova</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Serum IgG, mucosal IgA, Th1/Th2/Th17, CTL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B49-vaccines-09-00917" ref-type="bibr">49</xref>,<xref rid="B93-vaccines-09-00917" ref-type="bibr">93</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">cGAMP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IN, single dose</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inactivated whole virus H7N9 vaccine </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Enhanced humoral, cellular, and mucosal immune responses. significantly higher nucleoprotein-specific CD4<sup>+</sup> and CD8<sup>+</sup> T-cell responses</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Protection against a high lethal dose, effective cross-protection against H1N1, H3N2, and H9N2 influenza virus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B127-vaccines-09-00917" ref-type="bibr">127</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">cGAMP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IN</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HA vaccine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Enhanced IgA, IgG, and T cell responses, including in nasal-associated lymphoid tissue</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B128-vaccines-09-00917" ref-type="bibr">128</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">cGAMP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pigs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ID</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">H5N1 and 2009 H1N1 pandemic influenza vaccines</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vigorous immune responses elicited with no overt skin irritation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B129-vaccines-09-00917" ref-type="bibr">129</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">cGAMP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Biomimetic liposomes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice,<break/>ferrets</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IN</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">H1N1 vaccine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vigorously augmented humoral and CD8<sup>+</sup> T-cell responses, importance of alveolar epithelial cells in heterosubtypic immunity</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Strong cross-protection against distant H1N1 and heterosubtypic H3N2, H5N1, and H7N9 viruses</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B130-vaccines-09-00917" ref-type="bibr">130</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">cGAMP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Microneedle patches and<break/>saponin (Quil-A)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Aged mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Microneedle patches</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">H1N1 vaccine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased IgG and IgG2a</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Complete protection</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B131-vaccines-09-00917" ref-type="bibr">131</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">cGAMP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IN, SC, IM</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">H. pylori</italic> urease A, urease B, and neutrophil-activating protein</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Serum IgG and mucosal IgA, Th1, and particularly Th17 responses (IN, SC), IL-17 responses (IN)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Significantly reduced gastric mucosal <italic toggle="yes">H. pylori</italic> colonization (IN, SC)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B132-vaccines-09-00917" ref-type="bibr">132</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">cGAMP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IM</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">M. tuberculosis</italic> Rv3852 (H-NS)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High serum levels of IL-2, IL-12p40, and TNF-&#945;, specific CD4 and CD8 T-cell responses</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reduced bacterial counts in the spleen but not in the lung after H37Rv challenge</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B133-vaccines-09-00917" ref-type="bibr">133</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">cGAMP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CpG-C ODN</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HPV 16 E7 (E7GRG)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High IgG level and cell proliferation; IFN-&#947; and granzyme B levels</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Suppressed TC-1 tumour growth</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B134-vaccines-09-00917" ref-type="bibr">134</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">cGAMP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not specified</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HBsAg</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Significantly enhanced humoral and cellular immune responses</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B135-vaccines-09-00917" ref-type="bibr">135</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">cGAMP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Alum (Alhydrogel)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice<break/>(newborns)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IM</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rHA influenza vaccine (Flublok)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Enhanced HA-specific IgG2a/c titers, IFN&#947; production by CD4<sup>+</sup> T cells, increased T follicular helper cell and GL-7<sup>+</sup>CD138<sup>+</sup> germinal centre B cell responses in newborns</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B136-vaccines-09-00917" ref-type="bibr">136</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3&#8242;3&#8242; cGAMP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Acetalated dextran (Ace-DEX) microparticules</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IM</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Influenza matrix protein 2 (M2e)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Humoral and cellular responses, broadly protective immunity</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Substantial cross-protection against distant H1N1 and heterosubtypic H3N2, H5N1, and H7N9 viruses</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B137-vaccines-09-00917" ref-type="bibr">137</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3&#8242;3&#8242; cGAMP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Bacillus anthracis</italic> protective antigen (PA)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Higher serum IgG and saliva IgA than PA + cholera toxin; Th1, Th2, and Th17 responses;<break/>rapid IFN-&#946; and IL-10 responses in sublingual tissues and cervical lymph</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B138-vaccines-09-00917" ref-type="bibr">138</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RR-CDG</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IN, SC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antigen-85B, ESAT-6, Rv1733c, Rv2626c, and RpfD fusion protein</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IN: significantly boosted BCG-induced immunity; elicited both Th1 and Th17 immune responses</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IN: superior protection than BCG</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B139-vaccines-09-00917" ref-type="bibr">139</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RR-CDG</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> Nanoparticles</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Y. pestis</italic> F1-V</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Induced rapid and long-lived protective immunity</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100% protected from <italic toggle="yes">Y. pestis</italic> lethal challenge within 14 days post-immunization, and 75% protected at 182 days post-immunization</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B140-vaccines-09-00917" ref-type="bibr">140</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rBCG-disA-OE</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Endogenous c-di-AMP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Guinea pigs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ID</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BCG</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Significantly stronger TNF-&#945;, IL-6, IL-1&#946;, IRF3, and IFN-&#946; levels than BCG in murine macrophages culture</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Significantly reduced lung weights, pathology scores, and bacterial counts in lungs vs. BCG</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B104-vaccines-09-00917" ref-type="bibr">104</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rBCG-DisA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Endogenous c-di-AMP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BCG</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Produced more IFN-&#947;, IL-2, and IL-10,<break/>stronger expression of H3K4me3 vs. BCG</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No additional protection against <italic toggle="yes">M. tuberculosis</italic> infection</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B103-vaccines-09-00917" ref-type="bibr">103</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rBCG (BCG&#916;BCG1419c)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BCG</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Better activation of specific T-cell population vs. BCG</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No difference in protection vs. BCG</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B102-vaccines-09-00917" ref-type="bibr">102</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rBCG-Rv1357c</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">c-di-GMP phosphodiesterase gene Rv1357c</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ID</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BCG</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">More phagocytosed vs. BCG</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Similar protection against <italic toggle="yes">M. tuberculosis</italic> challenge vs. BCG</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B101-vaccines-09-00917" ref-type="bibr">101</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>SC, Subcutaneous; Beta-gal, Beta-galactosidase; Th1/Th2, Type 1/type 2 T helper cells; IN, Intranasal; OVA, Ovalbumin; CTL, Cytotoxic T lymphocytes; IM, Intramuscular; IL, Interleukin; TNF-&#945;, Tumor necrosis factor type; HI, Hemagglutination inhibition; IFN, Interferon; TLR, Toll-like receptors; IP, Intraperitoneal; Th17, T helper cells type 17; TRM cells, Tissue-resident memory T cells; ClfA, Clumping factor A; mSEC, mutant Staphylococcal enterotoxin C; PdB, genetic toxoid derivative of Pneumolysin; PspA, Pneumococcal surface protein A; PsaA, Pneumococcal surface adhesin A; ID, Intradermal; AT1R, Angiotensin II type 1 receptor; ESAT-6, 6 kDa Mycobacterium tuberculosis early secretory antigenic target; i.v, Intravenous; HCV, Hepatitis C virus; HPV, Human papillomaviruses; HBsAg, Hepatitis B surface antigen; BCG, Bacille Calmette-Gu&#233;rin.</p></fn></table-wrap-foot></table-wrap><table-wrap id="vaccines-09-00917-t002" orientation="portrait" position="float"><object-id pub-id-type="pii">vaccines-09-00917-t002_Table 2</object-id><label>Table 2</label><caption><p>Selected examples of cyclic dinucleotides (CDNs) delivery systems.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">CDNs</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Deliver Systems</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Function</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CDN</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Biodegradable, poly(beta-amino ester) nanoparticles</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cytosol delivery and 10-fold improved treatment potency in established B16 melanoma tumours with anti-PD-1 in mice compared to free CDN</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B80-vaccines-09-00917" ref-type="bibr">80</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">c-di-GMP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Liposomes made of a synthetic, pH-sensitive lipid of high fusogenicity (YSK05)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Deliver into the cytosol and induced melanoma regression</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B160-vaccines-09-00917" ref-type="bibr">160</xref>,<xref rid="B161-vaccines-09-00917" ref-type="bibr">161</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">c-di-GMP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Liposome nanoparticles</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Targeting lymphatics and draining lymph nodes after parental injection</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B162-vaccines-09-00917" ref-type="bibr">162</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">c-di-GMP and 3&#8242;3&#8242;-cGAMP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cell-penetrating peptide</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Enhanced both cellular delivery and biological activity of the c-di-GMP in murine splenocytes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B97-vaccines-09-00917" ref-type="bibr">97</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">c-di-GMP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cytotoxic cationic silica nanoparticles</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Local retention and potent melanoma growth inhibition</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B79-vaccines-09-00917" ref-type="bibr">79</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">c-di-GMP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mesoporous silica nanoparticle (immuno-MSN)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Brain delivery for treatment of glioblastoma multiforme</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B77-vaccines-09-00917" ref-type="bibr">77</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">c-di-GMP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rhodamine B isothiocyanate fluorescent mesoporous silica nanoparticles, synthesized and modified with poly(ethylene glycol) and an ammonium-based cationic molecule</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8220;In situ vaccination&#8221; strategy; dramatic inhibition of 4T1 breast tumour growth in mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B78-vaccines-09-00917" ref-type="bibr">78</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">c-di-GMP and c-di-AMP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Microneedles (MN)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Skin delivery better than SC and MN-based alum</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B163-vaccines-09-00917" ref-type="bibr">163</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">c-di-AMP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Surfactant-based inverse micellar sugar glass nanoparticles (NPs)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Needle-free transfollicular antigen delivery from intact skin; better than polylactic-co-glycolic acid (PLGA) and chitosan-PLGA NPs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B164-vaccines-09-00917" ref-type="bibr">164</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">c-di-AMP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cationic liposomes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Enhanced <italic toggle="yes">M. hyopneumoniae</italic>-specific antibody and T-cell responses</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B126-vaccines-09-00917" ref-type="bibr">126</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">cGAMP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A polymersome delivery platform</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Improved half-life of cGAMP, enhanced immune activation, and tumour growth suppression</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B74-vaccines-09-00917" ref-type="bibr">74</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">cGAMP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Linear polyethyleneimine/hyaluronic acid hydrogels</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Delivered into phagocytic macrophage cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B165-vaccines-09-00917" ref-type="bibr">165</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">cGAMP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cationic liposomes with varying surface polyethylene glycol levels</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cytosolic delivery and delivery to metastatic melanoma tumour sites and APCs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B166-vaccines-09-00917" ref-type="bibr">166</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">cGAMP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Microneedle skin patches (MNPs)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased IgG and IgG2a responses to influenza vaccines in aged mice (21-month-old), and full protection against challenge</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B131-vaccines-09-00917" ref-type="bibr">131</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">cGAMP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lipidoid nanoparticle (93-O17S-F)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cytosolic delivery</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B167-vaccines-09-00917" ref-type="bibr">167</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>PD-1, programmed cell death protein 1; SC, subcutaneous; APCs, antigen-presenting cells.</p></fn></table-wrap-foot></table-wrap></floats-group></article></pmc-articleset>